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General introduction and outline of thesis 
epidemiology of obesity and diabetes
There is currently a growing worldwide epidemic of obesity and type 2 diabetes mellitus 
(DM). In the last 40 years, the number of obese adults has increased 6-fold to an esti-
mated 640 million worldwide.1 Obesity is a risk factor for cardiovascular diseases and 
some cancers, but is the strongest risk factor for developing DM. The latest estimates 
by the International Diabetes Federation suggested that there are 425 million diabetics 
in 2017, and is projected to increase by 48% to 629 million by 2045.2 Furthermore, an 
estimated 212 million adults aged 20-79 years are unaware of their DM diagnosis, and 
DM accounted for 10.7% of global all-cause mortality (higher than the combined deaths 
from infectious diseases).2 Global healthcare expenditure for DM patients aged 20-79 
years grew from US$ 232 billion in 2007 to US$ 727 billion in 2017, a three-fold increase 
within 10 years.2
Although coronary atherosclerosis (i.e. coronary heart disease [CHD]) is the most com-
mon and well recognized complication arising from obesity and DM, patients often 
can develop cardiac structural and functional changes independent of CHD that are 
detrimental and associated with long term adverse outcomes.3-5 Known as metabolic 
heart disease, it is characterized by altered myocardial energetics with mitochondrial 
dysfunction, abnormal substrate usage with steatosis, cardiac autonomic neuropathy 
and increased interstitial collagen deposition.6, 7 These pathological processes initially 
result in subclinical myocardial contractile dysfunction with preservation of left ven-
tricular (LV) ejection fraction (EF), but eventually progresses to overtly reduced LVEF.8-11
Myocardial metabolism
In a normal heart, there is a balance between myocardial oxygen delivery (supply) and 
metabolism (demand). Adenosine triphosphate (ATP) is the primary molecule that 
provides energy to drive myocardial contraction and is primarily produced within the 
mitochondria via oxidative phosphorylation. The heart normally uses both glucose and 
free fatty acids as energy substrates for ATP production via the citric acid cycle (Krebs 
cycle) (Figure 1).12 Acetyl coenzyme A (acetyl-CoA) is the key molecule that delivers the 
acetyl group to the Krebs cycle to produce reduced nicotinamide adenine dinucleotide 
(NADH) and CO2. NADH is subsequently used by the oxidative phosphorylation pathway 
to generate ATP (Figure 1).
Within the mitochondria, 10-40% of acetyl-CoA is produced from the oxidation of glu-
cose/pyruvate via the glycolysis pathway, and 60-90% is produced via β-oxidation of 
free fatty acids.12 Under normal physiological conditions, 70–90% of the free fatty acids 
entering the myocytes are immediately oxidized and 10–30% enter the intracellular 
triglyceride pool.13 This intracellular triglyceride pool is an important source of fatty 
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acids, with the rate of lipolysis and its contribution to overall myocardial ATP production 
being inversely related to the concentration of exogenous free fatty acids. Increased ATP 
production from increased cardiac work is due to increased ATP hydrolysis and oxida-
tive phosphorylation, but the total ATP pool remains relatively constant.14
Although the heart can utilize both glucose and free fatty acid for metabolism, obese 
and diabetic patients preferentially uses free fatty acid as its main energy source despite 
the prevailing hyperglycemia. Consequently, there is a shift in myocardial energy pro-
duction towards mitochondrial free fatty acid β-oxidation, and the excess free fatty acid 
is converted and stored as triglycerides within the cellular cytoplasm (i.e. steatosis).16, 17 
Although the intracellular triglyceride is inert, it reflects the increased concentration of 
free fatty acid in the myocardium. The high concentration of free fatty acid inhibits pyru-
vate dehydrogenase which impairs the mitochondrial citric acid cycle and ATP produc-
tion.6 The excessive free fatty acid exceeds the mitochondrial β-oxidative capacity and 
leads to accumulation of toxic lipid intermediates such as ceramide and diacylglycerol, 
causing cellular apoptosis, replacement fibrosis and myocardial contractile dysfunc-
tion.18, 19
There is a direct relationship between myocardial steatosis and contractile dysfunction. 
Previous animal study demonstrated that LV contractile function is less when free fatty 
 
Figure 1. Graphical representation of myocardial substrate metabolism. Cardiac myocytes utilizes glucose, 
free fatty acid, and ketones as energy substrates to produce ATP. Majority of the ATP is produced via oxida-
tive phosphorylation in the mitochondria. BDH: β-hydroxybutyrate dehydrogenase; CPT-1: carnitine palmito-
yltransferase-1; FAT: fatty acid transporter/CD36; G6P: glucose 6-phosphate; GLUT: glucose transporters; MCT: 
monocarboxylic acid transporters; PCr: phosphocreatine; PDH: pyruvate dehydrogenase; SCOT: succinyl-CoA-
3-oxaloacid CoA transferase; SR: sarcoplasmic reticulum. Adapted from Stanley et al. and Karwi et al.12, 15
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acids rather than glucose are the sole exogenous energy substrate.20 In humans, myocar-
dial steatosis is associated with LV diastolic dysfunction.21 Currently, myocardial steato-
sis can be quantified by magnetic resonance spectroscopy (MRS) as well as multi-echo 




Magnetic resonance spectroscopy (MRS) is a non-invasive tool that can quantify myocar-
dial metabolism. It can be performed on any atom that has an odd number of nucleons 
(i.e. protons and neutrons) within its nucleus, such as hydrogen/proton (1H), carbon (13C) 
and phosphorus (31P). When these nuclei are subjected to a magnetic field, they will 
align and precess about the axis of the magnetic field at a specific frequency (Figure 2). 
However, the nuclei of atoms in a molecule (e.g. water [H2O] or lipid methylene [–CH2–] 
or CH3 moieties) are shielded from the applied magnetic field by the circulating electron, 
resulting in slight differences in the resonant frequencies of the nucleus depending on 
the chemical bonds within the molecule. These chemical shifts are measured in parts 
per million (ppm) of the main resonant frequency.
In biological tissue, 1H is the most abundant nucleus to perform MRS. For in-vivo 1H- 
MRS, water resonates at 4.7 ppm whilst the lipid methylene [–CH2–] and CH3 moieties 
resonate at 1.2 and 0.9 ppm respectively (Figure 3). Due to the intense concentration 
of water compared to lipids within the myocardium, water suppression techniques are 
applied to attenuate the water peak in order to quantify the lipid signals. As the heart 
moves within the mediastinum due to systolic/diastolic motions and within the chest 
cavity due to respiration, MRS of the myocardium is usually performed with both cardiac 
and respiratory gating. This usually result in long scan durations in order to achieve 
 
Figure 2. Representation of a proton precession (red arrows) about the axis of the applied magnetic field (B0).
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adequate spectrograms to quantify intramyocardial triglyceride content.22 Further-
more, the placement of the volume-of-interest is usually limited to the proximal and 
mid interventricular septum to avoid potential contamination from epicardial adipose 
tissue (EAT). Presently, 1H-MRS is considered the clinical gold-standard for quantifying 
intramyocardial triglyceride content.
Water-fat separated imaging
Intramyocardial fat can also be quantified using multi-echo Dixon water and fat sepa-
rated imaging with variable projection (VARPRO).23-25 It similarly exploits differences in 
resonance frequencies between water and fat to quantify intramyocardial fat content. 
The VARPRO method utilizes ≥ 3 echo times to derive water-only, fat-only, in-phase and 
out-of-phase images using a single breathhold.23-25 This method provides excellent dis-
crimination between water and fat, and the images generally have low signal-to-noise 
ratio (Figure 4).
Unlike 1H-MRS, this technique permits quantification of regional and global intramyo-
cardial fat content. Images are also obtained in a single breath-hold. Most importantly, 
it can be coupled with other multiparametric CMR techniques such as T1 mapping and 
late gadolinium enhancement. However, VARPRO will tend to overestimate myocardial 
triglyceride content compared to 1H-MRS due to its inherent T1 bias.
 
 
Figure 3. Quantification of myocardial triglyceride content by 1H-MRS. Examples of unsuppressed (left panel) 
and water-suppressed (right panel) spectra.  The water-suppressed spectrum shows the peaks from triglyc-
eride, unsaturated fat, creatine and choline. Myocardial triglyceride content is calculated and expressed as a 
percentage that is based on the signal amplitude of myocardial triglyceride divided by the signal amplitude 
of water. In patients with obesity or diabetes, the triglyceride peaks will be increased relative to the water 
peak, resulting in a higher ratio.
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epicardial adipose tissue
Epicardial adipose tissue (EAT) may also play an important role in cardiac substrate 
utilization. It is embryologically similar to mesenteric and omental visceral fat, having 
developed from the splanchnopleuric mesoderm.26 EAT is bounded between the epicar-
dium and pericardium, and is not separated from the underlying myocardium by any 
fibrous tissue. It lies directly over the myocardium, preferentially within the atrioven-
tricular and interventricular grooves following the coronary arteries, right ventricular 
free wall and around both atria.27 Previous study has suggested that EAT may act as a 
lipid store for the myocardium, and directly releases free fatty acids for myocardial lipid 
and energy homeostasis.28 Both increasing obesity and diabetes are directly associated 
with increased EAT volume, and there is a direct correlation between EAT thickness and 
myocardial steatosis.29 Increased EAT volume is also independently associated with 
various cardiac pathologies including increased LV mass, myocardial dysfunction, left 
atrial dysfunction, atrial fibrillation and CHD.30-38 Total EAT volume can be accurately 
quantified using 3-dimensional imaging techniques modalities such as computed to-
mography (CT) and CMR (Figure 5), and are superior to 2-dimensional techniques such 
as echocardiography that offers only linear measurements.26
 
Figure 4. Quantification of myocardial fat. Example of a Dixon multiecho gradient variable projection 
(VARPRO) sequence with fat–water separation imaging in a healthy individual. Left panel is the water-only 
image and right panel is the fat-only image. Myocardial fat content is calculated and expressed as a percent-
age that is based on the mean pixel signal intensity of the left ventricular fat-only image divided by the mean 




Patients with metabolic heart disease can develop increased interstitial fibrosis leading 
to increased LV stiffness, impaired systolic and diastolic function, and eventual clini-
cal heart failure. Unlike “traditional” late gadolinium enhancement that is dependent 
on relative regional differences in contrast distribution, recent advent of CMR with T1 
mapping allows quantification of diffuse LV interstitial fibrosis by means of calculating 
post-contrast T1 time or extracellular volume (ECV) fraction.39 Post-contrast T1 time 
and ECV fraction calculations rely on T1 shortening of extracellular gadolinium contrast 
that accumulates within the extracellular space (Figure 6). Large histological validation 
studies have demonstrated an excellent correlation between post-contrast T1 time and 
fibrosis burden on endomyocardial biopsies.40, 41
 
 
Figure 5. Quantification of epicardial fat volume. Examples of epicardial fat volume quantification with the 
use of cardiac magnetic resonance black blood imaging (top 2 panels) in a patient with diabetes, and CT 
(bottom 2 panels) in a healthy individual. In the top left panel, the pericardium is the thin rim of black line 
surrounding the heart in black blood imaging. Therefore, epicardial adipose tissue is bounded between the 
pericardium and the epicardium, and appears bright in black blood imaging. In top right panel, the computer 
software automatically highlights and calculate the total epicardial adipose tissue volume based on pixel 
signal intensity. In bottom left panel, the pericardium is the thin rim of bright line on CT coronary angiogram. 
In bottom right panel, the computer software automatically highlights and calculate the total epicardial adi-
pose tissue volume based on Hounsfield units. Patients with obesity or diabetes usually have larger epicardial 
adipose tissue volume compared to normal healthy individuals.
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In a small head-to-head comparison study, native T1 time had no correlation with his-
tological collagen volume fraction, and ECV fraction may be superior to post-contrast 
T1 time.42 From the CMR technical perspective, the advantages of ECV fraction over 
post-contrast T1 time includes independence of magnetic field strength, the type of T1 
mapping sequence, and timing of post-contrast image acquisition.
Myocardial contractile function
There is extensive literature on the prognostic value of LVEF in predicting patient mor-
bidity and mortality.43-45 However, LVEF is an insensitive measure of LV systolic function 
and is usually preserved during the early stages of the disease process where there are 
only subtle reductions in myocardial contractility. This early subtle reduction in myocar-
dial contractile function before appearance of clinical symptoms is known as subclinical 
myocardial dysfunction and can be detected using advanced echocardiographic tech-
niques such as 2-dimensional (2D) strain imaging.
Strain is a dimensionless index and is defined as the amount of deformation (i.e. change 




In a small head-to-head comparison study, native T1 time had no correlation 
with histological collagen volume fraction, and ECV fraction may be superior to post-
contrast T1 time.42 From the CMR technical perspective, the advantages of ECV 
fraction over post-contrast T1 time includes independence of magnetic field strength, 
the type of T1 mapping sequence, and timing of post-contrast image acquisition. 
Myocardial contractile function 
There is extensive literature on the prognostic value of LVEF in predicting 
patient morbidity and mortality.43-45 However, LVEF is an insensitive measure of LV 
systolic function and is usually preserved during the early stages of the disease 
process where there are only subtle reductions in myocardial contractility. This early 
subtle reduction in myocardial contractile function before appearance of clinical 
symptoms is known as subclinical myocardial dysfunction and can be detected using 
advanced echocardiographic techniques such as 2-dimensional (2D) strain imaging. 
Strain is a dimensionless index and is defined as the amount of deformation 
(i.e. change in length) normalised to its original length. It is represented by the 
symbol ε and expressed mathematically as: 
𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆𝑆 (ε)  =  𝐿𝐿 − 𝐿𝐿0𝐿𝐿0
× 100% 
where L is the length of myocardium after deformation (i.e. end-systole) and L0 is the 
original length (i.e. end-diastole). By convention, strain is defined as positive when 
the myocardium is lengthening, and defined as negative when the myocardium is 
shortening. As shown in Figure 8, LV myocardial contraction is comprised of 
longitudinal shortening (negative strain), circumferential shortening (negative strain), 
and radial thickening (positive strain). 
where L is the length of myocardium after deformation (i.e. end-systole) and L0 is the 
original length (i.e. end-diastole). By convention, strain is defined as positive when the 
myocardium is lengthening, and defined as negative when the myocardium is short-
ening. As shown in Figure 7, LV myocardial contraction is comprised of longitudinal 
shortening (negative strain), circumferential shortening (negative strain), and radial 
thickening (positive strain).
 
Figure 6. Quantification of interstitial fibrosis. CMR with T1 mapping allows the quantification of diffuse in-
terstitial fibrosis in the left ventricle by calculation of extracellular volume (ECV) fraction with the use of left 
ventricular native (left panel) and post-contrast (right panel) T1 maps.
18  
 
Of these 3 strain directions, longitudinal strain is primarily determined by subendo-
cardial fibers and is the most sensitive indicator of subclinical myocardial dysfunction. 
This is due to the endocardium having the lowest oxygen tension compared to the 
epicardium and is therefore most vulnerable to relative ischemia even with subtle re-
ductions in myocardial blood flow.46 Compared to LVEF, longitudinal strain is a superior 
prognosticator for all-cause mortality and cardiovascular morbidity.47 Figure 8 shows 
the derivation of peak global longitudinal strain from the 3 apical views.
objectives and outline of thesis
The objectives of this thesis were to elucidate the pathogenesis of metabolic heart dis-
ease, evaluate the associated changes in myocardial structure and contractile function, 
and determine the long-term prognostic implications of subclinical myocardial dysfunc-
tion on all-cause mortality.
Chapter 1 summarizes the utility of various advanced cardiac imaging modalities in 
elucidating the pathogenesis of metabolic heart disease. Next, echocardiographic 2D 
speckle tracking strain analysis was used to detect subclinical myocardial contractile 
dysfunction in diabetic (Chapter 2) and obese (Chapter 3) patients with preserved LVEF. 
In Chapters 4-6, CMR and cardiac CT were used to evaluate the associations between 
myocardial steatosis, interstitial fibrosis and EAT with subclinical myocardial contractile 
dysfunction. Finally, the thesis will conclude with the prognostic implications of sub-
 
 
Figure 7. Graphical representation of the left ventricular myocardial contraction according to the cardiac 
axis. During systole, there is longitudinal shortening (black arrow) from the basal to apical motion of the left 
ventricle, circumferential shortening (red arrow) in the short axis, and radial thickening (blue arrow) in the 
short axis.
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clinical myocardial contractile dysfunction and its incremental clinical usefulness using 
decision curve analysis (Chapter 7).
In this thesis, all patients had normal LVEF and peak global longitudinal strain (GLS) 
was used to detect subclinical myocardial contractile dysfunction. In Chapters 2 and 3, 
GLS was used to evaluate the impact of DM and obesity on myocardial contractility. In 
Chapters 3 to 6, the thesis explored the association between GLS and pathogenesis of 
metabolic heart disease (i.e. steatosis, interstitial fibrosis and epicardial adipose tissue 
[EAT] volume). In Chapter 7, the prognostic significance and clinical usefulness of GLS 
was evaluated.
 
Figure 8. Example of 2D speckle tracking analyses. Individual longitudinal strain measurements are initially 
performed from the 4-chamber (top left panel), 2-chamber (top right panel) and 3-chamber (bottom left pan-
el) views. Individual longitudinal strain curves are generated from each view and combined to automatically 
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Diabetic heart disease is currently defined as left ventricular dysfunction that occurs 
independently of coronary artery disease and hypertension. Its underlying etiology is 
likely to be multifactorial, acting synergistically together to cause myocardial dysfunc-
tion. Multimodality cardiac imaging such as echocardiography, nuclear, computed 
tomography and magnetic resonance imaging can provide invaluable insight into dif-
ferent aspects of the disease process, from imaging at the cellular level for altered 
myocardial metabolism to microvascular and endothelial dysfunction, autonomic 
neuropathy, coronary atherosclerosis, and finally interstitial fibrosis with scar forma-
tion. Furthermore, cardiac imaging is pivotal in diagnosing diabetic heart disease. Thus, 
the aim of the present review is to illustrate the role of multimodality cardiac imaging 
in elucidating the underlying pathophysiological mechanisms of diabetic heart disease.
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InTRoDUCTIon
Diabetes mellitus is the most common endocrine disease in the world. Recent estimates 
from the World Health Organization indicate that more than 170 million people world-
wide have diabetes, and that number is projected to increase to more than 360 million by 
the year 2030.1, 2 Diabetic patients are at an increased risk of developing cardiovascular 
disease,3 and can develop heart failure independent of myocardial ischemia.4 Similarly, 
the incidence of diabetes is also increased in patients with heart failure.5, 6 Epidemiologi-
cal studies have established diabetes as an independent risk factor for developing heart 
failure, even after correcting for the presence of coronary artery disease.3, 4, 7 Since it 
was first described by Rubler et al. more than 3 decades ago,8 diabetic cardiomyopathy 
is currently defined as left ventricular (LV) dysfunction that occurs independently of 
significant coronary artery disease and hypertension.9 However, the clinical spectrum of 
diabetes and heart failure is wide, ranging from subclinical disease to overt clinical heart 
failure. Thus, the term diabetic cardiomyopathy is usually reserved for diabetic patients 
with overt myocardial dysfunction with signs and symptoms of congestive heart fail-
ure.8 In contrast, diabetic heart disease is a better description for diabetic patients with 
evidence of subclinical myocardial dysfunction without overt heart failure symptoms.
Various mechanisms underlie the etiology of diabetic heart disease, including processes 
such as altered myocardial metabolism with subsequent steatosis and lipotoxicity, 
endothelial dysfunction with microvascular disease, autonomic neuropathy, altered 
myocardial structure with fibrosis and atherosclerosis.10 Often, these processes are not 
mutually exclusive, but act synergistically together and result in myocardial dysfunc-
tion. Multimodality imaging such as echocardiography, nuclear imaging, computed to-
mography (CT) and magnetic resonance imaging (MRI) can all reveal different etiological 
aspects of diabetic heart disease (Table 1). The present manuscript will illustrate the 
role of multimodality cardiac imaging in elucidating the pathogenesis of diabetic heart 
disease, starting from imaging at the cellular level for altered myocardial metabolism 
to microvascular and endothelial dysfunction, autonomic neuropathy, coronary athero-
sclerosis, and finally interstitial fibrosis with scar formation. Furthermore, features of 
myocardial diastolic and systolic dysfunction that are consequent to these pathophysi-
ological processes will also be examined.
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a) IMaGInG THe PaTHoGenesIs of DIabeTIC HeaRT DIsease
1. altered metabolism
Increasingly, evidence is emerging that diabetic patients have myocardial functional 
and structural changes that are independent of coronary artery disease or hyperten-
sion.9-11 Although the mechanisms leading to diabetic heart disease are complex and 
not fully understood, one of the pathophysiological causes is the excessive fatty acid 
accumulation within organs such as the heart (known as steatosis), eventually leading 
to irreversible cellular death through complex mechanisms (also known as lipotoxic-
ity).12-14
Under physiological conditions, fatty acids are normally absorbed through the intestines 
and are mostly stored as triglycerides within adipocytes with minimal accumulation 
within other tissues such as the heart. However, increased nutritional fatty acid intake 
and increased lipolysis in diabetes or obesity will lead to increased free fatty acid deliv-
ery to non-adipose tissues.13-15 When the amount of free fatty acids uptake by the heart 
exceeds its oxidative capacity, excessive fatty acids will be stored as triglycerides within 
the myocyte cytoplasm. However, part of the fatty acid is redirected into non-oxidative 
Table 1. Pathogenesis of diabetic heart disease and the applications of multimodality imaging in elucidating 
the underlying mechanisms
Altered metabolism
 Magnetic resonance spectroscopy
Endothelial dysfunction and microvascular disease
 Flow mediated dilatation
 Stress echocardiography
 Myocardial contrast echocardiography
 Nuclear myocardial perfusion imaging
 Positron emission tomography
 Contrast-enhanced magnetic resonance imaging
Cardiac autonomic dysfunction
 123-iodine metaiodobenzylguanidine (123I MIBG) SPECT
 Positron emission tomography
Coronary atherosclerosis
 Coronary artery calcium scoring
 Coronary CT angiography
Myocardial structural changes with fibrosis
 Echocardiographic intergrated backscatter
 Magnetic resonance imaging
SPECT: single photon emission computed tomography; CT: computed tomography
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pathways giving rise to toxic fatty acid intermediates such as ceramide. These toxic fatty 
acid intermediates disrupt normal cellular signalling and alter myocyte function and 
structure by complex mechanisms, eventually leading to cellular apoptosis and replace-
ment fibrosis. Thus, it is currently accepted that intracellular triglycerides are probably 
inert, but are reflective of the increased intracellular concentrations of toxic fatty acid 
intermediates. At present, myocardial triglycerides can be quantified by using hydrogen 
1 magnetic resonance spectroscopy (1H MRS).16
Magnetic resonance spectroscopy. Currently, 1H MRS can be performed using MR 
systems with a high field strength (1.5 Tesla or above). Often, cardiac and respiratory 
motion triggering are employed to improve the reliability and spectral quality of myo-
cardial 1H MRS by reducing cardiac and respiratory motion artefacts, and reduce the 
chance of contamination by signals arising from the epicardial fat.17 A typical myocardial 
1H MR spectrum will display signals arising from water, creatine, choline and fat (Figure 
1). As the water signal is approximately 100-1000 times that of the fat signal, acquisi-
tion of 1H MR spectra both with and without water suppression is essential for reliable 
quantification of intramyocardial triglyceride content. Using dedicated software, signal 
amplitudes from the intracellular triglycerides and water are quantified and expressed 
as triglyceride/water ratio.
Several studies have utilized 1H MRS to relate myocardial triglyceride content and LV 
function in healthy volunteers, and in obese and diabetic patients.16, 18-22 It is known 
that myocardial triglyceride content increases with normal physiological aging, and 
is inversely correlated with the age-related decline in myocardial function.21 Similarly, 
myocardial triglyceride content is increased in obese and diabetic patients.19, 20, 23 Fur-
thermore, the accumulation of myocardial triglyceride was associated with myocardial 
dysfunction in these patients. These findings are in agreement with experimental animal 
studies showing direct toxic effects of fatty acid intermediates on the myocardium.24, 25
Several human studies have examined the reversibility of myocardial dysfunction 
associated with steatosis. Both Hammer et al. and Schrauwen-Hinderling et al. have 
demonstrated that weight loss was able to partially reverse myocardial triglyceride ac-
cumulation in diabetic and obese patients respectively, and this was associated with 
improvements in LV function.18, 26 In contrast, there is currently conflicting evidence 
on the role of medications in reducing intramyocardial triglyceride accumulation.22, 27 
For example, Zib and co-workers demonstrated that pioglitazone (a thiazolidinedione 
which increases whole-body insulin sensitivity) significantly reduced myocardial and 
hepatic triglyceride contents, but there were no significant changes in LV mass and 
ejection fraction (EF).27 On the other hand, van der Meer and co-workers demonstrated 
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significant improvement in LV diastolic function in diabetic patients treated with piogli-
tazone, but myocardial triglyceride content remained unchanged.22 Future studies are 
clearly needed to further investigate the role of medications in reversing myocardial 
steatosis. However, as previously noted, intracellular triglycerides are probably inert, 
and the relationship between myocardial triglyceride accumulation and LV dysfunction 
likely represents an association rather than a causal relationship. Furthermore, there is 
currently no evidence to suggest that myocardial triglyceride accumulation will eventu-
ally result in clinical heart failure.
 
Figure 1. Examples of image acquisition and spectra from a patient. Panel A and B: 4-chamber and short axis 
views with the volume of interest placed in the interventricular septum; Panel C: Typical unsuppressed spec-
trum showing the water peak; Panel D: Typical water-suppressed spectrum showing the various peaks from 
triglyceride, unsaturated fat, creatine and choline. The amplitudes of the spectra are in arbitrary units, and 
concentrations of triglyceride are usually expressed as a ratio relative to the peak water amplitude.
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2. endothelial dysfunction and microvascular disease
One of the mechanisms underlying diabetic cardiomyopathy is the presence of endothe-
lial dysfunction and microvascular disease. The normal function of endothelial cells is 
to maintain vascular homeostasis in order to ensure adequate blood flow and nutrient 
delivery to tissues while preventing thrombosis and leukocyte diapedesis.28 This is per-
formed through the competing and opposing synthesis and release of nitric oxide (which 
causes smooth muscle relaxation and vasodilatation) and vasoconstrictor prostanoids 
and endothelin (which results in vasoconstriction). Endothelial-derived nitric oxide 
protects against atherosclerosis by preventing platelet and leukocyte adhesion to the 
vascular wall, and inhibition of smooth muscle cell proliferation.29-31 Reduction or loss of 
endothelial nitric oxide availability results in monocyte and vascular smooth muscle cell 
migration into the vascular intima layer and the formation of macrophage foam cells, 
the initial stages of atherosclerosis.32 In diabetic patients, the associated hyperglyce-
mia, increased circulating free fatty acids levels and insulin resistance lead to increased 
mitochondrial superoxide generation, reduced endothelial nitric oxide production with 
reciprocal increase in vasoconstrictor prostanoids and endothelin syntheses. This will 
eventually result in endothelial dysfunction and atherosclerosis.32, 33 Furthermore, dys-
regulation of vascular smooth muscle function is exacerbated by impairments in sym-
pathetic nervous system function, as is often seen in diabetic autonomic neuropathy 
(see below).34 Various imaging techniques such as flow mediated dilatation (FMD), stress 
echocardiography, myocardial contrast echocardiography, nuclear perfusion imaging, 
positron emission tomography (PET) and contrast-enhanced MRI may be employed to 
evaluate endothelial function and microvascular disease.
Flow mediated dilation. FMD of the brachial artery provides a non-invasive estimation 
of systemic endothelial function.35 In this method, the brachial artery diameter is mea-
sured using B-Mode ultrasound or a wall-tracking system, before and after an increase in 
shear stress that is induced by reactive hyperemia. FMD is thus defined as the percent-
age change in diameter of the brachial artery and measures the function of endothelium 
dependent vasodilatation (Figure 2). The observed brachial artery dilatation has been 
shown to be closely related to coronary endothelial function and vasoreactivity.36
FMD has been widely used in research to study the natural course of endothelial function 
with age and its role in the initiation and progression of vascular disease.37 For example, 
FMD ranges from approximately 20% in young adults to 0% in patients with established 
CAD, while mean FMD values were also reduced (range 0-12%) in diabetic patients.38 
Often, diabetic patients may show evidence of myocardial perfusion defects without a 
corresponding obstructive epicardial coronary artery disease, suggestive of endothelial 
dysfunction with microvascular disease.39 Accordingly, a recent study demonstrated a 
32  
 
significant lower FMD in diabetic patients with perfusion defects compared to those 
without perfusion defects on single photon emission computed tomography (SPECT) 
(FMD 3.6 ± 2.4% vs. 6.4 ± 2.6%, p < 0.001), despite the absence of obstructive coronary 
disease.40 This observation emphasizes the potential role of endothelial dysfunction 
and corresponding microvascular disease on myocardial perfusion in diabetic patients.
Detection of microangiopathy by stress echocardiography. Previous echocardiographic 
studies have also evaluated the relationship between myocardial blood flow and LV sys-
tolic and diastolic dysfunction in diabetic patients.41, 42 Fang et al. evaluated 41 diabetic 
patients with normal resting LVEF and without coronary artery disease as demonstrated 
by a normal dobutamine stress echocardiography.41 Systolic myocardial velocity (Sm) 
was measured at rest and at peak dobutamine dose with color-coded tissue Doppler 
imaging. Compared to healthy controls, diabetic patients showed significantly reduced 
resting Sm (4.2 ± 0.9 cm/s vs. 4.7 ± 0.9 cm/s, p = 0.012). At peak dobutamine dose, Sm 
increased in diabetic patients and controls reaching comparable values (8.9 ± 1.8 cm/s 
vs. 9.6 ± 2.1 cm/s, p = not significant).41 Therefore, this normal response to stress sug-
gested that ischemic etiology might not be a cause for the resting left ventricular systolic 
dysfunction. These results were later confirmed by another study from the same group 
using myocardial contrast echocardiography to assess myocardial blood flow.42
 
 
Figure 2. Assessment of flow mediated dilatation. The brachial artery is visualized distal to the elbow using 
ultrasonography. Next, ischemia is induced in the forearm distal to the location of the transducer by inflating 
a blood pressure cuff for 5 minutes at a pressure of at least 200 mmHg. After cuff deflation, ultrasonography is 
continued for 5 minutes with measurements at approximately 30-second intervals. Widest lumen diameter is 
used as maximal vasodilation achieved during reactive hyperemia. Flow mediated dilatation is expressed as 
the percentage change relative to the baseline diameter.
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Detection of microangiopathy by myocardial contrast echocardiography. Echocardio-
graphic microbubble contrast agents are normally used for LV opacification to enhance 
endocardial border detection, thus improving the accuracies of LV volume quantifica-
tion and wall motion analyses. In addition, the microbubble contrast agents also permit 
evaluation of myocardial perfusion and myocardial blood flow.43 As these microbubble 
contrast agents have similar microvascular rheology as red blood cells, they stay within 
the intravascular compartment. Using a low mechanical index during imaging, these 
microbubbles resonate and appear bright on echocardiography. When a high mechani-
cal index ultrasound pulse is transmitted, the microbubbles are destroyed within the 
myocardium, thereby reducing the myocardial contrast intensity to nearly zero. The rate 
of replenishment within the myocardium is thus dependent on the presence of intact 
microvasculature and myocardial blood flow rate, and the intensity at which the con-
trast effect plateaus is dependent on myocardial blood volume. Thus, normally perfused 
myocardium appears as enhanced myocardium, whereas those areas with impaired 
perfusion appear as dark or patchy areas (Figures 3A and 3B).
In a study by Moir and co-workers who recruited 26 healthy controls and 22 type 2 dia-
betic patients with normal LVEF and absent coronary artery disease, the relationship 
between myocardial flow reserve post-stress and myocardial function was explored.42 
Myocardial blood flow and function were quantified by myocardial contrast echocar-
diography and tissue Doppler strain/strain rate imaging respectively. Compared to 
controls, resting longitudinal peak systolic strain (-14.4 ± 4.6% vs. -18.7 ± 3.1%, p = 0.006) 
was significantly lower in diabetic patients, but resting myocardial blood flow was 
comparable (5.1 ± 3.5 vs. 4.6 ± 3.2, p = 0.62). Post-stress, myocardial blood flow reserve 
was significantly lower in diabetic patients (2.4 ± 1.0 vs. 3.8 ± 2.1, p = 0.01). However, 
there was no correlation between myocardial blood flow reserve and resting myocardial 
function (Figure 3C). Thus, the authors concluded that although subclinical myocardial 
dysfunction and microvascular disease may coexist, it may not be the sole causative 
factor in diabetic heart disease.
34  
 
Nuclear myocardial perfusion imaging. Myocardial perfusion imaging by thallium-201 
or technetium-99m sestamibi SPECT is a widely used and validated non-invasive tool for 
the diagnosis of myocardial ischemia. ECG-gated SPECT allows both quantitative evalu-
ation of cardiac function and myocardial perfusion to detect ischemia during exercise 
testing or pharmacological stress with adenosine, dipyridamole or dobutamine (Figure 
4).44 The presence of myocardial perfusion defects during stress is due to heteroge-
neous flow distribution as a result of two potential mechanisms: obstructive epicardial 
coronary artery disease due to atherosclerosis and subsequently reduced flow during 
stress;45 or insufficient vasomotor response in the coronary microvasculature due to 
endothelial dysfunction resulting in relative hypoperfusion during stress.46
 Figure 3. Examples of myocardial contrast echocardiography assessing myocardial blood flow. After a high 
mechanical index ultrasound pulse, the microbubbles are initially destroyed before returning to reperfuse 
the myocardium. Areas with normal myocardial blood flow show a homogeneous replenishment of the myo-
cardium (panel A). In contrast, areas with impaired perfusion appear as dark patchy, non-replenished areas 
(arrows, panel B). In diabetic cardiomyopathy, myocardial blood flow reserve post-stress did not correlated 
with resting myocardial function as assessed by tissue Doppler strain rate imaging (panel C).
SR: strain rate; MBF: myocardial blood flow. Adapted with permission from Moir et al. Heart 2006;92:1414–
1419.
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The prevalence of myocardial perfusion defects as assessed by SPECT myocardial perfu-
sion imaging in asymptomatic diabetic patients ranges from 20 – 40% in several pro-
spective studies,47-49 and the prognostic value of SPECT myocardial perfusion imaging in 
diabetic patients has been confirmed in several previous studies.48-50 For example, in a 
large cohort of 1271 diabetic patients, Kang et al. described a favorable cardiovascular 
prognosis in patients with a normal myocardial perfusion SPECT study (coronary event 
rates 1-2% per year), which increases to 3 – 4% per year in patients with mild perfusion 
defects, to > 7% per year for patients with moderate to severe perfusion defects. The 
incremental cardiovascular predictive value of SPECT in diabetic patients has been 
attributed to both the direct detection of underlying obstructive epicardial coronary 
disease, and its ability to reflect on endothelial dysfunction within the coronary micro-
vasculature.51
 Figure 4. Myocardial perfusion using gated SPECT at rest and after adenosine stress. Resting images and 
stress images in the short axis, horizontal and vertical long axes are depicted. In the current example, no 
persistent perfusion defects were observed. Reversible perfusion defects were observed in the inferior, infero-
septal, anterior and anteroseptal regions (arrows).
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It has been previously shown that coronary endothelial dysfunction is a precursor to 
overt atherosclerosis and is reversible to a certain extent, such as with statin thera-
pies.52, 53 Accordingly, in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) 
study, inducible myocardial ischemia at baseline was shown to resolve in up to 79% of 
asymptomatic patients with diabetes at 3 years follow-up.54 This resolution was sug-
gested by the authors to be secondary to improvements in endothelial dysfunction and 
stabilization of atherosclerotic plaques as a result of treatment with statins, aspirin and 
angiotensin-converting enzyme inhibitors.
Positron emission tomography. Although SPECT imaging is routinely used in the clinical 
setting, image quality may be suboptimal in obese and female diabetic patients due to 
attenuation artifacts. As such, assessment of myocardial perfusion by PET may be a good 
alternative in situations where SPECT imaging quality is suboptimal.55 Myocardial perfu-
sion imaging by PET uses high energy gamma photons produced by positron-emitting 
radionuclides, and has superior spatial resolution compared to conventional SPECT.56 
By combining readily available attenuation correction algorithms for photon attenua-
tion, scatter and random events, PET imaging can provide a truly quantitative measure 
of myocardial blood flow (in ml/min/g) and coronary flow reserve in absolute terms.57-59 
Thus far, this technique has been applied in research to examine coronary microvascular 
reactivity in various study populations.60-64 Several studies have demonstrated dysregu-
lation of myocardial microvascular reactivity in diabetic patients.62-64 For example, Kjaer 
and co-workers demonstrated endothelial dysfunction using 13N-ammonia PET imaging 
in type 2 diabetic patients without evidence of epicardial coronary disease compared 
to normal controls.62 Similarly, Prior and co-workers demonstrated a significantly lower 
total vasodilator capacity in normotensive diabetic (-17%) and hypertensive diabetic 
(-34%) patients compared to insulin sensitive individuals.64
Magnetic resonance perfusion imaging. In MRI, myocardial perfusion imaging relies 
on the injection of a gadolinium-based paramagnetic contrast agent which alters the 
relaxation properties of the proton nuclei in its vicinity. The subsequent transit of the 
contrast agent through the cardiovascular system and into the myocardium can be 
detected using pulse sequences which focus on T1 weighted images (Figure 5). Thus, us-
ing dipyridamole as a pharmacological stressor, magnetic resonance perfusion imaging 
allows non-invasive quantification of myocardial perfusion during baseline conditions 
and during maximal hyperemia.
There are currently a limited number of studies that have assessed MRI myocardial per-
fusion imaging in diabetic patients. In a small study by Taskiran et al., 19 type 1 diabetic 
patients were compared against 10 healthy controls.65 All the diabetic patients had no 
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major microvascular disease, and were divided into the presence or absence of auto-
nomic neuropathy. After induction of maximal hyperemia by dipyridamole, myocardial 
perfusion index was significantly lower in diabetic patients with autonomic neuropathy 
compared to those without neuropathy or normal controls (p < 0.001). Thus, altered 
myocardial perfusion associated with autonomic neuropathy may be a potential 
pathophysiological mechanism underlying the increased mortality observed in diabetic 
patients.
 
Figure 5. Example of myocardial perfusion imaging by magnetic resonance imaging during the first pass of 
an intravenously injected contrast bolus. Prior to contrast injection, the blood pool, right and left ventricular 
myocardium are dark (Panel A). Following contrast injection, contrast enhancement is then first observed in 
the right ventricular cavity (Panel B), followed by the left ventricular cavity (Panel C), and finally followed by 




3. Cardiac autonomic dysfunction
Diabetic neuropathies are a heterogeneous group of diabetic complications that affects 
different parts of peripheral nervous system. Its pathophysiology is likely to be multi-
factorial, involving alterations in metabolism, micro- and macrovascular dysfunction, 
deficiency of neurohormonal growth factor and autoimmune nerve damage.66 Although 
diabetic autonomic neuropathy can affect every system in the body, cardiac autonomic 
neuropathy (CAN) is particularly associated with an increased risk of silent myocardial 
infarction and sudden cardiac death, thus contributing to significant cardiovascular 
morbidity and mortality.67 The prevalence of CAN in type 2 diabetic patients is estimated 
to be around 20 – 30% of patients.68 Clinical manifestations of CAN include the presence 
of resting tachycardia (heart rate > 100 beats/min), postural hypotension (fall in systolic 
blood pressure > 20mmHg or diastolic blood pressure > 10mmHg upon standing) with-
out an appropriate reflex increase in heart rate, exercise intolerance due to blunting of 
cardiac output in response to exercise, or silent myocardial infarction.69, 70
The presence of CAN conveys a poor clinical outcome. Previous meta-analysis by Vinik 
and co-workers assessed the prognostic value of CAN in diabetic patients.70 Using the 
pooled analyses from 12 studies involving a total of 1486 study subjects, they estimated 
that the pooled prevalence rate risk for silent myocardial infarction in diabetic patients 
was 1.96 (95% confidence interval 1.53 – 2.51, p < 0.001).70 In the same review, the pooled 
estimate of the relative risk for mortality, based on 15 studies with 2900 patients, was 
2.14 (95% confidence interval 1.83 – 2.51, p < 0.0001) for diabetic patients with CAN. 
Thus, it was estimated that the 5 year mortality rate is 5 times higher in diabetic patients 
with CAN compared to patients without evidence of CAN.69, 70 Therefore, early diagnosis 
and recognition of CAN is crucial as it may impact on the clinical decision making of 
these patients.
Diagnosis of CAN involves assessment of both parasympathetic and sympathetic ner-
vous system using a range of different tests. Assessment of parasympathetic nervous 
system includes the resting heart rate, beat-to-beat variation with deep breathing (E:I 
ratio), 30:15 heart rate ratio with standing, Valsalva ratio, and spectral analysis of heart 
rate variation.69 Assessment of sympathetic nervous system includes the resting heart 
rate, spectral analysis of heart rate variation, postural blood pressure, hand grip blood 
pressure, cold pressor response, sympathetic skin galvanic response, sudorometry, 
and cutaneous blood flow.69 However, all these tests are indirect assessments of the 
autonomic nervous system and are less sensitive than direct assessments by cardiac 
radionuclide imaging with SPECT or PET.71, 72
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Currently, SPECT and PET imaging are available for the assessment of cardiac sympa-
thetic adrenergic innervation and activation.72-74 Essentially, adrenergic nerve imaging 
is based on two principles; synthesis of false neurotransmitters (catecholamine analogs) 
or the labeling of true adrenergic neurotransmitters. Both techniques allow evaluation 
of abnormalities in cardiac sympathetic innervation by visualizing the uptake and stor-
age of radiolabeled neurotransmitters transported into the presynaptic nerve terminals.
123-iodine metaiodobenzylguanidine (123I MIBG) SPECT. Abnormalities in sympathetic 
innervation can be assessed using 123-iodine metaiodobenzylguanidine (123I MIBG), 
a norepinephrine analog that is taken up and accumulated in the presynaptic nerve 
terminals.68, 75, 76 Currently, 123I MIBG represents the most commonly used tracer in 
clinical cardiology to evaluate cardiac sympathetic innervation patterns.76 Planar and 
tomographic SPECT images are acquired 10-20 minutes (early) or 3-4 hours (late) after 
MIBG administration. From the planar images, semi-quantitative measurements such as 
heart-to-mediastinum (H/M) ratio and cardiac washout rate are used to evaluate global 
sympathetic innervation. SPECT images are used to assess regional abnormalities in 
sympathetic innervation as depicted in Figure 6. At present, several studies using 123I 
MIBG imaging have demonstrated the presence of global and regional abnormalities in 
sympathetic innervation in diabetic patients.68, 75, 77 Turpeinen and co-workers performed 
123I MIBG scintigraphy to evaluate regional abnormalities in sympathetic innervation 
pattern in 7 type 1 and 13 type 2 diabetic patients.77 Type 2 diabetic patients showed 
reduced 123I MIBG uptake in the inferoposterior segments compared to type 1 diabetic 
patients. However, conventional indirect measures of autonomic function by power 
spectral analysis of heart rate variability failed to detect any differences between the 2 
groups.
Nagamachi and co-workers subsequently evaluated the prognostic value of cardiac 
MIBG imaging by retrospectively evaluating 144 type 2 diabetic patients for the occur-
rence of cardiac events (arrhythmia, heart failure or acute myocardial infarction), and 
all-cause mortality.68 After a mean follow-up period of 7.2 ± 3.2 years, 17 (11.8%) patients 
experienced a cardiac event, of which 7 died. An additional 9 patients died due to non-
cardiac causes. On multivariate analysis, the presence of CAN (relative risk 6.75, 95% 
confidence interval 1.16 – 39.3, p = 0.03) was an independent predictor of cardiac events 
on follow-up. Similarly, the presence of CAN (relative risk 17.1, 95% confidence interval 
1.07 – 27.9, p = 0.04) and a reduced H/M ratio on delayed 123I MIBG imaging (relative 




Positron emission tomography. PET imaging is the only technique that permits abso-
lute quantification of myocardial sympathetic innervation pattern. Using carbon-11 me-
tahydroxyephedrine (11C HED) in PET imaging has the advantage of accurately detecting 
regional abnormalities in sympathetic innervation. Stevens and co-workers evaluated 
regional abnormalities in cardiac sympathetic innervation with 11C HED PET imaging 
in 29 diabetic patients and compared to 10 healthy subjects.72 The diabetic patients 
were categorized into the presence of mild or severe diabetic autonomic neuropathy. 
Using the absolute difference in tracer uptake of the myocardium, the extent of regional 
sympathetic denervation was expressed as the percentage of the LV in all subjects with 
diabetes. The study showed that the extent of regional sympathetic denervation was sig-
nificantly larger in patients with severe autonomic neuropathy as compared to patients 
with mild autonomic neuropathy (48 ± 19% vs. 6 ± 5%, p < 0.01). Furthermore, there was 
evidence of sympathetic dysinnervation with increased innervation in the basal myo-
cardial segments but decreased innervation in the apical myocardial segments (Figure 
7). Thus, this observed regional myocardial variation in sympathetic innervation and 
could contribute to myocardial electrical instability and potentially life-threatening ar-
rhythmias.
 
Figure 6. Sympathetic innervation as assessed with 123I MIBG SPECT imaging. Panel A: Example of a patient 
with normal sympathetic innervation on 123I MIBG SPECT imaging. Panel B: Example of a patient with regional 
abnormalities as assessed with 123I MIBG SPECT imaging (arrows).
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4. Coronary atherosclerosis
As previously alluded to, the presence of microvascular disease and endothelial dysfunc-
tion in diabetic patients are often the precursors of vascular atherosclerosis. Although 
the presence of significant coronary stenosis will result in myocardial dysfunction and 
is thus strictly not considered as “diabetic heart disease”, its prevalence in diabetic 
patients is higher than non-diabetics, and is associated with significant cardiovascular 
morbidity and mortality.78 Furthermore, the presence of coronary atherosclerosis with-
out significant luminal narrowing may not be entirely benign.79 Indeed, previous stud-
ies have demonstrated that myocardial infarction and unstable angina are frequently 
caused by coronary lesions deemed to be non-significant prior to the event.80, 81 Thus, it 
may be useful to identify and risk-stratify patients into normal coronary arteries without 
atherosclerosis, non-significant coronary artery disease, and significant coronary artery 
disease. At present, computed tomography (CT) techniques such as coronary artery cal-
cium (CAC) scoring and coronary CT angiography (CTA) are considered the most robust 
imaging techniques for non-invasive visualization of coronary atherosclerosis.
Coronary artery calcium scoring. CAC score can characterize the location and burden of 
coronary atherosclerosis by detecting calcium present within atherosclerotic plaques. 
Image acquisition for CAC scoring typically involves acquiring multiple, non-contrast, 
thick slice images of the entire heart. Using a cut-off value of greater than 130 Hounsfield 
units to define calcium, coronary calcifications can be identified as bright white struc-
tures on the CT images (Figure 8).
 
Figure 7. PET imaging of a patient with severe diabetic autonomic neuropathy. Top row: short and long axis 
images of the left ventricle showing normal blood flow as indicated by homogenous 13N NH3 tracer uptake. 
Bottom row: extensive abnormalities in 11C HED PET imaging. The basal myocardial segments showed exces-
sively high 11C HED retention suggestive of increased innervation, whereas there was decreased innervation 
in the apical myocardial segments as demonstrated by absent tracer uptake. Adapted with permission from 
Stevens et al., J Am Coll Cardiol 1998;31:1575-1584.
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Semi-quantification of coronary calcium is commonly expressed by the Agatston score, 
which uses the plaque size, density and a weighting factor to calculate a value ranging 
from 0 (absence of detectable calcium) to over 1000 (indicating the presence of exten-
sive coronary calcifications). Importantly, there is a clear relationship between the CAC 
score and the extent of coronary atherosclerosis, as well as the presence of significant 
coronary stenosis.82 However, the association between CAC score and extent of coronary 
atherosclerosis is not linear as severe coronary stenosis can occur at sites with limited 
calcium deposition. Likewise, extensive CAC scores can be observed in the absence of 
significant luminal narrowing. Thus, rather than being a diagnostic test for obstructive 
CAD, CAC scoring may be more valuable as a risk stratification tool to identify at-risk 
patients with underlying atherosclerosis who might benefit from further investigations.
In the general population, CAC scoring has indeed been shown to provide strong 
prognostic information. An elevated CAC score has consistently been associated with 
increased mortality and adverse cardiovascular events, independently of coronary risk 
factors.83 Similar findings have been observed in diabetic patients.84 In one of the largest 
series to date, Raggi et al. compared baseline CAC scores and outcomes among 9474 
non-diabetic and 903 diabetic patients.84 During a mean follow-up period of 5 years, CAC 
score was identified as the best predictor of all-cause mortality in both diabetic and 
non-diabetic individuals (Figure 9).
Moreover, further analysis revealed that for each level of CAC score, mortality was higher 
in diabetic patients compared to non-diabetics. Thus, CAC scoring may be a promis-
ing tool in identifying diabetic patients with increased likelihood of coronary events 
who might benefit from further functional evaluation and more aggressive, individu-
ally targeted preventive treatment strategies. Indeed, Anand and co-workers recently 
 
Figure 8. Example of a diabetic patient with extensive coronary calcification in all 3 coronary arteries. Total 
coronary calcium score was 1599. IM: intermediate branch; LAD: left anterior descending coronary artery; LCx: 
left circumflex artery; RCA: right coronary artery.
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demonstrated in 510 asymptomatic type 2 diabetic patients that while the incidence of 
ischemia was low in patients with no or limited CAC, the likelihood of ischemia increases 
with higher CAC scores (Figure 10).85
Coronary CT angiography. More detailed information on the coronary anatomy can be 
derived from non-invasive contrast-enhanced coronary CTA which permits direct visu-
alization of the coronary arteries (Figure 11). Particularly with the newer generations of 
multi-detector row CT scanners (64-slice and higher), high sensitivities and specificities 
can be obtained for the detection of significant coronary stenoses. Importantly, this high 
diagnostic accuracy has been shown to be maintained in the presence of diabetes.86, 87 
The advantage of this technique is the high negative predictive value which approaches 
100%. Notably, coronary CTA is also unlikely to miss severe coronary artery diseases 
such as left main or three-vessel diseases. Moreover, this technique allows identifica-
tion of coronary atherosclerotic plaques in the absence of calcium or stenosis, thus 
permitting visualization of early, subclinical atherosclerotic disease. To a limited extent, 
information on plaque composition can also be derived, although it is less precise and 
detailed as compared to invasive techniques such as intravascular ultrasound (IVUS) or 
optical coherence tomography.
 
Figure 9. Cox proportional hazards survival demonstrating significantly lower survival with increasing coronary 
artery calcium scores by electron beam computed tomography. Comparison of survival curves show that dia-
betic patients have significantly lower survival with each coronary artery calcium score category compared to 
non-diabetic patients. Adapted with permission from Raggi et al. J Am Coll Cardiol 2004;43:1663-1669.
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Using coronary CTA, Pundziute et al. recently demonstrated that diabetic patients have 
more extensive, diffuse coronary atherosclerosis compared to matched non-diabetic 
patients.88 Interestingly, this increased plaque burden was mainly attributable to an 
increased number of non-obstructive lesions, while the incidence of significant stenosis 
was similar amongst both populations. In a smaller population, these observations were 
later confirmed by the same group using MSCT and invasive plaque imaging with grey-
scale and virtual histology IVUS (VH IVUS) (Figure 12).89
 
Figure 10. Relationship between the extent of coronary calcification and the prevalence/severity of myocar-
dial perfusion abnormality. Increasing coronary artery calcium score was associated with both an increased 
incidence of perfusion abnormalities, and larger perfusion defects. Adapted with permission from Anand et 
al. Eur Heart J 2006;27:713-721.
 
Figure 11. Evaluation of coronary artery disease with coronary CT angiography in patients with type 2 diabe-
tes. Panel A: curved multiplanar reformation (cMPR) of the left anterior descending coronary artery without 
any evidence of atherosclerosis. Panel B: cMPR of the right coronary artery revealing diffuse atherosclerosis 
in the absence of significant stenosis. Panel C: cMPR of the left anterior descending coronary artery revealing 
extensive atherosclerosis with multiple significant ( > 50% luminal narrowing) lesions.
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Diabetic patients had significantly higher plaque burden and more calcified lesions 
than non-diabetics.89 In another study composed of 80 asymptomatic type 2 diabetic 
patients, Ambrose and co-workers compared CAC scoring and CTA and demonstrated 
that CTA may reveal substantial plaque burden even in patients with zero or low CAC 
scores (Figure 13).90 Thus, coronary CTA may be more accurate in evaluating the pres-
ence and extent of coronary atherosclerosis in diabetic patients compared to CAC 
scoring. Preliminary results suggest that CTA has an incremental prognostic information 
over baseline clinical variables in both diabetic and non-diabetic patients.91
5. Myocardial structural changes with fibrosis
Although the etiology of diabetic heart disease is multifactorial, the final common path-
way is accelerated myocyte apoptosis, formation of advanced glycation end-products, 
and development of interstitial fibrosis.92-94 Several animal and human studies have 
demonstrated increased interstitial fibrosis in diabetic patients.92-94 These structural 
changes lead to increased LV stiffness, impaired systolic and diastolic function, and ul-
timately the development of clinical heart failure. As such, both echocardiography and 
MRI can be used to detect and quantify myocardial fibrosis.
 
Figure 12. Example of coronary atherosclerosis in a 
type 2 diabetic patient as demonstrated by coronary 
CTA (Panel A), gray-scale intravascular ultrasound 
(IVUS, Panel B), and virtual histology IVUS (VH IVUS, 
Panel C). Panel A: Curved multiplanar reformation of 
the right coronary artery by CTA demonstrated dif-
fuse atherosclerosis along the course of the artery, 
and a mixed plaque was observed in the proximal 
part of the artery in both longitudinal and transverse 
images. Panel B: The presence of diffuse atheroscle-
rosis was confirmed in longitudinally reconstructed 
IVUS image. Panel C: Corresponding VH IVUS image 
at the minimal luminal area site of the atheroscle-
rotic plaque, demonstrating the features of a fibro-
calcific plaque. Fibrous areas were marked in green, 
fibro-fatty in yellow, calcium in white and necrotic 
core in red. Adapted with permission from Pundziute 
et al., J Nucl Cardiol 2009;16:376-383.
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Echocardiographic integrated backscatter. Integrated backscatter analysis using 
2-dimensional echocardiography has been used to non-invasively evaluate myocar-
dial fibrosis.95 The increased deposition of collagen alters the ultrasound reflectivity 
(backscattering) of the myocardial tissue and previous study has demonstrated a linear 
correlation between the myocardial backscatter magnitude and the amount of fibrosis 
content on histology.95 The measurement of myocardial integrated backscatter is usu-
ally performed in the parasternal long-axis view by placing a region of interest in the 
interventricular septum and the posterior wall (Figure 14). The value of myocardial in-
tegrated backscatter obtained at end-diastole is corrected by the integrated backscatter 
value of the pericardium, thereby providing the calibrated integrated backscatter value.
In diabetic patients without hypertension or coronary artery disease, the myocardial 
ultrasound reflectivity is significantly increased compared to healthy age matched con-
trols, suggesting the presence of increased myocardial fibrosis.96 This observation was 
later confirmed by Fang and co-workers, who included 48 diabetic patients without 
coronary artery disease and normal LVEF, 45 diabetic patients with left ventricular hy-
pertrophy, 45 patients with only left ventricular hypertrophy and 48 normal controls.97 
Calibrated integrated backscatter at the interventricular septum and posterior wall were 
significantly higher in the three groups of patients as compared to controls. Furthermore, 
diabetic patients with concomitant LV hypertrophy had the highest calibrated integrated 
 
Figure 13. Bar graph demonstrating the distribution of both obstructive and non-obstructive coronary artery 
disease per coronary artery calcium score category in asymptomatic type 2 diabetic patients. Diabetic pa-
tients can have significant plaque burden despite zero or low ( < 10) calcium score. Adapted with permission 
from Scholte et al. Heart 2008;94:290-295.
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backscatter value (Figure 14). Similar trends were observed in the LV myocardial func-
tion as determined by tissue Doppler-derived strain analyses. Therefore, the presence 
of subclinical myocardial dysfunction in diabetic heart disease is associated with the 
presence of increased myocardial fibrosis. This observation of increased myocardial 
fibrosis was in concordance with histological studies of diabetic hearts without signifi-
cant coronary disease that showed increased collagen deposition in the perivascular 
and interstitial regions.94, 98, 99
Magnetic resonance imaging. Currently, MRI with delayed contrast enhancement 
(DCE) is the gold standard for non-invasive visualization of myocardial scar tissue. This 
technique is based on an inversion recovery pulse sequence and delayed imaging of the 
heart at approximately 10 – 20 minutes after administration of gadolinium-based con-
trast agents. Due to the chemical charge and molecular size of these gadolinium-based 
contrast agents, they rapidly diffuse from the intravascular to extracellular space, but do 
 Figure 14. Evaluation of myocardial fibrosis with integrated backscatter. From LV parasternal long-axis view 
(panel A), the ultrasound reflectivity or integrated backscatter of the myocardium is measured at the inter-
ventricular septum and posterior wall, and corrected for the pericardial integrated backscatter value.
Compared to normal controls, diabetic patients and non-diabetic patients with LV hypertrophy had signifi-
cantly lower longitudinal peak strain and higher myocardial integrated backscatter value. However, diabetic 
patients with LV hypertrophy had the highest myocardial integrated backscatter with the lowest longitudi-
nal peak strain. PS: cIB: calibrated integrated backscatter; CON: control; DH: diabetic patients with left ven-
tricular hypertrophy; DM: diabetic patients; LVH: patients with left ventricular hypertrophy; PS: peak strain. 
Adapted with permission from Fang et al. J Am Coll Cardiol 2003;41:611–7.
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not enter the intracellular space. Consequently, contrast accumulates within infarcted or 
scarred myocardial tissues. By selecting an appropriate inversion time to “null” normal 
myocardium, scar tissue will appear as bright hyperenhanced regions (Figure 15). The 
ability of MRI DCE to accurately depict scar tissue has been previously validated.100 In the 
seminal paper by Kim et al., ex-vivo DCE images were displayed next to histopathologi-
cal specimens of infarcted myocardial tissues, providing compelling evidence that the 
extent of delayed enhancement on MRI corresponded to histopathological infarct size.100
Kwong and co-workers demonstrated the prognostic value of identifying DCE in a cohort 
of 107 diabetic patients without previous clinical history of myocardial infarction.101 
The presence of DCE, indicative of silent myocardial infarction, was associated with 
significantly higher all-cause mortality compared to diabetic patients without DCE (log 
rank p = 0.02). On multivariate analysis, the presence of DCE was the strongest inde-
pendent predictor of major adverse cardiac outcomes (combination all-cause mortality, 
new acute myocardial infarction, hospitalization for unstable angina or heart failure, 
ventricular arrhythmias requiring implantable cardiac defibrillators, and acute cerebro-
vascular accidents) and all-cause mortality.
b) IMaGInG LefT VenTRICULaR MYoCaRDIaL DYsfUnCTIon In 
DIabeTIC HeaRT DIsease
Although the etiology of diabetic heart disease is diverse and a source of on-going 
research, patients eventually develop evidence of increased myocardial fibrosis.102 
These structural changes result in increased LV stiffness and impairment of diastolic and 
systolic performance. Although it is not a prerequisite for patients to have preexisting 
diabetic heart disease in order to develop heart failure, the presence of diabetic heart 
 
Figure 15. Examples of MRI delayed contrast-enhanced images. Panel A: normal study without evidence of de-
layed enhancement. Note that the normal myocardium appears black due to nulling by the inversion recovery 
pulse sequence. Panel B: non-transmural scarring in the anteroseptal and anterior segments appearing as 
white hyperenhanced regions indicative of previous subendocardial infarction in the left anterior descending 
artery territory. Panel C: transmural scarring in the septal, anteroseptal and anterior walls.
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disease increases the risk for subsequent development of heart failure. Thus, early 
detection of diabetic heart disease may permit early treatment and prevention of heart 
failure progression.
Currently, diagnosis of diabetic heart disease requires the demonstration of myocardial 
dysfunction that is independent of other causes such as significant coronary stenosis or 
hypertension. Thus, in diabetic patients with overt heart failure symptoms, the presence 
of echocardiographic features of LV dysfunction without other explanatory causes is 
often confirmatory for the diagnosis of diabetic cardiomyopathy. However, non-invasive 
imaging is usually required for the diagnosis of diabetic heart disease in patients with-
out clinical signs and symptoms of heart failure. Often, echocardiography is utilized to 
demonstrate LV diastolic and systolic dysfunction in diabetic heart disease.
1. Diastolic function
Traditionally, LV diastolic function is categorized into normal, impaired relaxation, 
pseudonormal and restrictive filling patterns based on transmitral flow on echocardiog-
raphy. These filling patterns occur sequentially with progressively worsening LV diastolic 
function. However, the interpretation of transmitral inflow pattern is severely hampered 
by its load- and age-dependency, and is also influenced by other factors such as atrial 
and ventricular compliance, mitral valve competency and left atrial pressures.103
With the advent of tissue Doppler imaging, quantification of longitudinal myocardial ve-
locities has significantly simplified the interpretation of LV diastolic function (Figure 16). 
Previous studies have demonstrated that the peak early diastolic e’ velocity correlated 
significantly with the time constant of LV isovolumic relaxation (Tau), the gold standard 
of LV diastolic function.104, 105 Transmitral inflow goes through a pseudonormalized 
pattern which can potentially be misinterpreted as normal, early diastolic e’ velocity 
progressively declines with worsening LV diastolic function. However, tissue Doppler 
myocardial velocity imaging may be influenced by the passive translational motion and 
tethering effects from surrounding myocardial tissues. In contrast, myocardial strain 
and strain rate imaging permits site-specific quantification of active myocardial defor-
mation that is independent of the translational motion and tethering artifacts.106 Using 
strain rate imaging, LV diastolic function could be quantified by strain rate e’ (Figures 
17 and 18).107 More recently, newer sophisticated echocardiographic techniques such 
as 2-dimensional speckle tracking have also been used to evaluate LV diastolic function 
(Figure 19).108-110 Unlike tissue Doppler imaging, 2-dimensional speckle tracking is angle 





Figure 16. Example of pulsed wave tissue Doppler trace at the lateral mitral annulus. The cardiac cycle is 
presented by s’ during systole, followed by early diastolic relaxation (e’) and late diastolic atrial contraction 
(a’) during diastole. LV systolic and diastolic function can be quantified by the peak s’ (9.8 cm/s) and peak e’ 
(15.2 cm/s) velocities respectively.
 
Figure 17. Example of strain rate tracing derived from color-coded tissue Doppler imaging of the mid septum. 
Similar to myocardial velocity imaging, myocardial strain rate can be divided into systolic (s’), early diastolic 
(e’), and late diastolic atrial (a’) contractions. Myocardial systolic and diastolic function can be quantified 
by the peak s’ (-0.84 s-1) and e’ (1.40 s-1) strain rates respectively. AVO: aortic valve opening; AVC: aortic valve 
closure.
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The most frequent finding in an asymptomatic patient with diabetic heart disease is 
diastolic dysfunction with normal LVEF. Even in well-controlled, normotensive and as-
ymptomatic type 2 diabetic patients, the prevalence of diastolic dysfunction is reported 
to be up to 47% of patients, of which 30% had impaired relaxation and 17% had pseudo-
normalized filling pattern.111 However, newer and more sophisticated echocardiographic 
techniques such as tissue Doppler or 2-dimensional speckle tracking imaging are more 
sensitive in identifying subtle myocardial dysfunctions.109, 112-114 For example, using 
tissue Doppler imaging, Fang and co-workers determined that subclinical LV diastolic 
dysfunction was present in 21% of type 2 diabetic patients.114 This was in contrast to 
standard echocardiographic parameters such as transmitral inflow pattern, decelera-
tion time and isovolumic relaxation time, which failed to identify subclinical diabetic 
heart disease. However, as the definition of significant subclinical LV dysfunction in that 
study was based on greater than 1 standard deviation less than the mean normal value 
derived from healthy controls, the true incidence of diabetic heart disease diagnosed 
with tissue Doppler imaging is likely to be significantly higher.114 Accordingly, Boyer and 
co-workers demonstrated that using a mitral annular velocity of < 8cm/s identified up to 
63% of diabetic patients as having evidence of diastolic dysfunction.112
 
 
Figure 18. Examples of tissue Doppler derived strain rate and strain in a type 2 diabetic patient (Panels A and 
B respectively) and a normal healthy control (Panels C and D). Both the diabetic patient and normal control 
had comparable left ventricular ejection fraction (63% versus 66% respectively). However, the diabetic patient 
had significantly lower basal septal peak systolic strain rate and strain (-0.72 s-1 and -15.8% respectively, ar-
rows) by tissue Doppler imaging compared to the normal healthy control (-1.50 s-1 and -19.9% respectively, 




Traditionally, the clinical standard in the assessment of global LV systolic function is 
primarily based on the quantification of LV chamber volumes to derive LVEF. Although 
quantification of systolic function by LVEF is easily understandable and reasonably 
reproducible, it is highly dependent in preload and afterload. Due to the relative insen-
sitivity of LVEF in detecting subtle myocardial dysfunction, demonstrating LV systolic 
dysfunction in diabetic patients has been more difficult. In contrast, myocardial velocity, 
strain and strain rate imaging are more sensitive systolic markers than LVEF. Similarly, 
quantification of systolic function by myocardial velocity (Figure 16), strain and strain 
rate imaging (Figures 17-19) has been shown to be significantly correlated with global LV 
systolic function.106, 115-117
Previous studies have demonstrated subclinical myocardial systolic dysfunction in 
diabetic patients.97, 109, 113, 118, 119 Using color-coded tissue Doppler imaging, Fang and 
co-workers demonstrated reduced myocardial longitudinal systolic function in diabetic 
patients compared to age-matched controls.113 In that study, diabetic patients had sig-
nificantly lower peak systolic strain rate compared to controls (1.4 ± 0.3 s-1 vs. 1.6 ± 0.3 
 
Figure 19. Examples of 2-dimensional speckle tracking strain and strain rate in the same diabetic patient and 
normal control. The diabetic patient had significantly lower peak global systolic strain rate and strain (-0.69 
s-1 and -16.3% respectively, arrows) by 2-dimensional speckle tracking compared to the normal control (-1.22 
s-1 and -20.1% respectively, arrows). AVC: aortic valve closure.
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s-1, p = 0.006), suggesting the presence of subtle myocardial contractile dysfunction de-
spite normal LVEF. Similarly, Galderisi and co-workers examined the value of myocardial 
systolic velocity and strain rate during dobutamine stress echocardiography in 24 dia-
betic patients and 16 normal controls.119 The group demonstrated that diabetic patients 
had evidence of reduced myocardial contractile reserve compared to non-diabetics. 
Therefore, tissue Doppler imaging is more sensitive than conventional LVEF in detecting 
subclinical myocardial systolic dysfunction. More recently, Ng and co-workers utilized 
2-dimensional speckle tracking echocardiography to compare type 2 diabetic patients 
with normal healthy controls.109 Despite all the diabetic patients having good glycemic 
control and asymptomatic without evidence of diabetic complications, coronary 
artery disease and hypertension, 2-dimensional speckle tracking was able to identify 
significant subclinical LV dysfunction compared to the controls.109 Diabetic patients had 
significantly lower global longitudinal strain (-18.3 ± 2.2% vs. -19.9 ± 1.9%, p < 0.001) 
and systolic strain rate (-0.99 ± 0.17 s-1 vs. -1.07 ± 0.13 s-1, p = 0.009) compared to healthy 
controls.109
3. Regional differences in myocardial dysfunction in diabetic heart 
disease
The LV myocardial architecture is a complex array of longitudinally and circumferentially 
orientated fibres located predominately in the epicardium/endocardium and mid-wall 
respectively.120 Newer and more sophisticated echocardiographic techniques allow 
site-specific and multidirectional assessments of myocardial strain and strain rate, 
thereby permitting exploration of regional differences in myocardial functional changes 
in subclinical diabetic heart disease. Using color-coded tissue Doppler imaging, both 
Fang et al. and Vinereanu et al. demonstrated reduced longitudinal myocardial function 
with a compensatory increase in radial function.113, 118 Similarly, using multidirectional 
speckle tracking analyses, Ng and co-workers demonstrated reduced longitudinal strain 
and strain rate (predominantly derived from epicardial/endocardial fibre contraction) 
but preserved circumferential and radial strains and strain rates (predominantly derived 
from mid-wall circumferential fibres contraction) in asymptomatic diabetic patients.109 
These findings suggest that myocardial dysfunction in early diabetic cardiomyopathy 
may start in the subendocardium, and the preservation of circumferential and radial 
functions account for the initial preservation of LV volumes and EF.
C) ConCLUsIons
Over the last few decades, there is increasing recognition that diabetic heart disease is 
a real disease entity rather than a nebulous concept, supported by evidence from epi-
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demiological and experimental studies that demonstrated an independent association 
between diabetes and heart failure. Numerous studies have explored the underlying 
pathophysiological mechanisms triggering the disease onset and progression to overt 
clinical heart failure. However, the etiology of diabetic heart disease remains unclear 
and is likely to be multifactorial, such as altered myocardial metabolism, endothelial 
dysfunction, autonomic neuropathy, coronary atherosclerosis and increased myocardial 
fibrosis. Multimodality imaging including echocardiography, nuclear imaging, CT and 
MRI all provide valuable insights into the disease process. In addition, cardiac imaging is 
essential for diagnosing diabetic heart disease by demonstrating LV myocardial dysfunc-
tion that is independent of significant coronary artery disease and hypertension. Finally, 
multimodality cardiac imaging may be useful for monitoring disease progression and 
evaluate the effectiveness of medical interventions.
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background: Regional left ventricular (LV) myocardial functional changes in early dia-
betic cardiomyopathy are not well documented.
Methods: LV multidirectional strain and strain rate (SR) analyses by 2D speckle tracking 
were utilized to detect subtle myocardial dysfunction in 47 asymptomatic, male patients 
(57 ± 6years) with type 2 diabetes mellitus. Results were compared to 53 male controls 
matched by age, body mass index and body surface area.
Results: There were no differences in LV end-diastolic volume index (40.7 ± 8.9 vs. 44.1 ± 
7.8mL/m2, p = ns), end-systolic volume index (16.0 ± 4.8 vs. 17.8 ± 4.3mL/m2, p = ns), ejec-
tion fraction (61.0 ± 5.5 vs. 59.8 ± 5.3%, p = ns). Transmitral E/A (0.95 ± 0.21 vs. 1.12 ± 0.32, 
p = 0.007) and pulmonary S/D ratios (1.45 ± 0.28 vs. 1.25 ± 0.27, p = 0.001) were more 
impaired in diabetic patients.  Importantly, diabetic patients had impaired longitudinal 
but preserved circumferential and radial systolic and diastolic function. Diabetes mel-
litus was an independent predictor for longitudinal strain, systolic SR and early diastolic 
SR on multiple linear regression analysis (all p < 0.001).
Conclusion: LV longitudinal systolic and diastolic functions were impaired but circum-
ferential and radial functions were preserved in uncomplicated type 2 diabetic patients.
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InTRoDUCTIon
Diabetic cardiomyopathy is defined as left ventricular (LV) dysfunction that occurs 
independently of coronary artery disease and hypertension.1 The pathogenesis of 
diabetic cardiomyopathy is likely to be multifactorial, including microvascular disease, 
altered myocardial metabolism, and altered myocardial structure with fibrosis. Patients 
with early diabetic cardiomyopathy often have evidence of global diastolic dysfunc-
tion but preserved systolic function as reflected by a normal LV ejection fraction (EF).2 
Compared to LVEF, myocardial velocity, strain and strain rate (SR) analyses are more 
sensitive indices of LV function and have been demonstrated to be abnormal in diabetic 
patients.3-8 However, these studies often included patients with diabetic complications 
or associated co-morbidities which may introduce important biases on LV functional 
evaluation.3-8 Currently, there is no extensive information on the effects of diabetes mel-
litus on LV mechanics. Thus, we evaluated multidirectional LV myocardial systolic and 
diastolic functions in a group of truly uncomplicated, normotensive, diabetic patients 
using 2-dimensional (2D) speckle tracking echocardiography.
MeTHoDs
Forty-seven patients with type 2 diabetes mellitus were recruited in this study. The 
inclusion and exclusion criteria for all the diabetic patients have previously been re-
ported.2 Briefly, women were not recruited to avoid possible confounding influences 
of gender and plasma estrogen levels on lipid metabolism and myocardial triglyceride 
accumulation. Inclusion criteria for all diabetic patients included: 1) Type 2 diabetes 
mellitus diagnosed according to World Health Organization criteria9 and treated with 
sulfonylurea derivatives in stable doses, 2) HbA1c below 8.5%, and 3) resting blood pres-
sure < 150/85 mmHg, with or without antihypertensive medication. In addition, as an 
inclusion criterion, the presence of myocardial ischemia was excluded in all patients by 
a negative high-dose dobutamine stress echocardiogram.2 Exclusion criteria included 
known cardiovascular disease or diabetes related complications including proliferative 
retinopathy, autonomic neuropathy as excluded by Ewing’s tests10, and microalbumin-
uria as excluded by measurements of albumin/creatinine ratio in a urine sample.
Fifty-three male control subjects recruited were frequency matched for age, body mass 
index and body surface area (BSA). All control subjects had normal physical examina-
tions and normal echocardiograms. Exclusion criteria for the control subjects included 
history of diabetes mellitus, smoking, hypertension and cardiomyopathy. The insti-




Transthoracic echocardiography was performed with the subjects at rest using commer-
cially available ultrasound transducer and equipment (M3S probe, Vivid 7, GE-Vingmed, 
Horten, Norway). All images were digitally stored on hard disks for offline analysis 
(EchoPAC version 07.00, GE-Vingmed, Horten, Norway). A complete 2D, color, pulsed 
and continuous-wave Doppler echocardiogram was performed according to standard 
techniques.11, 12 Left ventricular mass index was calculated from 2D echocardiographic 
measurements using the area-length formula at end-diastole 13, and corrected for BSA.14 
LV end-diastolic volume index (EDVI) and end-systolic volume index (ESVI) were calculated 
using Simpson’s biplane method of discs and corrected for BSA. LVEF was calculated and 
expressed as a percentage.
Mitral inflow and pulmonary venous velocities were recorded using conventional 
pulsed-wave Doppler echocardiography in the apical 4 chamber view using a 2 mm 
sample volume. Transmitral early (E wave) and late (A wave) diastolic velocities as well 
as deceleration time were recorded at the mitral leaflet tips. LV isovolumic relaxation 
time was also recorded. The pulmonary venous peak systolic (S) and diastolic (D) veloci-
ties were recorded with the sample volume positioned 1 cm below the orifice of the right 
superior pulmonary vein in the left atrium. Septal E/E’ ratio was determined using color-
coded tissue Doppler imaging (frame rates > 100 frames/sec) with the sample volume 
placed in the basal septum.
2D speckle tracking analyses were performed on grey scale images of the LV obtained 
in the apical 2-, 3- and 4-chamber views and short-axis mid-ventricular views. Left 
ventricular radial and circumferential functions were determined in the mid-ventricular 
short-axis view, and longitudinal function was determined in the 3 apical views. During 
analysis, the endocardial border was manually traced at end-systole and the region of 
interest width adjusted to include the entire myocardium. The software then automati-
cally tracks and accepts segments of good tracking quality and rejects poorly tracked 
segments, while allowing the observer to manually override its decisions based on visual 
assessments of tracking quality. Peak systolic strain, peak systolic SR (SR Sm) and peak 
early diastolic SR (SR Em) for the 3 orthogonal myocardial functions were determined. 
Mean global longitudinal strain/SR were calculated from the 3 individual apical global 
longitudinal strain/SR curves respectively whereas mean global circumferential strain/
SR and mean radial strain/SR were obtained from the mid-ventricular short-axis view. 
All strain and SR measurements were exported to a spreadsheet (Microsoft ® Excel 2002, 
Microsoft Corporation, Redmond, WA).
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To define intra- and inter-observer variability, strain and SR measurements were re-
peated for 10 randomly selected patients at least 4 weeks apart by the same observer on 
the same echocardiographic images, and by a second independent observer.
statistical analysis
Continuous variables were presented as mean ± 1 SD unless otherwise stated. Unpaired 
Student’s t test and Mann-Whitney U test were used to compare 2 groups of unpaired 
data of Gaussian and non-Gaussian distribution respectively. Multivariate linear regres-
sion analysis (enter method) was used to identify independent clinical determinants of 
LV strain/SR. To avoid multicolinearity between the univariate predictors, a tolerance of 
> 0.5 was set. Intra- and inter-observer variability of strain and SR measurements by 2D 
speckle tracking were expressed as mean absolute differences and assessed by Bland-
Altman analysis.15 A 2-tailed p value of < 0.05 was considered significant. All statistical 
analyses were performed using SPSS for Windows (SPSS Inc, Chicago), version 16.
ResULTs
The mean age, body mass index and body surface area were 57.1 ± 6.2 years, 27.0 ± 
3.1 kg/m2, and 2.07 ± 0.18 m2 respectively, and there were no significant differences be-
tween diabetic patients and controls (Table 1). The median diabetes mellitus diagnosis 
duration was 4 years (range 1 to 11 years), and the mean HbA1c level was 6.4 ± 0.7%. Al-
though there was no evidence of autonomic neuropathy in the patients as documented 
by Ewing’s test, the mean heart rate and systolic blood pressure of the diabetic patients 
was increased relative to the controls.
Table 1.  Clinical Parameters in Patients with Diabetes and Healthy Subjects






Age (years) 58.0 ± 5.5 56.2 ± 6.6 NS
Body mass index (kg/m2) 27.6 ± 3.2 26.4 ± 3.0 NS
Body surface area (m2) 2.10 ± 0.18 2.05 ± 0.18 NS
Mean heart rate (beats/min) 72.5 ± 10.5 65.8 ± 8.2 0.001
Systolic blood pressure (mmHg) 137 ± 11 128 ± 13  < 0.001
Medications
Beta blockers (%) 2.1 - -
Calcium channel antagonist (%) 6.4 - -
Angiotensin converting enzyme inhibitors (%) 27.7 - -
Angiotensin receptor blocker (%) 12.8 - -
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Table 2 outlines the echocardiographic parameters. There were no significant differ-
ences in the indexed LV volumes and EF between the diabetic patients and healthy con-
trols. Transmitral E/A and pulmonary S/D ratios were significantly impaired in diabetic 
patients as compared to controls. There was also no significant difference in septal E/E’ 
ratio between diabetic patients and healthy controls.
The mean frame rates for the apical and short-axis views were 82.3 ± 18.2 and 90.0 ± 19.5 
frames/s respectively. Compared to healthy controls, diabetic patients had significantly 
impaired longitudinal systolic and diastolic strain and SR, but preserved circumferential 
and radial strains and SR (Table 2).
To investigate the independent clinical determinants of LV longitudinal strain, SR Sm 
and SR Em, multivariate linear regression analyses were performed with age, body 
mass index, mean heart rate, systolic blood pressure and presence of diabetes mellitus 
Table 2.  Echocardiographic Parameters in Patients with Diabetes and Healthy Subjects





Left ventricular mass index (g/m2) 87.4 ± 13.8 83.9 ± 15.6 NS
Left ventricular end-diastolic volume index (mL/m2) 40.7 ± 8.9 44.1 ± 7.8 NS
Left ventricular end-systolic volume index (mL/m2) 16.0 ± 4.8 17.8 ± 4.3 NS
Left ventricular ejection fraction (%) 61.0 ± 5.5 59.8 ± 5.3 NS
Doppler
Transmitral E/A ratio 0.95 ± 0.21 1.12 ± 0.32 0.007
Deceleration time (ms) 192.2 ± 37.5 196.1 ± 39.3 NS
Isovolumic relaxation time (ms) 83.3 ± 13.9 84.6 ± 19.9 NS
Pulmonary S/D ratio 1.45 ± 0.28 1.25 ± 0.27 0.001
Septal E/E’ ratio 9.21 ± 1.80 8.50 ± 1.96 NS
Longitudinal function
Mean global strain (%) -18.3 ± 2.2 -19.9 ± 1.9  < 0.001
Mean global systolic strain rate (s-1) -0.99 ± 0.17 -1.07 ± 0.13 0.009
Mean global early diastolic strain rate (s-1) 1.04 ± 0.25 1.26 ± 0.26  < 0.001
Circumferential function
Global strain (%) -22.7 ± 2.9 -23.0 ± 3.2 NS
Global systolic strain rate (s-1) -1.40 ± 0.28 -1.37 ± 0.23 NS
Global early diastolic strain rate (s-1) 1.79 ± 0.46 1.99 ± 0.61 NS
Radial function
Mean strain (%) 40.6 ± 11.1 42.7 ± 12.1 NS
Mean systolic strain rate (s-1) 1.71 ± 0.45 1.80 ± 0.48 NS
Mean early diastolic strain rate (s-1) -1.98 ± 0.57 -2.14 ± 0.70 NS
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entered as covariates (Table 3). The presence of diabetes mellitus was an independent 
correlate of longitudinal strain (multiple R = 0.496, p = 0.001), SR Sm (multiple R = 0.612, 
p < 0.001) and SR Em (multiple R = 0.552, p < 0.001) on all the linear regression models.
Intra- and inter-observer variabilities for the myocardial strain and SR measurement 
were evaluated (Table 4). Assessments of LV longitudinal strain/SR had the lowest intra- 
and inter-observer measurement variability compared to assessments of circumferential 
and radial strains/SR. Bland and Altman analysis showed small biases with no significant 
trend for all the intra- and inter-observer strain and strain rate measurements.
Table 3.  Independent Correlates of Global Longitudinal Strain, Global Longitudinal Systolic Strain Rate, and 







β p value β p value β p value
Age (years) -0.216 0.052 -0.095 0.341 -0.129 0.223
Body mass index (kg/m2)  0.118 0.272  0.129 0.189 -0.153 0.140
Mean heart rate (beats/min) -0.232 0.038 -0.551  < 0.001  0.167 0.118
Systolic blood pressure 
(mmHg)
-0.055 0.638 -0.084 0.429 -0.053 0.637
Presence of diabetes  0.508  < 0.001  0.513  < 0.001 -0.477  < 0.001
Table 4.  Intra-observer and Inter-observer Variability of Left Ventricular Strain and Strain Rate Measurements
Variable Intra-observer Inter-observer
absolute Difference absolute Difference
Longitudinal function
Mean global strain (%) 1.2 ± 0.5 0.9 ± 1.0
Mean global systolic strain rate (s-1) 0.10 ± 0.06 0.09 ± 0.08
Mean global early diastolic strain rate (s-1) 0.08 ± 0.05 0.13 ± 0.09
Circumferential function
Global strain (%) 1.2 ± 1.0 2.3 ± 2.4
Global systolic strain rate (s-1) 0.08 ± 0.08 0.16 ± 0.09
Global early diastolic strain rate (s-1) 0.31 ± 0.27 0.39 ± 0.45
Radial function
Mean strain (%) 4.3 ± 2.3 6.5 ± 5.4
Mean systolic strain rate (s-1) 0.27 ± 0.18 0.34 ± 0.24




The present study demonstrated the presence of subclinical myocardial systolic and dia-
stolic dysfunctions in type 2 diabetic patients with no diabetic related complications and 
good glycemic control. Despite normal LV mass, volumes and EF, the diabetic population 
showed impairments of LV longitudinal strain and SR but preserved circumferential and 
radial strain and SR. The presence of diabetes mellitus was an independent predictor of 
LV longitudinal strain, systolic SR and diastolic SR on multiple linear regression analysis.
The pathogenesis of diabetic cardiomyopathy is likely to be multifactorial, ranging 
from microvascular disease, altered myocardial metabolism, and structural changes 
in the myocardium with increased fibrosis. Increasingly, evidence is emerging on the 
role of myocardial lipotoxic injury from lipid oversupply. Visceral adipose tissue insulin 
resistance leads to increased myocardial fatty acid delivery and uptake with associated 
myocardial triglyceride accumulation.16, 17  It is assumed that the subsequent accumula-
tion of fatty acid intermediates is associated with mitochondrial dysfunction, leading to 
cell damage, apoptosis, replacement with fibrosis and myocardial contractile dysfunc-
tion.17 Recent studies have evaluated the relationship between increased myocardial 
steatosis and LV dysfunction in patients with type 2 diabetes mellitus.2, 18 Rijzewijk et al 
demonstrated diastolic dysfunction in a group of uncomplicated diabetic patients with 
documented myocardial steatosis on magnetic resonance spectroscopy.2 In contrast, 
McGavock et al showed no association between myocardial triglyceride accumulation 
and LV function in a heterogeneous group of diabetic patients.18 Of note, their results 
could be influenced by the use of insulin (a lipogenic agent) and the presence of un-
diagnosed coronary artery disease in their patient population, whereas Rijzewijk et al 
excluded patients with potential confounding comorbid conditions such as hyperten-
sion and coronary artery disease (excluded by dobutamine stress echocardiography). 
2, 18 Both studies demonstrated normal global systolic function as reflected by a normal 
LVEF. Similarly, the present study demonstrated the presence of diastolic dysfunction 
(indicated by significantly greater impairments of transmitral E/A and pulmonary S/D 
ratios) but preserved global LVEF in diabetic patients compared to normal controls.
Previous epidemiological studies have demonstrated increased prevalence of diabetes 
mellitus in heart failure populations, and this increased prevalence is seen particularly 
in heart failure patients with normal LVEF.19 However, LVEF is a relatively insensitive 
measure of LV systolic function compared to strain and strain rate imaging, especially 
in the context of subclinical LV systolic dysfunction.3-8 As the LV myocardial architecture 
is a complex array of longitudinally and circumferentially orientated fibres located 
predominately in the epicardium/endocardium and mid-wall respectively20, multidirec-
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tional analyses of longitudinal, circumferential and radial function allow understanding 
of regional LV myocardial functional changes in subclinical diabetic heart disease.
Both Fang et al and Vinereanu et al demonstrated decreased LV longitudinal function 
but compensatory increase in radial function in diabetic patients.3, 4 However, due to 
the angle limitations associated with tissue Doppler imaging, both studies could only 
assess the impact of diabetes mellitus on LV longitudinal and radial functions in a few 
limited myocardial segments, and circumferential myocardial function was not evalu-
ated. Using 2D speckle tracking to assess all myocardial segments, the present study 
demonstrated reduced longitudinal strain and SR (predominantly derived from epicar-
dial/endocardial fibre contraction) but preserved circumferential and radial strains and 
SR (predominantly derived from mid-wall circumferential fibres contraction) in diabetic 
patients. This finding suggests that myocardial dysfunction in early diabetic cardio-
myopathy may start in the subendocardium. On multivariate analysis, the presence of 
diabetes mellitus was an independent predictor of impaired longitudinal strain and SR 
in this unique group of truly uncomplicated type 2 diabetic patients.
ConCLUsIon
The novel aspect of the current study is the multidirectional strain and SR analysis by 
2D speckle tracking in patients with uncomplicated type 2 diabetes mellitus. The associ-
ated myocardial systolic and diastolic dysfunction detected on echocardiography was 
independent of age, body mass index and blood pressure. However, current 2D speckle 
tracking analysis cannot take into account “through plane” cardiac motion and that may 
influence the absolute strain/SR values. Furthermore, the exclusion of women in the 
study limits its generalizability. However, the widespread availability of echocardiogra-
phy and ease of use with 2D speckle tracking may allow serial assessments of patients 
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background: Diabetes and obesity are both a world-wide growing epidemic, and both 
are independently associated with an increased risk for heart failure and death. We 
aimed at examining the additive detrimental effect of both diabetes and increasing 
body mass index (BMI) category on left ventricular (LV) myocardial systolic and diastolic 
functions.
Methods: The present retrospective multicenter study included 653 patients (337 type 
2 diabetic and 316 non-diabetic) of increasing BMI category. All patients had normal LV 
ejection fraction. LV myocardial systolic (peak systolic global longitudinal strain, peak 
systolic global longitudinal strain rate) and diastolic (average mitral annular e’ velocity 
and early diastolic global longitudinal strain rate) functions were quantified by echocar-
diography.
Results: Increasing BMI category was associated with progressively more impaired LV 
myocardial function in diabetic patients (p < 0.001). Diabetic patients had significantly 
more impaired LV myocardial function at all BMI categories compared to non-diabetic 
patients (p < 0.001). On multivariate analysis, both diabetes and obesity were inde-
pendently associated with an additive detrimental effect on LV myocardial systolic 
and diastolic functions. However, obesity was associated with greater LV myocardial 
dysfunction than diabetes.
Conclusion: Both diabetes and increasing BMI category had an additive detrimental 
effect on LV myocardial systolic and diastolic functions. Furthermore, increasing BMI 
category was associated with greater LV myocardial dysfunction than diabetes. As they 
frequently coexist together, future studies on diabetic patients should also focus on 
obesity.
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InTRoDUCTIon
There is currently a worldwide epidemic of obesity and type 2 diabetes. The latest pro-
jection by the World Health Organization estimated that globally in 2005, approximately 
1.6 billion adults over the age of 15 years were overweight, and at least 400 million 
adults were obese (www.WHO.int). Due to the obesity epidemic, there is a concomi-
tant increase in the prevalence of type 2 diabetes. In the year 2000, the World Health 
Organization estimated more than 170 million people worldwide had diabetes and the 
prevalence was projected to double in the next 20 years.1 Both obesity and diabetes are 
independently associated with an increased risk of heart failure.2 Although the patho-
physiological mechanisms underlying obesity and diabetic cardiomyopathy are not 
identical, the combination of insulin resistance, hyperinsulinemia and hyperglycemia 
leads to inflammation, neurohormonal activation of the renin-angiotensin-aldosterone 
system, and eventual myocardial structural and functional changes.3-8 Despite previous 
studies showing obesity to be an independent risk factor for subsequent development 
of diabetes and heart failure,2, 9, 10 few have examined the simultaneous impact of in-
creasing body mass index (BMI) category and concomitant diabetes on changes in left 
ventricular (LV) myocardial function. We hypothesized that both increasing BMI category 
and diabetes are independently associated with progressive impairment of LV myocar-
dial systolic and diastolic functions, and that the association is additive and not syner-
gistic. Thus, we conducted a multicenter retrospective study (Leiden University Medical 
Center, The Netherlands, and Liverpool Hospital, Australia) whereby both diabetic and 
non-diabetic patients without coronary artery disease were evaluated with the aim to:
1. examine the impact of increasing BMI category on LV myocardial systolic (peak 
systolic global longitudinal strain, peak systolic global longitudinal strain rate) and 
diastolic functions average mitral annular e’ velocity and early diastolic global longi-
tudinal strain rate) as quantified by echocardiography in type 2 diabetic patients;
2. compare LV myocardial systolic and diastolic functions with increasing BMI category 
between diabetic and non-diabetic patients; and
3. determine the independent and additive detrimental effect of increasing BMI cat-
egory and diabetes on LV myocardial systolic and diastolic functions.
MeTHoDs
Patient population
The overall patient population consisted of a mix of 653 patients recruited from 2 
institutions (104 from Liverpool Hospital [Australia] and 549 from Leiden University 
Medical Center [The Netherlands]). All patients were identified over a 10 year period 
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from each Australian and Dutch departmental combined echocardiographic and clinical 
databases. Of these, 337 had type 2 diabetes, which was diagnosed according to World 
Health Organization criteria.11 Although BMI does not take into account the wide varia-
tion in body fat distribution, it is the most useful population-level measure of obesity 
and is recommended by the World Health Organization to define overweight and obesity 
within a population and the risks associated with it.12 Furthermore, several multicenter 
and epidemiology studies have demonstrated the independent prognostic value of BMI 
as a measure of general obesity for predicting all-cause mortality.13-15 As there were only 
2 diabetic patients with BMI < 20 kg/m2 measured at the time of echocardiography, all 
337 diabetic patients were divided into 3 categorical groups: 80 lean diabetics (BMI < 25 
kg/m2); 139 overweight diabetics (BMI 25 – 29.9 kg/m2); and 118 obese diabetics (BMI ≥ 
30kg/m2).
Type 2 diabetic patients were compared against 316 non-diabetic patients of similar 
age, gender and BMI. All non-diabetic patients were clinically referred for assessment 
of LV and/or valvular function, and had structurally normal heart on echocardiography. 
Similarly, as there were only 5 non-diabetic patients with BMI < 20kg/m2, all 316 non-
diabetic patients were divided into 3 categorical groups: 89 lean non-diabetics (BMI < 25 
kg/m2); 134 overweight non-diabetics (BMI 25 – 29.9 kg/m2); and 93 obese non-diabetics 
(BMI ≥ 30kg/m2).
The exclusion criteria for all diabetic and non-diabetic patients included age  < 18 years, 
rhythm other than sinus rhythm, LV ejection fraction (EF) < 50%, moderate or severe 
valvular stenosis or regurgitation, and congenital heart disease. To avoid coronary 
artery disease as a potential confounding factor for any changes observed in myocardial 
function, all patients with known significant underlying coronary artery disease, previ-
ous myocardial infarction, previous coronary artery bypass surgery or percutaneous 
coronary intervention, presence of segmental wall motion abnormalities on echocar-
diography, or positive stress testing were excluded.
All patients underwent a history, physical, biochemical, and transthoracic echocar-
diographic examination. Baseline biochemical analyses included hemoglobin level, 
glomerular filtration rate (GFR) calculated by the Modification of Diet in Renal Disease 
formula as recommended by the National Kidney Foundation, Kidney Disease Outcomes 
Quality Initiative Guidelines16, and glycated hemoglobin (HbA1c) level. The definition 
of hypertension was different between diabetic and non-diabetic patients. In diabetic 
patients, the cut-off was > 130/80 mmHg on 2 separate occasions after > 5min of rest. 
In non-diabetic patients, the cut-off was > 140/90 mmHg on 2 separate occasions after 
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> 5min of rest. All clinical and biochemical variables were collected by an independent 
observer blinded to the echocardiographic results.
The impact of increasing BMI categories on LV structure (LV volumes, mass) and func-
tion were initially assessed in the type 2 diabetic patients. LV myocardial function 
within each BMI category (lean, overweight, obese) in the diabetic population were then 
compared against non-diabetic patients. Finally, to determine the independent and ad-
ditive detrimental effect of increasing obesity and diabetes on LV myocardial function, 
multivariate analysis was performed with BMI categories and the presence/absence of 
diabetes entered as covariates, adjusted for baseline age, gender, systolic blood pres-
sure, heart rate, LV mass and LV volume. Echocardiographic analyses for all diabetic and 
non-diabetic patients, including 2D speckle tracking, were performed offline. Therefore, 
the present evaluation does not tabulate the results summarized in clinical reports.
The institutional review boards approved the study. The institutional review board 
of the Leiden University Medical Center waived the need for patient written informed 
consent for retrospective analysis of clinically acquired data anonymously handled.
echocardiography
Transthoracic echocardiography was performed in all subjects at rest using commer-
cially available ultrasound systems (Vivid 7 and E9, GE-Vingmed, Horten, Norway). All 
images were digitally stored on hard disks for offline analysis (EchoPAC version 108.1.5, 
GE-Vingmed, Horten, Norway). A complete 2D, color, pulsed and continuous-wave 
Doppler echocardiogram was performed according to standard techniques.17, 18 LV 
end-diastolic volume (EDV) and end-systolic volume (ESV) were calculated using the 
Simpson’s biplane method of discs. LVEF was calculated and expressed as a percentage. 
LV mass was calculated from the formula as recommended by the American Society of 
Echocardiography.19
Transmitral inflow velocities were recorded using conventional pulsed-wave Doppler 
echocardiography in the apical 4-chamber view using a 2 mm sample volume. Trans-
mitral early (E wave) and late (A wave) diastolic velocities as well as deceleration time 
were recorded at the mitral leaflet tips. Average mitral annular e’ velocity and average 
E/e’ ratio were obtained from the septal and lateral annulus as recommended by cur-
rent guidelines.20 Maximal left atrial volume was calculated using the Simpson’s biplane 
method of discs in the 4- and 2-chamber views.
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Myocardial functional assessment by 2D speckle tracking
Quantification of longitudinal myocardial function was performed using 2D speckle 
tracking echocardiography in the 3 apical (2-, 3- and 4 chamber) views. During image 
analysis, the LV endocardial border was manually traced at end-systole and the region 
of interest width adjusted to include the entire myocardium. The 2D speckle tracking 
software then automatically tracks the motion of LV myocardial segments throughout 
the entire cardiac cycle. LV myocardial segments of good tracking quality were auto-
matically accepted for further analyses whereas poorly tracked segments were rejected, 
while simultaneously allowing the user to manually override the software’s decisions 
based on visual assessments of tracking quality. From the 3 individual apical views, 
peak systolic global longitudinal strain, peak systolic global longitudinal strain rate and 
early diastolic global longitudinal strain rate were calculated.
Variability analysis
Intraobserver and interobserver measurement variabilities were performed in 20 ran-
domly selected patients and expressed as mean absolute difference ± 1 standard devia-
tion (SD). The respective intraobserver and interobserver measurement variabilities for 
peak systolic global longitudinal strain were 1.2 ± 0.6% and 1.2 ± 1.0%, peak systolic 
global longitudinal strain rate were 0.10 ± 0.06s-1 and 0.11 ± 0.08s-1, and early diastolic 
global longitudinal strain rate were 0.09 ± 0.05s-1 and 0.16 ± 0.09s-1.
statistical analysis
All continuous variables were tested for Gaussian distribution as determined by 
Kolmogorov-Smirnov test. Continuous variables were presented as mean ± 1 SD and 
categorical variables were presented as frequencies and percentages. Unpaired Stu-
dent’s t-test was used to compare 2 independent groups of continuous variables and 
the Chi-square test with Yates’ correction was used to compare categorical variables. 
To assess the univariable linear relationship between 2 variables: Pearson correlation 
was performed between 2 continuous variables, Spearman correlation was performed 
between 1 continuous variable and 1 ordinal variable (e.g. BMI categories), and point-
biserial correlation was performed between 1 continuous and 1 dichotomous variable 
(e.g. gender and presence of diabetes categories).
One-way analysis of variance (ANOVA) was initially used to examine the influence of 
increasing BMI subgroup categories on LV myocardial function (peak systolic global 
longitudinal strain, peak systolic global longitudinal strain rate, average mitral annular 
e’ velocities, average E/e’ ratio and early diastolic global longitudinal strain rate) in type 
2 diabetic patients. Next, factorial ANOVA was used to compare peak systolic global 
longitudinal strain, peak systolic global longitudinal strain rate, average mitral annular 
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e’ velocities, average E/e’ ratio and early diastolic global longitudinal strain rate changes 
with increasing BMI category between diabetic and non-diabetic patients. Finally, 
multiple linear regression analyses were used to determine the independent and addi-
tive detrimental effect of increasing BMI category and diabetes on peak systolic global 
longitudinal strain, peak systolic global longitudinal strain rate, average mitral annular 
e’ velocities and early diastolic global longitudinal strain rate, with correction for base-
line age, gender, systolic blood pressure, heart rate, LV mass and LVESV. Standardized 
coefficients were presented to demonstrate the relative contribution of each variable to 
the multivariable linear regression model. To avoid multicolinearity, a tolerance of > 0.5 
was set. All post-hoc multiple pairwise comparisons were performed with Bonferroni 
corrections. A 2-tailed p value of < 0.05 was considered significant. All statistical analyses 
were performed using SPSS for Windows (SPSS Inc, Chicago), version 17.
ResULTs
Increasing bMI category in diabetic patients
Table 1 outlines the clinical, biochemical and echocardiographic characteristics of the 
entire cohort of type 2 diabetic patients, and the 3 diabetic groups categorized accord-
ing to BMI category. The mean age was 57 ± 12 years, 63.2% men. With increasing BMI 
category, there were progressive increases in systolic (p by one-way ANOVA = 0.002) and 
diastolic (p by one-way ANOVA < 0.001) blood pressures, and higher HbA1c level (p by 
one-way ANOVA = 0.046).
On echocardiography, increasing BMI category was associated with LV structural chang-
es with progressive increases in LVEDV, LVESV and LV mass. Assessment of LV systolic 
function showed that LVEF did not differ significantly across the diabetic BMI subgroups. 
However, increasing BMI category was significantly associated with progressively more 
impaired peak systolic global longitudinal strain (p by one-way ANOVA < 0.001). Multiple 
pairwise comparisons with Bonferroni corrections showed that peak systolic global lon-
gitudinal strain became increasingly more impaired with each increase in BMI category 
(both p < 0.001). Similarly, increasing BMI category was also significantly associated with 
progressively more impaired peak systolic global longitudinal strain rate (p by one-way 
ANOVA < 0.001), and multiple pairwise comparisons with Bonferroni corrections showed 
that peak systolic global longitudinal strain rate was significantly more impaired in over-
weight versus lean diabetic patients (p = 0.008), and in obese versus overweight diabetic 
patients (p = 0.003).
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Assessment of LV diastolic function showed that increasing BMI category in the dia-
betic patients was significantly associated with progressive prolongation of transmitral 
deceleration time, and a non-significant trend towards worsening of transmitral E/A 
ratio. Increasing BMI category was also significantly associated with progressively more 
impaired average mitral annular e’ velocity (p by one-way ANOVA < 0.001) and average 
E/e’ ratio (p by one-way ANOVA = 0.004). Similarly, increasing BMI was significantly as-
sociated with progressively more impaired early diastolic global longitudinal strain rate 
(p by one-way ANOVA < 0.001). On multiple pairwise comparisons with Bonferroni cor-
rections, early diastolic global longitudinal strain rate was significantly more impaired 
in overweight versus lean diabetic patients (p = 0.001), and in obese versus overweight 
diabetic patients (p = 0.004).























Age (years) 57 ± 12 56 ± 12 57 ± 12 56 ± 11 0.63
Male gender (%) 63.2 67.5 74.1 47.5  < 0.001
Height (cm) 173 ± 10 173 ± 10 172 ± 11 173 ± 10 0.83
Weight (kg) 84 ± 17 69 ± 10 81 ± 11 101 ± 15  < 0.001
BMI (kg/m2) 28.9 ± 5.6 22.8 ± 1.5 27.2 ± 1.4 35.0 ± 4.4  < 0.001
Hypertension (%) 56.4 42.5 56.1 66.1 0.005
Hyperlipidemia (%) 51.0 40.0 54.0 55.1 0.076
Family history of ischemic heart disease (%) 15.7 20.0 16.5 11.9 0.29
Current smoker (%) 29.4 28.8 25.9 33.9 0.37
Systolic blood pressure (mmHg) 139 ± 20 134 ± 20 139 ± 19 144 ± 20 0.002
Diastolic blood pressure (mmHg) 81 ± 11 78 ± 11 81 ± 10 85 ± 11  < 0.001
biochemical
Hemoglobin (g/dL) 13.9 ± 1.6 13.6 ± 1.8 14.1 ± 1.5 13.9 ± 1.6 0.076
Glomerular filtration rate (mL/min/1.73m2) 87.7 ± 26.9 85.2 ± 22.8 87.1 ± 27.7 90.2 ± 28.6 0.42
HbA1c (%) 7.3 ± 1.5 7.1 ± 1.4 7.2 ± 1.5 7.6 ± 1.4 0.046
echocardiography
Heart rate (beats/min) 74 ± 13 72 ± 13 74 ± 12 75 ± 14 0.20
Left ventricular end-diastolic volume (mL) 93 ± 24 88 ± 23 93 ± 25 98 ± 24 0.020
Left ventricular end-systolic volume (mL) 38 ± 12 36 ± 12 37 ± 12 40 ± 12 0.048
Left ventricular ejection fraction (%) 59 ± 5 59 ± 5 60 ± 5 59 ± 5 0.53
Left ventricular mass (g) 183 ± 49 161 ± 42 182 ± 47 200 ± 48  < 0.001
Chapter 3 85
Impact of Diabetes and Increasing Body Mass Index Category on Left Ventricular Systolic and Diastolic Function
Comparisons between diabetic and non-diabetic patients
Table 2 compares the clinical and echocardiographic characteristics of the diabetic pa-
tients versus non-diabetic patients. There were no significant differences in age, gender 
and BMI. Diabetic patients were more likely to have a positive history of hypertension 
and hyperlipidemia. However, there were no significant differences in systolic and dia-
stolic blood pressure at the time of echocardiographic examination.
On echocardiography, there were no significant differences in LVEDV, LVESV and LV 
mass. Assessment of LV systolic function demonstrated that there was no significant 
difference in LVEF between diabetic and non-diabetic patients (59 ± 5 vs. 60 ± 5%, p = 
0.40). However, diabetic patients had significantly more impaired peak systolic global 
longitudinal strain compared to non-diabetic patients (-17.6 ± 2.3 vs. -18.9 ± 2.4%, p < 
0.001). Furthermore, diabetic patients had more impaired peak systolic global longitu-
dinal strain than non-diabetic patients across all BMI subgroups (p by factorial ANOVA 
< 0.001), and there was no significant interaction between the presence of diabetes and 
BMI categories (p by factorial ANOVA = 0.31, Figure 1). Thus, lean diabetic patients had 
similar peak systolic global longitudinal strain as overweight non-diabetic patients (-18.9 
± 2.2 vs. -19.0 ± 2.2%, p > 0.99 with Bonferroni correction); overweight diabetic patients 
had similar peak systolic global longitudinal strain as obese non-diabetic patients (-17.7 
± 1.9 vs. -17.4 ± 2.3%, p = 0.70 with Bonferroni correction); and obese diabetic patients 
had the most impaired peak systolic global longitudinal strain (-16.6 ± 2.3%).























Transmitral E/A ratio 0.97 ± 0.32 1.04 ± 0.40 0.96 ± 0.28 0.94 ± 0.30 0.084
Deceleration time (msec) 198 ± 54 190 ± 58 192 ± 45 209 ± 58 0.016
Average mitral annular e’ velocity (cm/s) 6.7 ± 2.0 7.5 ± 2.2 6.5 ± 1.9 6.3 ± 1.8  < 0.001
Average E/e’ ratio 10.9 ± 5.3 9.5 ± 4.6 10.7 ± 4.1 12.1 ± 6.6 0.004
Maximal left atrial volume (mL) 58.5 ± 17.9 54.6 ± 14.7 57.3 ± 16.7 62.5 ± 20.3 0.006
Peak systolic global longitudinal strain (%) -17.6 ± 2.3 -18.9 ± 2.2 -17.7 ± 1.9 -16.6 ± 2.3  < 0.001
Peak systolic global longitudinal strain rate (s-1) -0.93 ± 0.16 -1.01 ± 0.17 -0.94 ± 0.14 -0.88 ± 0.16  < 0.001
Early diastolic global longitudinal strain rate (s-1) 0.99 ± 0.27 1.13 ± 0.28 1.00 ± 0.25 0.89 ± 0.25  < 0.001
* p value by one-way analysis of variance. BMI: body mass index; HbA1c: glycated hemoglobin.
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Similarly, diabetic patients had more impaired peak systolic global longitudinal strain 
rate than non-diabetic patients across all BMI subgroups (p by factorial ANOVA < 0.001), 
and there was no significant interaction between the presence of diabetes and BMI cat-
egories (p by factorial ANOVA = 0.67, Figure 2). Thus, lean diabetic patients had similar 
peak systolic global longitudinal strain rate as overweight non-diabetic patients (-1.01 ± 
0.17 vs. -0.98 ± 0.16s-1, p = 0.68 with Bonferroni correction); overweight diabetic patients 
had similar peak systolic global longitudinal strain rate as obese non-diabetic patients 
(-0.94 ± 0.14 vs. -0.92 ± 0.15s-1, p = 0.80 with Bonferroni correction); and obese diabetic pa-
tients had the most impaired peak systolic global longitudinal strain rate (-0.88 ± 0.16s-1).








Age (years) 57 ± 14 57 ± 12 0.83
Male gender (%) 62.7 63.2 0.89










Hypertension (%) 27.5 56.4  < 0.001
Hyperlipidemia (%) 14.2 51.0  < 0.001
Current smoker (%) 11.4 15.7 0.11
Systolic BP (mmHg) 136 ± 24 139 ± 20 0.08
Diastolic BP (mmHg) 82 ± 12 81 ± 11 0.29
echocardiography
Heart rate (beats/min) 71 ± 13 74 ± 13 0.010
Left ventricular end-diastolic volume (mL) 95 ± 25 93 ± 24 0.30
Left ventricular end-systolic volume (mL) 39 ± 12 38 ± 12 0.57
Left ventricular ejection fraction (%) 60 ± 5 59 ± 5 0.40
Left ventricular mass (g) 183 ± 51 183 ± 49 0.94
Transmitral E/A ratio 1.10 ± 0.47 0.97 ± 0.32  < 0.001
Deceleration time (msec) 212 ± 60 198 ± 54 0.001
Average mitral annular e’ velocity (cm/s) 7.5 ± 2.5 6.7 ± 2.0  < 0.001
Average E/e’ ratio 10.2 ± 4.1 10.9 ± 5.3 0.06
Maximal left atrial volume (mL) 59.4 ± 21.3 58.5 ± 17.9 0.56
Peak systolic global longitudinal strain (%) -18.9 ± 2.4 -17.6 ± 2.3  < 0.001
Peak systolic global longitudinal strain rate (s-1) -0.99 ± 0.16 -0.93 ± 0.16  < 0.001
Early diastolic global longitudinal strain rate (s-1) 1.15 ± 0.32 0.99 ± 0.27  < 0.001
BMI: body mass index
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 Figure 1. Comparisons of peak systolic global longitudinal strain in diabetic versus non-diabetic patients 
across body mass index (BMI) categories. Increasing BMI was associated with progressive impairment of peak 
systolic global longitudinal strain. Furthermore, diabetic patients had more impaired peak systolic global 
longitudinal strain across all BMI categories.
 Figure 2. Comparisons of peak systolic global longitudinal strain rate in diabetic versus non-diabetic patients 
across body mass index (BMI) categories. Increasing BMI was associated with progressive impairment of peak 
systolic global longitudinal strain rate. Diabetic patients had more impaired peak systolic global longitudinal 
strain across all BMI categories.
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On assessment of LV diastolic function, diabetic patients had more impaired LV diastolic 
function as measured by average mitral annular e’ velocity (6.7 ± 2.0 vs. 7.5 ± 2.5cm/s, 
p < 0.001), and across all BMI categories (p by factorial ANOVA < 0.001, Figure 3). There 
was no significant interaction between the presence of diabetes and BMI categories 
in average mitral annular e’ velocity (p by factorial ANOVA = 0.63). As shown in Figure 
3, lean diabetic patients had similar average mitral annular e’ velocity as overweight 
non-diabetic patients (7.5 ± 2.2 vs. 7.3 ± 2.8cm/s, p > 0.99 with Bonferroni correction); 
overweight diabetic patients had similar peak systolic global longitudinal strain rate 
as obese non-diabetic patients (6.5 ± 1.9 vs. 6.8 ± 2.0cm/s, p = 0.56 with Bonferroni 
correction); and obese diabetic patients had the most impaired peak systolic global 
longitudinal strain rate (6.3 ± 1.8cm/s).
In contrast, there was no significant difference in the assessment of LV filling pressure 
between diabetic and non-diabetic patients as quantified by average E/e’ ratio in dia-
betic patients (10.9 ± 5.3 vs. 10.2 ± 4.1, p = 0.06).
Finally, diabetic patients also had more impaired early diastolic global longitudinal 
strain rate than non-diabetic patients across all BMI categories (p by factorial ANOVA < 
0.001). Interestingly, there was a significant interaction between presence of diabetes 
and increasing BMI categories (p by factorial ANOVA = 0.005). Evaluation of Figure 4 
demonstrated that non-diabetic patients had a greater initial decline in early diastolic 
 
 Figure 3. Comparisons of average mitral annular e’ velocity in diabetic versus non-diabetic patients across 
body mass index (BMI) categories. Increasing BMI was associated with progressive impairment of average 
mitral annular e’ velocity. Diabetic patients had more impaired average mitral annular e’ velocity across all 
BMI categories.
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global longitudinal strain rate from normal weight to overweight compared to diabetic 
patients. Similarly, lean diabetic patients had similar early diastolic global longitudinal 
strain rate as overweight non-diabetic patients (1.13 ± 0.28 vs. 1.11 ± 0.29s-1, p > 0.99 with 
Bonferroni correction); overweight diabetic patients had similar early diastolic global 
longitudinal strain rate as obese non-diabetic patients (1.00 ± 0.25 vs. 0.99 ± 0.26s-1, p 
> 0.99 with Bonferroni correction); and obese diabetic patients had the most impaired 
early diastolic global longitudinal strain rate (0.89 ± 0.25s-1).
Diabetes, obesity and myocardial dysfunction
To examine the independent and additive detrimental effect of both increasing obesity 
and diabetes on peak systolic global longitudinal strain, peak systolic global longitudi-
nal strain rate, average mitral annular e’ velocity and early diastolic global longitudinal 
strain rate, multiple linear regression analyses were performed with the presence of 
diabetes and BMI categories entered as covariates, corrected for baseline age, gender, 
systolic blood pressure, heart rate, LV mass and LVESV.
Table 3 shows that both increasing BMI category and the presence of diabetes were 
independently associated with peak systolic global longitudinal strain (model R = 0.56, p 
< 0.001). Furthermore, increasing BMI (standardized beta = 0.379, p < 0.001) was associ-
ated with greater LV myocardial dysfunction than diabetes (standardized beta = 0.231, p 
 
 Figure 4. Comparisons of early diastolic global longitudinal strain rate in diabetic versus non-diabetic pa-
tients across body mass index (BMI) categories. Increasing BMI was associated with progressive impairment 
of early diastolic global longitudinal strain rate. Diabetic patients had more impaired early diastolic global 
longitudinal strain across all BMI categories. However, non-diabetic patients with a normal BMI had a greater 
decline in early diastolic global longitudinal strain rate with increasing BMI.
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< 0.001). There was no significant interaction between the presence of diabetes and in-
creasing obesity, suggesting an additive (not synergistic) detrimental effect of diabetes 
and obesity on LV myocardial function. Similar results were also obtained when BMI was 
modeled as a continuous variable (standardized beta = 0.355, p < 0.001), when systolic 
blood pressure was substituted by diastolic blood pressure or history of hypertension, 
or when all hypertensive patients were excluded from the multivariate analysis.
Table 4 shows the multivariable regression analysis for peak systolic global longitudinal 
strain rate (model R = 0.53, p < 0.001). Similarly, increasing BMI category (standardized 
beta = 0.285, p < 0.001) was associated with greater LV myocardial dysfunction by peak 
systolic global longitudinal strain rate compared to the presence of diabetes (standard-
Table 3. Independent determinants of left ventricular peak systolic global longitudinal strain
Variable Peak systolic global longitudinal strain
*Univariable r p value standardized β p value
Age -0.027 0.49 0.027 0.49
Male gender 0.063 0.11 0.063 0.087
Systolic blood pressure 0.124 0.002 -0.022 0.55
Heart rate 0.196  < 0.001 0.190  < 0.001
Left ventricular mass 0.200  < 0.001 -0.035 0.41
Left ventricular end-systolic volume 0.265  < 0.001 0.246  < 0.001
Presence of diabetes 0.274  < 0.001 0.231  < 0.001
BMI categories 0.434  < 0.001 0.379  < 0.001
BMI: body mass index. *Pearson correlation performed for 2 continuous variables, Spearman correlation performed for 1 
continuous variable and 1 ordinal variable (i.e. BMI categories), and point-biserial correlation performed for 1 continuous 
variable and 1 dichotomous variable (i.e. gender, presence of diabetes).
Table 4. Independent determinants of left ventricular peak systolic global longitudinal strain rate
Variable Peak systolic global longitudinal strain rate
*Univariable r p value standardized β p value
Age -0.019 0.63 0.060 0.13
Male gender -0.118 0.003 -0.177  < 0.001
Systolic blood pressure 0.088 0.027 0.014 0.72
Heart rate -0.199  < 0.001 -0.202  < 0.001
Left ventricular mass 0.145  < 0.001 -0.069 0.12
Left ventricular end-systolic volume 0.324  < 0.001 0.332  < 0.001
Presence of diabetes 0.179  < 0.001 0.180  < 0.001
BMI categories 0.352  < 0.001 0.285  < 0.001
BMI: body mass index. *Pearson correlation performed for 2 continuous variables, Spearman correlation performed for 1 
continuous variable and 1 ordinal variable (i.e. BMI categories), and point-biserial correlation performed for 1 continuous 
variable and 1 dichotomous variable (i.e. gender, presence of diabetes).
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ized beta = 0.180, p < 0.001). Similar results were also obtained when BMI was modeled 
as a continuous variable (standardized beta = 0.247, p < 0.001).
Table 5 shows the multivariable regression analysis for average mitral annular e’ veloc-
ity (model R = 0.68, p < 0.001). Increasing BMI (standardized beta = -0.157, p < 0.001) was 
associated with greater LV diastolic dysfunction by average mitral annular e’ velocity 
compared to the presence of diabetes (standardized beta = -0.146, p < 0.001).
Finally, Table 6 shows the multivariable regression analysis for early diastolic global lon-
gitudinal strain rate (model R = 0.64, p < 0.001). Increasing BMI category (standardized 
beta = -0.337, p < 0.001) was associated with greater LV myocardial dysfunction by early 
diastolic global longitudinal strain rate compared to the presence of diabetes (standard-
Table 5. Independent determinants of average mitral annular e’ velocity
Variable average mitral annular e’ velocity
*Univariable r p value standardized β p value
Age -0.591  < 0.001 -0.520  < 0.001
Male gender 0.069 0.09 0.043 0.21
Systolic blood pressure -0.367  < 0.001 -0.078 0.027
Heart rate -0.165  < 0.001 -0.105 0.001
Left ventricular mass -0.240  < 0.001 -0.103 0.010
Left ventricular end-systolic volume 0.167  < 0.001 0.080 0.034
Presence of diabetes -0.175  < 0.001 -0.146  < 0.001
BMI categories -0.238  < 0.001 -0.157  < 0.001
BMI: body mass index. *Pearson correlation performed for 2 continuous variables, Spearman correlation performed for 1 
continuous variable and 1 ordinal variable (i.e. BMI categories), and point-biserial correlation performed for 1 continuous 
variable and 1 dichotomous variable (i.e. gender, presence of diabetes).
Table 6. Independent determinants of left ventricular early diastolic global longitudinal strain rate
Variable early diastolic global longitudinal strain rate
*Univariable r p value standardized β p value
Age -0.400  < 0.001 -0.399  < 0.001
Male gender -0.068 0.08 -0.071 0.039
Systolic blood pressure -0.298  < 0.001 -0.020 0.56
Heart rate -0.128 0.001 -0.098 0.002
Left ventricular mass -0.313  < 0.001 -0.043 0.28
Left ventricular end-systolic volume -0.095 0.015 -0.119 0.002
Presence of diabetes -0.257  < 0.001 -0.230  < 0.001
BMI categories -0.392  < 0.001 -0.337  < 0.001
BMI: body mass index. *Pearson correlation performed for 2 continuous variables, Spearman correlation performed for 1 
continuous variable and 1 ordinal variable (i.e. BMI categories), and point-biserial correlation performed for 1 continuous 
variable and 1 dichotomous variable (i.e. gender, presence of diabetes).
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ized beta = -0.230, p < 0.001). Finally, similar results were also obtained when BMI was 
modeled as a continuous variable (standardized beta = -0.297, p < 0.001).
DIsCUssIon
The present multicenter observational study demonstrated that increasing BMI category 
was associated with progressive and detrimental changes in LV structure, systolic and 
diastolic functions in diabetic patients. Compared to non-diabetic patients of similar 
age, gender and BMI, diabetic patients had more impaired LV function at all categories 
of BMI. Multivariate analysis showed that both increasing BMI category and diabetes 
were independent predictors of impaired LV myocardial systolic and diastolic functions 
despite preserved LVEF. Furthermore, both diabetes and increasing BMI category had an 
additive detrimental effect on LV myocardial function, and increasing BMI was a stronger 
determinant of impaired LV myocardial function than diabetes.
Pathogenesis of diabetic and obesity cardiomyopathy
Various mechanisms underlie the etiology of diabetic cardiomyopathy, including pro-
cesses such as altered myocardial metabolism with subsequent steatosis and lipotoxic-
ity, endothelial dysfunction with microvascular disease, autonomic neuropathy, altered 
myocardial structure with fibrosis and atherosclerosis.21-26 Often, these processes 
act together and result in myocardial hypertrophy, increased interstitial fibrosis with 
increased LV stiffness, and manifesting as diastolic dysfunction in early diabetic heart 
disease.5 Over time, there is progressive loss of myocardial contractile function resulting 
in global LV systolic dysfunction.
Recent large epidemiological studies had unequivocally demonstrated increased all-
cause mortality in patients with higher levels of BMI.15, 27 Furthermore, increasingly obese 
patients had progressively higher cardiovascular mortality.15 Compared to diabetic 
cardiomyopathy, obesity cardiomyopathy is a clinically less well-recognized phenom-
enon. Obesity cardiomyopathy is characterized by a variety of cardiac structural and 
hemodynamic changes.6 Previous studies have shown that obese patients have larger 
LV chamber sizes and increased hypertrophy compared to their lean counterparts.28-31 
These cardiac structural changes are associated with changes in cardiovascular he-
modynamics, including an increased total blood volume, cardiac output and reduced 
systemic vascular resistance.6, 32 Although it has been suggested that the association 
between obesity and incident heart failure may be secondary to these hemodynamic 
and cardiac structural changes6, recent evidence suggests that the relationship may be 
mediated by obesity-related metabolic, inflammatory and neurohormonal changes.2, 7, 8 
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The presence of obesity-related insulin resistance, systemic vascular and adipose tissue 
inflammation, increased free fatty acid delivery, and activation of the renin-angiotensin-
aldosterone system all contribute to atherosclerosis, myocardial hypertrophy, increased 
interstitial fibrosis and subsequent myocardial dysfunction.2, 7, 8, 29
Although the underlying pathogenesis of diabetic and obesity cardiomyopathy may not 
be identical, the final common pathway appears to be an increased interstitial fibrosis 
followed by initial myocardial diastolic dysfunction and eventually systolic dysfunction. 
However, few studies to date have evaluated the combined detrimental effects of both 
diabetes and obesity on LV function. In the present study, both diabetes and increasing 
BMI category were associated with LV myocardial systolic and diastolic dysfunction. 
Figure 4 demonstrated that non-diabetic patients had a greater initial decline in early 
diastolic global longitudinal strain rate from normal weight to overweight compared to 
diabetic patients. This suggests that early diastolic global longitudinal strain rate is most 
sensitive to the detrimental LV myocardial functional changes secondary to diabetes 
or increasing BMI, and is in agreement with the pathophysiological process of diastolic 
dysfunction occurring before systolic dysfunction.
Diabetes, obesity and myocardial dysfunction
Numerous echocardiographic studies examining diabetes have demonstrated the 
presence of both LV diastolic and systolic dysfunction compared to normal controls.33-35 
Similarly, studies on non-diabetic obese subjects have also demonstrated LV diastolic 
and systolic dysfunction compared to lean controls.29, 30, 36 Although diabetes and obesity 
frequently co-exist together,37 few studies to date have evaluated the combined impact 
of both diabetes and obesity on LV function.38, 39 Kuperstein and co-workers recruited a 
large number of predominately obese subjects and demonstrated a synergistic effect 
of obesity and diabetes on LV mass.38 However, the study was confounded by the small 
number of diabetic patients (6% of the total study population) and that all of the obese 
diabetic patients were women.38 Furthermore, the combined impact of diabetes and 
obesity on LV function in their study was unknown. Di Stante and co-workers demon-
strated LV diastolic dysfunction in 40 obese diabetic patients compared to 93 obese 
non-diabetic patients.39 However, the impact of increasing obesity on LV dysfunction 
was not evaluated, and multivariate analysis identifying independent determinants of 
LV dysfunction was not performed.
In contrast, the present study is the largest to date evaluating the combined impact 
of diabetes and increasing BMI category on LV myocardial function. Both diabetes 
and increasing BMI were independent determinants of LV myocardial dysfunction. 
Furthermore, both increasing BMI and obesity had an additive detrimental effect on LV 
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myocardial function, and increasing BMI was associated with a greater impairment of 
LV myocardial function than diabetes. This was demonstrated in the standardized beta 
coefficients that demonstrated increasing BMI had a greater relative contribution to 
the multiple linear regression models than the presence of diabetes, despite similar p 
values. Importantly, the present study excluded all patients with known or suspected 
significant underlying coronary artery disease. Therefore, it was unlikely that the 
presence of undiagnosed significant coronary artery disease could have significantly 
influenced the results. Similarly, although increasing BMI and diabetes were associ-
ated with a higher incidence of hypertension, the independent associations between 
diabetes, obesity and myocardial dysfunction were still significant despite adjusting for 
differences in systolic blood pressure on multivariate analysis. Similar results were also 
obtained when systolic blood pressure was substituted by diastolic blood pressure or 
history of hypertension, or when all hypertensive patients were excluded from analysis.
study Limitations
As the present study was a cross-sectional analysis on the effects of diabetes and BMI 
on myocardial function, there were no longitudinal follow-up clinical outcome data. 
Similarly, there was no information on the influences of weight loss and intensity of dia-
betic control on myocardial function. Finally, there was a potential enrolment/selection 
bias as clinical patients were referred for a clinical echocardiogram, thereby possibly 
increasing the incidence of subclinical myocardial dysfunction despite a normal LVEF.
Clinical implications
Both obesity and diabetes are world-wide growing epidemics. Previous epidemiological 
studies demonstrated that both diabetes and obesity were independent risk factors for 
the development of heart failure.9, 13, 40, 41 These studies have shown that diabetes and 
obesity were each associated with an approximately 2-fold increased risk of heart fail-
ure.9, 13, 41 However, these studies generally examined the prognostic impact of diabetes 
and obesity separately. The present study demonstrated that diabetes and obesity was 
independently associated with an additive detrimental effect on LV myocardial func-
tion, and increasing obesity was associated with greater LV myocardial dysfunction 
than diabetes. Thus, future clinical studies on diabetic patients should also focus on the 
frequently associated obesity problem in this patient population.
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ConCLUsIon
Both diabetes and obesity were independently associated with an additive detrimental 
effect on LV myocardial function. Furthermore, increasing BMI category was associated 
with greater LV myocardial dysfunction than diabetes. Therapies aiming at reducing car-
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background: Magnetic resonance (MR) spectroscopy can quantify myocardial triglyc-
eride content in type 2 diabetic patients. Its relation to alterations in left and right 
ventricular (LV/RV) myocardial functions is unknown.
Methods: A total of 42 men with type 2 diabetes were recruited. Exclusion criteria 
included HbA1c > 8.5%, known cardiovascular disease or diabetes-related complica-
tions, blood pressure > 150/85 mmHg. Myocardial ischemia was excluded by a negative 
dobutamine stress test. LV and RV volumes and ejection fraction (EF) were quantified by 
magnetic resonance imaging. LV global longitudinal and RV free wall longitudinal strain, 
systolic strain rate (SR) and diastolic SR were quantified by echocardiographic speckle 
tracking analyses. Myocardial triglyceride content was quantified by MR spectroscopy 
and dichotomized based on the median value of 0.76%.
Results: The median age was 59 years (25th and 75th percentiles [54, 62 years]). Median 
diabetes diagnosis duration was 4 years, and median glycated hemoglobin level was 
6.2% (5.9, 6.8%). There were no differences in LV and RV end-diastolic and end-systolic 
volume indices and EF between patients with high (≥ 0.76%) versus low ( < 0.76%) myo-
cardial triglyceride content. However, patients with high myocardial triglyceride content 
had greater impairment of LV and RV myocardial strain and strain rate. The myocardial 
triglyceride content was an independent correlate of LV and RV longitudinal strain, sys-
tolic SR and diastolic SR.
Conclusions: High myocardial triglyceride content is associated with more pronounced 
impairment of LV and RV functions in men with uncomplicated type 2 diabetes.
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InTRoDUCTIon
The etiological mechanisms underlying diabetic heart disease are likely to be multifac-
torial, ranging from altered myocardial metabolism, endothelial dysfunction, microvas-
cular disease, autonomic neuropathy, and altered myocardial structure with fibrosis.1 
Increasingly, evidence is emerging on the role of altered myocardial metabolism with 
subsequent lipotoxic injury from lipid oversupply. Recent studies have evaluated the 
role of myocardial triglyceride accumulation (steatosis) and diastolic dysfunction in 
patients with type 2 diabetes.2, 3 Although differences in transmitral flow patterns indica-
tive of diastolic dysfunction were seen in diabetics compared to normal controls, there 
was no significant difference in global systolic function as determined by ejection frac-
tion (EF).2, 3 In contrast, strain and strain rate (SR) imaging are more sensitive indices of 
myocardial function and have been shown to be impaired in diabetic patients.4-10 How-
ever, no studies to date have evaluated the relationship between myocardial triglyceride 
content and both left (LV) and right ventricular (RV) myocardial functions. Therefore, the 
aim of the present study was to relate myocardial triglyceride content as determined by 
magnetic resonance (MR) spectroscopy, with biventricular myocardial strain and SR as 
determined by echocardiographic 2-dimensional (2D) speckle tracking analysis.
MeTHoDs
Patient sample
The original PIRAMID (Pioglitazone Influence on tRiglyceride Accumulation in the 
Myocardium In Diabetes) trial included a total of 78 diabetic patients recruited from 2 
centers (Leiden University Medical Center, Leiden, and VU University Medical Center, 
Amsterdam, The Netherlands).11 The present study only included 42 diabetic patients 
who underwent a comprehensive MR (including spectroscopy) and echocardiographic 
examination at baseline from a single center (Leiden University Medical Center, Leiden, 
The Netherlands).
The inclusion and exclusion criteria have previously been reported.11 Briefly, only male 
diabetics were recruited to avoid possible confounding influences of female gender and 
plasma estrogen levels on lipid metabolism and myocardial triglyceride accumulation. 
Inclusion criteria included: 1) Type 2 diabetes mellitus diagnosed according to World 
Health Organization criteria12 and treated with sulfonylurea derivatives in stable doses, 
2) glycated hemoglobin level between 6.5% to 8.5%, and 3) resting blood pressure < 
150/85 mmHg, with or without antihypertensive medication. In addition, as an inclusion 
criterion, the presence of myocardial ischemia was excluded in all patients by a nega-
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tive high-dose dobutamine stress echocardiogram.3 Exclusion criteria included known 
cardiovascular disease or diabetes related complications including proliferative reti-
nopathy, autonomic neuropathy as excluded by Ewing’s tests,13 and microalbuminuria 
as excluded by measurements of albumin/creatinine ratio in a urine sample.
study protocol
All patients underwent magnetic resonance imaging (MRI) examinations with MR spec-
troscopy and transthoracic echocardiography at baseline. Both LV and RV volumes and 
EF were quantified by MRI, whereas LV and RV myocardial strain and SR were quantified 
by echocardiographic 2D speckle tracking analyses. The myocardial triglyceride content 
was measured by MR spectroscopy and the study sample was then dichotomized into 
2 groups based on the median value. Biventricular volumes, EF and myocardial strain/
SR were then compared between the 2 groups, and independent correlates of LV and RV 
myocardial functions were identified.
Cardiac magnetic resonance imaging protocol
All patients underwent MRI examinations for assessment of biventricular volumes 
and functions, and myocardial triglyceride content after an overnight fast with a 1.5-T 
whole-body MR scanner (Gyroscan ACS/NT15; Philips, Best, the Netherlands). During 
the examinations, the entire heart was imaged in the short-axis orientation with ECG-
gated breath-hold balanced steady state free-precession imaging. Imaging parameters 
included the following: echo time = 1.7 ms, repetition time = 3.4 ms, flip-angle = 35°, 
slice thickness = 10 mm with a gap of 0 mm, field of view = 400 x 400 mm, reconstructed 
matrix size = 256 x 256.
LV and RV end-diastolic volume index (EDVI) and end-systolic volume index (ESVI) 
were measured and corrected for body surface area (BSA).14 LVEF and RVEF were then 
calculated and expressed as percentages. LV mass (excluding papillary muscles) was 
also measured and indexed to BSA. LV mass-cavity ratio (which is conceptually similar 
to relative wall thickness) was calculated as previously described, with a higher mass-
cavity ratio indicating increasing relative wall thickness.15 All images were digitally 
stored on hard disks and analyzed offline using dedicated quantitative software (MASS, 
Medis, Leiden, the Netherlands).
Cardiac Proton MR spectroscopy
Cardiac proton MR spectroscopy ([1H]-MRS) was performed as previously described.16 
Briefly, myocardial [1H]-MRS spectra were obtained from the interventricular septum to 
avoid contamination from epicardial fat. Spectroscopic data acquisitions were double-
triggered with ECG triggering and respiratory navigator echoes to minimize motion 
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artifacts. Water-suppressed spectra were acquired to measure myocardial triglyceride 
content, and spectra without water suppression were acquired and used as an internal 
standard.16 [1H]-MRS data were fitted by use of Java-based MR user interface software 
( jMRUI version 2.2, Leuven, Belgium) as previously described.16 Myocardial triglyceride 
content relative to water was calculated and expressed as a percentage based on: (signal 
amplitude of triglyceride)/ (signal amplitude of water) x 100.16
echocardiography
Transthoracic echocardiography was performed with the subjects at rest using commer-
cially available ultrasound transducer and equipment (M3S probe, Vivid 7, GE-Vingmed, 
Horten, Norway). All images were digitally stored on hard disks for offline analysis 
(EchoPAC version 108.1.5, GE-Vingmed, Horten, Norway). A complete 2D, color, pulsed 
and continuous-wave Doppler echocardiogram was performed according to standard 
techniques.17, 18
Evaluation of the traditional parameters of LV diastolic function was performed by as-
sessing transmitral inflow and pulmonary venous velocities using conventional pulsed-
wave Doppler echocardiography in the apical 4 chamber view using a 2 mm sample 
volume. Transmitral early (E wave) and late (A wave) diastolic velocities as well as 
deceleration time were recorded at the mitral leaflet tips. LV isovolumic relaxation time 
was also recorded. The pulmonary venous peak systolic (S) and diastolic (D) velocities 
were recorded with the sample volume positioned 1 cm below the orifice of the right 
superior pulmonary vein in the left atrium.
Two-dimensional speckle tracking
2D speckle tracking analyses were performed on standard echocardiographic grey 
scale images. LV longitudinal function was determined from the 3 apical (2-, 3- and 
4-chamber) views whereas the RV free wall longitudinal function was determined from 
the apical 4-chamber view only (Figure 1). During analysis, the endocardial border was 
manually traced at end-systole and the region of interest width adjusted to include the 
entire myocardium. The software then automatically tracks and accepts segments of 
good tracking quality and rejects poorly tracked segments, while allowing the observer 
to manually override its decisions based on visual assessments of tracking quality. Peak 
longitudinal strain, peak systolic SR and peak early diastolic SR for both the LV and RV 
myocardium were determined. Mean LV global longitudinal strain/SR were calculated 
from the 3 individual apical global longitudinal strain/SR curves respectively, whereas 
RV free wall longitudinal strain/SR were obtained from the apical 4-chamber view. All 
strain and SR measurements were exported to a spreadsheet (Microsoft ® Excel 2002, 
Microsoft Corporation, Redmond, WA).
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Previous work has reported the intra- and inter-observer variabilities in our laboratory 
as expressed by mean absolute difference for longitudinal strain (1.2 ± 0.5% and 0.9 ± 
1.0%), systolic SR (0.10 ± 0.06 s-1 and 0.09 ± 0.08 s-1) and early diastolic SR (0.08 ± 0.05 s-1 
and 0.13 ± 0.09 s-1).10
The study was approved by the local institutional ethics committee and written informed 
consent was obtained from all patients.
statistical analysis
Due to the relatively small number of patients, all continuous variables were presented 
as median and 25th and 75th percentiles. Mann-Whitney U test was used to compare 2 
groups of unpaired data. Multivariable linear regression analysis was used to identify 
independent correlates of LV and RV strain/SR. To generate the multivariable models, 
univariate variables with p value ≤ 0.20 were entered as covariates. To avoid multico-
linearity between the univariate correlates, a tolerance level of > 0.5 (corresponding to 
 
Figure 1. Graphical example of the speckle tracking analyses to derive left and right ventricular myocardial 
strain and SR measurements. Mean LV global longitudinal strain/SR was calculated from the 3 individual (4-, 
2- and 3-chamber) strain/SR curves, whereas the RV free wall strain/SR was derived from the 4 chamber view 
only. The mean global LV longitudinal strain, systolic SR and diastolic SR were -16.6%, -0.85 s-1, and 1.01 s-1 
respectively. The mean RV free wall longitudinal strain, systolic SR and diastolic SR were -29.0%, -1.30 s-1, and 
1.31 s-1 respectively. LV = left ventricular; RV = right ventricular; SR = strain rate.
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a correlation coefficient of > 0.7) was set. A 2-tailed p value of < 0.05 was considered 
significant. All statistical analyses were performed using SPSS for Windows (SPSS Inc, 
Chicago), version 17.
The authors had full access to the data and take responsibility for its integrity. All authors 
have read and agree to the manuscript as written.
ResULTs
The median age was 59 years (54, 62 years), and the median diabetes diagnosis duration 
was 4 years (range 1 to 11 years). The mean myocardial triglyceride content was 0.78 
± 0.42%. When the study sample was dichotomized based on the median myocardial 
triglyceride level of 0.76%, there were no significant differences in blood glucose level, 
glycated hemoglobin levels and lipid profiles between the 2 groups (Table 1).
Left ventricular volumes and functions
Table 2 summarizes the LV volumes and EF derived from MRI, and LV myocardial strain 
and SR derived from echocardiographic 2D speckle tracking analyses. There were no 
Table 1. Clinical and biochemical characteristics





(n = 42) (n = 21) (n = 21)
Clinical
Age (years) 59 (54, 62) 58 (51, 62) 60 (55, 63) 0.20
Body mass index (kg/m2) 26.9 (25.0, 30.2) 26.9 (25.0, 28.9) 26.6 (25.0, 31.1) 0.67
Body surface area (m2) 2.08 (2.00, 2.22) 2.10 (2.01, 2.20) 2.06 (1.97, 2.25) 0.89
Waist circumference (cm) 98.5 (93.9, 106.0) 98.0 (93.0, 103.0) 102.0 (95.0, 108.0) 0.26
Diabetes duration (years) 4.0 (1.0, 7.3) 3.0 (1.5, 7.0) 4.0 (1.0, 7.5) 0.83
Heart rate (beats/min) 71 (65, 82) 72 (66, 82) 70 (64, 80) 0.68
Systolic blood pressure (mmHg) 139 (130, 144) 134 (126, 140) 141 (133, 148) 0.025
Diastolic blood pressure (mmHg) 77 (71, 82) 77 (71, 84) 76 (73, 81) 0.83
Biochemical
Blood glucose (mmol/L) 8.2 (7.3, 9.8) 8.1 (7.4, 9.0) 8.4 (7.1, 10.9) 0.35
Glycated hemoglobin (%) 6.2 (5.9, 6.8) 6.2 (5.9, 6.9) 6.0 (5.9, 6.7) 0.61
Plasma triglyceride (mmol/L) 1.50 (0.90, 2.30) 1.10 (0.85, 2.05) 1.80 (1.40, 2.80) 0.059
Total cholesterol (mmol/L) 4.60 (3.90, 5.10) 4.30 (3.85, 4.75) 4.90 (4.00, 5.30) 0.070
High-density lipoprotein cholesterol (mmol/L) 1.16 (0.98, 1.40) 1.24 (1.01, 1.44) 1.10 (0.89, 1.24) 0.097
Low-density lipoprotein cholesterol (mmol/L) 2.55 (2.00, 3.05) 2.40 (1.95, 2.90) 2.90 (2.05, 3.55) 0.17
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significant differences in LV volumes and LVEF between patients with high versus low 
myocardial triglyceride content. In addition, there were no differences in LV mass index 
(48.1 g/m2 [46.5, 53.1 g/m2] vs. 50.9 g/m2 [46.5, 55.8 g/m2], p = 0.37) and LV mass-cavity 
ratio (0.70 [0.61, 0.80] vs. 0.73 [0.61, 0.79], p = 0.79) between the 2 groups of patients. 
Similarly, there were no significant differences in traditional parameters of LV diastolic 
function including transmitral E/A ratio (0.89 [0.75, 1.11] vs. 0.97 [0.72, 1.12], p = 0.97), 
deceleration time (206 ms [157, 214 ms] vs. 192 ms [165, 203 ms], p = 0.35), isovolumic 
relaxation time (84 ms [77, 94 ms] vs. 78 ms [73, 92 ms], p = 0.44) and pulmonary S/D 
ratio (1.45 [1.23, 1.68] vs. 1.35 [1.17, 1.64], p = 0.37) between the 2 groups of patients. 
However, patients with higher myocardial triglyceride content had greater impairment 
of global LV longitudinal strain and SR (Table 2).
To identify the independent correlates of global LV longitudinal strain and SR, univari-
ate correlates with a p value ≤ 0.20 (age, systolic blood pressure, fasting blood glucose 
level, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol and 
Table 2. Left and right ventricular volumes, ejection fraction, strain and strain rate






(n = 42) (n = 21) (n = 21)
LEFT VENTRICLE
Magnetic Resonance Imaging
LVEDVI (mL/m2) 71.6 (64.5, 78.1) 73.2 (66.6, 80.8) 68.0 (63.4, 78.3) 0.31
LVESVI (mL/m2) 32.0 (27.6, 37.0) 32.2 (30.0, 37.3) 31.1 (25.6, 36.3) 0.23
LVEF (%) 54.6 (51.3, 58.1) 54.0 (50.5, 56.8) 55.1 (52.8, 58.8) 0.22
2D Speckle Tracking
LV global strain (%) -17.9 (-17.0, -19.6) -19.3 (-18.5, -20.1) -17.1 (-16.3, -17.7)  < 0.001
LV global systolic SR (s-1) -0.98 (-0.87, -1.06) -1.02 (-0.96, -1.14) -0.87 (-0.82, -0.98)  < 0.001
LV global diastolic SR (s-1) 1.05 (0.91, 1.16) 1.11 (1.05, 1.23) 0.93 (0.77, 1.11) 0.003
RIGHT VENTRICLE
Magnetic Resonance Imaging
RVEDVI (mL/m2) 70.7 (63.9, 73.9) 71.1 (64.0, 76.7) 69.3 (63.6, 73.0) 0.43
RVESVI (mL/m2) 33.2 (30.1, 35.9) 34.9 (30.2, 36.9) 31.9 (29.0, 35.8) 0.31
RVEF (%) 52.0 (49.5, 53.7) 52.0 (49.6, 53.4) 53.0 (48.8, 54.4) 0.63
2D Speckle Tracking
RV free wall strain (%) -26.2 (-23.5, -28.4) -27.7 (-25.1, -30.2) -24.5 (-19.0, -27.7) 0.016
RV free wall systolic SR (s-1) -1.83 (-1.62, -2.23) -2.11 (-1.77, -2.46) -1.74 (-1.44, -1.85) 0.005
RV free wall diastolic SR (s-1) 1.79 (1.44, 2.21) 2.10 (1.75, 2.61) 1.65 (1.12, 1.86) 0.001
LV = left ventricular; RV = right ventricular; EDVI = end-diastolic volume index; ESVI = end-systolic volume index; EF = ejec-
tion fraction; 2D = 2-dimensional; SR = strain rate
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myocardial triglyceride content) were all entered into multiple linear regression models. 
Total cholesterol was not included in the model due to high colinearity with low-density 
lipoprotein cholesterol. Table 3 showed that the myocardial triglyceride content mea-
sured by MR spectroscopy was an independent correlate of global LV longitudinal strain, 
systolic SR and diastolic SR.
Right ventricular volumes and functions
Table 2 summarizes the RV volumes, EF, free wall longitudinal strain and SR. Similarly, 
there were no significant differences in MRI derived RV volumes and RVEF between the 
2 groups of patients. However, patients with higher myocardial triglyceride content had 
greater impairment of RV free wall longitudinal strain and SR.
To identify independent correlates of RV free wall longitudinal strain and SR, age, fast-
ing blood glucose level, high-density lipoprotein cholesterol, low-density lipoprotein 
cholesterol and myocardial triglyceride content were all entered into the multiple linear 
regression models. Table 4 showed that myocardial triglyceride content was an inde-
pendent correlate of RV free wall longitudinal strain, systolic SR and diastolic SR.
Table 3. Independent correlates of left ventricular global longitudinal strain, global longitudinal systolic 
strain rate and global longitudinal diastolic strain rate


















Age -0.197 0.28 -0.092 0.62 -0.179 0.27
Systolic blood pressure 0.034 0.82 0.104 0.49 0.003 0.98
Blood glucose 0.192 0.23 0.209 0.20 -0.455 0.003
High-density lipoprotein 
cholesterol
-0.146 0.43 -0.043 0.82 -0.003 0.99
Low-density lipoprotein 
cholesterol
0.161 0.27 0.197 0.19 0.054 0.67
Myocardial triglyceride content 0.373 0.036 0.373 0.039 -0.326 0.038




In the present study, MRI assessment revealed similar LV/RV volumes and EF in type 2 
diabetic patients with high versus low myocardial triglyceride content, as measured by 
MR spectroscopy. However, 2D speckle tracking deformation imaging demonstrated 
greater impairments of biventricular strain/SR in patients with higher myocardial tri-
glyceride content. Myocardial triglyceride content was an independent correlate of LV 
and RV longitudinal strain, systolic SR and diastolic SR.
Myocardial substrate metabolism and steatosis
The etiology of diabetic heart disease is complex and multifactorial, ranging from al-
tered myocardial metabolism, up-regulation of the renin-angiotensin system, increased 
oxidative stress, endothelial dysfunction with microvascular disease, autonomic 
neuropathy, and altered myocardial structure with fibrosis.1 However, recent evidence 
suggests the role of myocardial lipotoxic injury from lipid oversupply contributing to 
diabetic heart disease.19
Under normal physiological conditions, fatty acids are absorbed through the intes-
tines and stored as triglycerides within adipocytes with minimal accumulation within 
non-adipose tissues such as the heart. However, the combination of diabetes with its 
metabolic derangements, insulin resistance, visceral adiposity and increased dietary 
fatty acid intake, all lead to increased myocardial fatty acid delivery and uptake. This 
results in the accumulation of intracellular triglyceride within the myocyte cytoplasm 
(also known as steatosis).19-22 However, part of the excess fatty acid is redirected into 
non-oxidative pathways giving rise to toxic fatty acid intermediates such as ceramide. 
These toxic fatty acid intermediates disrupt normal cellular signalling, leading to mito-
Table 4. Independent correlates of right ventricular free wall longitudinal strain, free wall longitudinal sys-
tolic strain rate and free wall longitudinal diastolic strain rate




















Age -0.084 0.67 -0.280 0.098 0.050 0.76
Blood glucose 0.064 0.73 0.162 0.30 -0.014 0.92
High-density lipoprotein cholesterol 0.094 0.69 -0.354 0.048 0.425 0.017
Low-density lipoprotein cholesterol -0.096 0.57 -0.331 0.024 0.288 0.044
Myocardial triglyceride content 0.457 0.020 0.321 0.048 -0.403 0.013
RV = right ventricular; SR = strain rate
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chondrial dysfunction, cellular damage, apoptosis, and eventual replacement fibrosis 
and myocardial contractile dysfunction. Thus, although it is currently accepted that 
intracellular triglycerides are probably inert, its intracellular concentration is reflective 
of an increased concentration of toxic fatty acid intermediates. Therefore, the observed 
relationship between intracellular triglyceride accumulation and myocardial dysfunc-
tion likely represents an association, mediated by the accumulation of toxic interme-
diates from increased non-oxidative fatty acid metabolism. Although animal studies 
have shown an association between myocardial triglyceride accumulation, eccentric 
LV hypertrophy and systolic dysfunction23, human studies showing similar association 
between myocardial steatosis and myocardial dysfunction have been limited.
Myocardial steatosis and myocardial dysfunction
Several studies have examined the relationship between myocardial triglyceride ac-
cumulation and LV function.2, 3  McGavock and co-workers showed that there was no 
association between myocardial triglyceride accumulation and LV diastolic function.2 
However, their results could be confounded by their inclusion of a heterogeneous group 
of diabetic patients and the use of insulin (a lipogenic agent).2 In contrast, Rijzewijk and 
co-workers were able to demonstrate diastolic dysfunction in a group of uncomplicated 
diabetic patients with myocardial steatosis when compared to healthy controls.3 How-
ever, both groups could not demonstrate a correlation between myocardial triglyceride 
content and LVEF.2, 3 Thus, these diabetic patients have traditionally been labeled as 
having diastolic dysfunction with normal systolic function. However, this is largely a 
misnomer due to the insensitivity of conventional systolic parameters such as LVEF in 
identifying subtle changes in myocardial contractility.24 In contrast, 2D speckle tracking 
derived myocardial strain and SR indices are more sensitive in detecting subclinical 
myocardial dysfunction and have been shown to be impaired in diabetic patients com-
pared to normal controls.4, 8, 10
To date, no studies have related myocardial strain and SR analyses by echocardiography 
to myocardial triglyceride accumulation. In the present study, MRI derived LV volumes 
and EF were similar between patients with high versus low myocardial triglyceride levels. 
However, the study was first to demonstrate that patients with high myocardial triglyc-
eride levels had significantly greater impairment of LV myocardial longitudinal strain, 
systolic SR and diastolic SR. Furthermore, as the diabetic metabolic derangements with 
subsequent myocardial steatosis should hypothetically have a similar adverse effect 
on the RV, the present study also demonstrated RV free wall myocardial systolic and 
diastolic dysfunctions in patients with high myocardial triglyceride levels. The present 
study was first to demonstrate an independent association between myocardial tri-
glyceride accumulation in diabetic patients and biventricular myocardial dysfunctions. 
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However, intracellular surplus triglyceride itself is likely to be relatively inert, while the 
lipid intermediates derived from non-oxidative pathways are probably responsible 
for lipotoxic injury and eventual cellular apoptosis.20 Thus, the observed relationship 
between myocardial triglyceride accumulation and myocardial dysfunction is probably 
an association secondary to the adverse diabetic metabolic profile rather than a causal 
relationship.
Clinical implications
The novel aspect of the current study was the demonstration of the independent as-
sociation between myocardial triglyceride content and biventricular myocardial systolic 
and diastolic functions. In animal studies, therapeutic interventions aiming at reducing 
myocardial triglyceride accumulation have demonstrated beneficial myocardial ef-
fects.23 Thus, future human studies assessing the effectiveness of anti-steatotic therapy 
in type 2 diabetics may include quantifications of myocardial triglyceride content by 
spectroscopy, and assessments of myocardial functions by strain/SR imaging on 2D 
speckle tracking echocardiography.
study limitations
This was a relatively small study and several characteristics such as LV and RV volumes 
were not statistically different between patients with high versus low myocardial triglyc-
eride content. Thus, future studies should include more patients to avoid possible type 
1 error.
ConCLUsIons
Uncomplicated type 2 diabetic patients with high levels of myocardial triglyceride con-
tent and no ischemia showed greater impairments of biventricular myocardial strain 
and SR but similar biventricular volumes and EF compared to patients with low levels 
of myocardial triglyceride. Myocardial triglyceride accumulation was an independent 
correlate of biventricular myocardial strain and SR.
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background: Diabetic patients have increased interstitial myocardial fibrosis on histo-
logical examination. Magnetic resonance imaging (MRI) T1 mapping is a previously vali-
dated imaging technique that can quantify the burden of global and regional interstitial 
fibrosis. However, the association between MRI T1 mapping and subtle left ventricular 
(LV) dysfunction in diabetic patients is unknown.
Methods: Fifty diabetic patients with normal LV ejection fraction (EF) and no underly-
ing coronary artery disease or regional macroscopic scar on MRI delayed enhancement 
were prospectively recruited. Diabetic patients were compared with 19 healthy controls 
who were frequency matched in age, sex and body mass index.
Results: There were no significant differences in mean LV end-diastolic volume index, 
end-systolic volume index and LVEF between diabetic patients and healthy controls. 
Diabetic patients had significantly shorter global contrast-enhanced myocardial T1 time 
(425 ± 72 ms vs. 504 ± 34 ms, p < 0.001). There was no correlation between global con-
trast-enhanced myocardial T1 time and LVEF (r = 0.14, p = 0.32) in the diabetic patients. 
However, there was good correlation between global contrast-enhanced myocardial 
T1 time and global longitudinal strain (r = -0.73, p < 0.001). Global contrast-enhanced 
myocardial T1 time was the strongest independent determinant of global longitudinal 
strain on multivariate analysis (standardized β  = -0.626, p < 0.001). Similarly, there was 
good correlation between global contrast-enhanced myocardial T1 time and septal E’ (r 
= 0.54, p < 0.001). Global contrast-enhanced myocardial T1 time was also the strongest 
independent determinant of septal E’ (standardized β = 0.432, p < 0.001).
Conclusions: A shorter global contrast-enhanced myocardial T1 time was associated 
with more impaired longitudinal myocardial systolic and diastolic function in diabetic 
patients.
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InTRoDUCTIon
Diabetic patients can develop changes in cardiac structure and myocardial dysfunction 
that are independent of hypertension and coronary artery disease.1-3 Although the 
underlying pathogenesis is likely to be multifactorial1-4, there is eventually accelerated 
cellular apoptosis and necrosis resulting in increased perivascular and diffuse intersti-
tial fibrosis within the myocardium.2 Importantly, previous studies have demonstrated 
histological evidence of increased diffuse microscopic fibrosis in the myocardium of 
diabetic patients.5, 6 In magnetic resonance imaging (MRI), gadolinium-based contrast 
agents accumulates and have increased wash-out times within these myocardial fibrous 
tissues due to the absence of viable myocytes and increased volume of distribution.7 Us-
ing MRI T1 mapping sequences, global contrast-enhanced T1 relaxation time can detect 
and quantify the extent of diffuse interstitial myocardial fibrosis. A recent independent 
study has histologically validated and demonstrated an inverse linear relationship 
between global contrast-enhanced myocardial T1 time and the burden of myocardial 
interstitial fibrosis.8 Thus, shorter global contrast-enhanced myocardial T1 time repre-
sent more interstitial fibrosis.8
Diabetic patients can develop subtle left ventricular (LV) myocardial dysfunction despite 
normal LV ejection fraction (EF).9, 10 Advanced echocardiographic techniques such as 
tissue Doppler imaging and 2-dimensional (2D) speckle tracking are highly sensitive for 
early detection of subclinical diabetic myocardial dysfunction.10, 11 Therefore, increased 
interstitial fibrosis within the diabetic myocardium may result in subtle LV dysfunction 
which can be detected by these sophisticated echocardiographic techniques. Thus, the 
aims of the present study were:
1) to quantify and compare global contrast-enhanced myocardial T1 time between 
diabetic patients with normal LVEF and normal controls, and
2) to correlate global contrast-enhanced myocardial T1 time with LV myocardial func-
tional assessment using global longitudinal strain by 2D speckle tracking analysis.12
MeTHoDs
Patient population and study protocol
Sixty-five diabetic patients (35 type 1 and 30 type 2) were prospectively recruited in 
the present study. Inclusion criteria included diabetes mellitus diagnosed according to 
World Health Organization criteria.13 Exclusion criteria included age < 18 years, rhythm 
other than sinus rhythm, significant coronary artery disease, previous myocardial 
infarction, presence of segmental wall motion abnormalities or presence of delayed 
118  
 
contrast enhancement (DCE) on MRI indicative of macroscopic fibrosis/scar from pre-
vious myocardial infarction, LVEF < 50%, and moderate or severe valvular stenosis or 
regurgitation. However, 15 type 2 diabetic patients were excluded from the study due to 
the presence of DCE on MRI that was indicative of previous silent myocardial infarction. 
Thus, a total of 50 diabetic patients (35 type 1 and 15 type 2) were included in the final 
analysis. The study was approved by the local institutional ethics committee and written 
informed consent was obtained.
In addition, 19 normal control subjects were also included. The normal controls were 
frequency matched against the diabetic patients for age, gender and body mass index. 
All control subjects were clinically referred for evaluation of atypical chest pain, palpita-
tions or syncope without murmur and had normal MRI examinations. Exclusion criteria 
for the control subjects included history of diabetes mellitus, hypertension, previous 
myocardial infarction, presence of segmental wall motion abnormalities or presence of 
DCE on MRI, LVEF < 50%, and moderate or severe valvular stenosis or regurgitation.
All subjects underwent a comprehensive MRI examination (including administration 
of gadolinium-based contrast for DCE and quantification of global contrast-enhanced 
myocardial T1 time).
All diabetic patients underwent a complete transthoracic echocardiographic examina-
tion including assessment of myocardial systolic and diastolic function by 2D speckle 
tracking strain and tissue Doppler septal E’ analyses respectively. Baseline clinical 
variables recorded included diabetic complications (including diabetic retinopathy, 
neuropathy and nephropathy), cardiac risk factors, and glomerular filtration rates (GFR) 
calculated by the Modification of Diet in Renal Disease formula as recommended by the 
National Kidney Foundation, Kidney Disease Outcomes Quality Initiative Guidelines.14
LV volumes, EF and mass were quantified in all the patients using MRI as gold standard. 
In addition, global contrast-enhanced myocardial T1 time was also quantified, with a 
shorter T1 time suggestive of more fibrosis.8 Previous study has demonstrated that the 
assessment of global longitudinal strain by 2D speckle tracking echocardiography is the 
most sensitive marker of myocardial systolic function in diabetic patients compared to 
circumferential or radial strain.10 Thus, to evaluate the effects of increasing interstitial fi-
brosis on LV systolic function, the linear correlations between global contrast-enhanced 
myocardial T1 time, LVEF and global longitudinal strain were explored. Similarly, the 
linear correlation between global contrast-enhanced myocardial T1 time and septal E’ 
was also determined. Finally, the independent effect of global contrast-enhanced myo-
cardial T1 time on global longitudinal strain (marker of myocardial systolic function) 
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and septal E’ (marker of myocardial diastolic function) were determined in a multivari-
ate analysis corrected for clinical and MRI covariates.
Cardiac magnetic resonance imaging
All patients underwent MRI examinations for assessment of LV volumes, LVEF, global 
contrast-enhanced myocardial T1 time and DCE with a 1.5-T whole-body MRI scanner 
(Gyroscan ACS/NT15; Philips, Best, the Netherlands). LV volumes and EF were assessed 
by imaging the entire heart in the short-axis orientation with ECG-gated breath-hold 
balanced steady state free-precession imaging. Cine imaging parameters included the 
following: echo time = 1.7 ms, repetition time = 3.4 ms, flip-angle = 35°, slice thickness 
= 10 mm with a gap of 0 mm, field of view = 400 x 400 mm, reconstructed matrix size = 
256 x 256 pixels.
DCE images were acquired 15 minutes after bolus injection of gadolinium diethylene-
triamine penta-acetic acid (Magnevist, Schering, Berlin, Germany; 0.15 mmol/kg) with 
an inversion recovery gradient echo sequence with parallel imaging (SENSE, accel-
eration factor 2). Inversion time was determined by real-time plan scan (Look-Locker 
sequence) to null normal myocardium signal. DCE images of the heart were acquired in 
1 breath-hold using 20 – 24 short-axis slices (depending on the heart size). DCE imaging 
parameters were: echo time = 1.06 ms, repetition time = 3.7 ms, flip-angle = 15°, slice 
thickness = 5 mm, field of view = 400 x 400 mm, reconstructed matrix size = 256 x 256 
pixels. All subjects included in the present study had no evidence of DCE suggestive of 
macroscopic myocardial scar/fibrosis.
Contrast-enhanced myocardial T1 mapping with the Look-Locker sequence was used 
to cycle through images over a range of inversion times.15 The sequence consisted of an 
ECG-gated, inversion recovery gradient echo sequence with parallel imaging (SENSE, 
acceleration factor 1.8). Thirty-three images were acquired sequentially at increasing 
inversion times 10 minutes after bolus injection of gadolinium diethylenetriamine 
penta-acetic acid in 1 breath-hold. The Look-Locker sequence imaging parameters were: 
echo time = 1.0 ms, repetition time = 3.79 ms, flip-angle = 8°, inversion time 150 ms, slice 
thickness = 10 mm, field of view = 370 x 370 mm, reconstructed matrix size = 256 x 256 
pixels. These images were then processed with a curve fitting technique to generate T1 
maps as described below.
Evaluation of LV mass, volumes and function. All MRI images were digitally stored on 
hard disks and analyzed offline using dedicated quantitative software (MASS, Medis, 
Leiden, The Netherlands). LV endocardial and epicardial borders were outlined on the 
short-axis cine images. Papillary muscles were considered as part of the LV cavity, and 
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epicardial fat was excluded. LV end-diastolic mass index, LV end-diastolic volume index 
(EDVI) and LV end-systolic volume index (ESVI) were measured and corrected for body 
surface area.16 LVEF was calculated and expressed as a percentage. Stroke volume was 
calculated as the difference between LV end-diastolic and end-systolic volumes, and 
cardiac output was calculated as the product of stroke volume and heart rate.
Evaluation of T1 mapping. T1 recovery is a basic fundamental parameter of magnetic 
resonance imaging and refers to the recovery of “longitudinal magnetization” of protons 
along the main magnetic field in the z-axis. The rate of this recovery can be described by 
the exponential equation: MZ(t) = MZ(t = ∞)[1 - e-t/T1], where MZ(t) is the sample magnetiza-
tion observed at time = t = inversion time for an inversion recovery experiment, and MZ(t 
= ∞) denotes the equilibrium magnetization in the z-axis. To quantify contrast-enhanced 
myocardial T1 time, LV endocardial and epicardial borders were outlined from a single 
mid-ventricular short-axis Look-Locker sequence of varying inversion times using MASS 
research software (MASS V2010-EXP, Leiden University Medical Center, Leiden, The 
Netherlands) (Figure 1).
As the different inversion recovery times fall into different cardiac phases during the 
Look-Locker sequence, it resulted in movement of the left ventricle. Thus, the endo- and 
epicardial contours were manually drawn in each image (total of 33 images) to ensure 
the inclusion of only myocardium and the exclusion of blood pool/epicardial fat. The 
software then permits automatic pixel-by-pixel quantification of contrast-enhanced 
myocardial T1 time by fitting data acquired at the various inversion times.17 The location 
of a pixel position within the myocardium can be described by its relative position across 
the local wall thickness (relative distance to the endocardial and epicardial contour) and 
its relative position along the length of the defined myocardial contours (for short-axis 
images, the longitudinal location is defined by the angular position relative to the pos-
terior junction of the RV free wall with the LV). Following this definition, signal intensity 
curves of matching pixels were reconstructed and used for T1 fitting. Prior to fitting, the 
signal intensity of initial phases was inverted. The best fit for T1 value (corresponding to 
the smallest fitting error) was determined iteratively by inverting initial phases up to a 
time corresponding to the zero crossing of the longest possible T1 value and performing 
a fit for each case. The Levenberg-Marquardt algorithm was used to perform a nonlinear 
fit of the model to the measured data. Only pixels where the χ2 test for goodness of fit 
was significant with level of significance α = 0.05 were included in the final average T1 
value.
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A global contrast-enhanced myocardial T1 time was subsequently automatically calcu-
lated as the average of all the individual contrast-enhanced myocardial T1 time from 
each pixel. As the function of gadolinium-based contrast agents normally shortens T1 
time, and its wash-out time increases within myocardial fibrous tissues due to increased 
volume of distribution7, a shorter global contrast-enhanced myocardial T1 time conse-
quently is suggestive of more interstitial fibrosis.8 The derived global contrast-enhanced 
myocardial T1 time is generally expected to be shorter than the true T1 time of myo-
cardium due to the multiple readout gradients from the Look-Locker sequence and the 
presence of gadolinium-based contrast agents.
Transthoracic echocardiography
Transthoracic echocardiography was performed with the diabetic patients at rest us-
ing commercially available ultrasound transducer and equipment (M4S probe, Vivid 7, 
GE-Vingmed, Horten, Norway). All images were digitally stored on hard disks for offline 
analysis (EchoPAC version 108.1.5, GE-Vingmed, Horten, Norway). A complete 2D, color, 
pulsed and continuous-wave Doppler echocardiogram was performed according to 
standard techniques.18, 19
Transmitral and pulmonary venous flow velocities were recorded using conventional 
pulsed-wave Doppler echocardiography in the apical 4 chamber view using a 2 mm 
sample volume. Transmitral early (E wave) and late (A wave) diastolic velocities as well 
as deceleration time were recorded at the mitral leaflet tips. The pulmonary venous 
peak systolic (S) and diastolic (D) velocities were recorded with the sample volume 
positioned 1 cm below the orifice of the right superior pulmonary vein in the left atrium.
Evaluation of myocardial systolic function. Quantification of myocardial systolic func-
tion was performed using 2D speckle tracking echocardiography.12 Briefly, 2D speckle 
tracking is a commercial software (EchoPAC version 108.1.5, GE-Vingmed, Horten, Nor-
way) that performs semi-automated frame-by-frame tracking of natural acoustic mark-
ers within the myocardium seen on standard 2D gray-scale echocardiographic images, 
and it permits direct quantification of global longitudinal myocardial function. Previous 
study has demonstrated that the assessment of global longitudinal strain and strain rate 
by 2D speckle tracking echocardiography is the most sensitive marker of myocardial 
systolic function in diabetic patients and is superior to LVEF, circumferential and radial 
strain/strain rate.10
To obtain global longitudinal strain/strain rate, 2D speckle tracking analyses were per-
formed on grey scale images of the LV obtained in the 3 apical (3-, 4- and 2-chamber) 
views (Figure 2). During analysis, the endocardial border was manually traced at end-
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systole and the region of interest width adjusted to include the entire myocardium. The 
software then automatically tracks and accepts segments of good tracking quality and 
rejects poorly tracked segments, while allowing the observer to manually override its 
decisions based on visual assessments of tracking quality. From the 3 individual apical 
views, myocardial systolic function was calculated as the average of the 3 peak global 
longitudinal strain.10 All strain measurements were exported to a spreadsheet (Microsoft 
® Excel 2002, Microsoft Corporation, Redmond, WA).
Evaluation of myocardial diastolic function. Quantification of myocardial diastolic 
function was performed using septal E’ and E/e’ ratio by tissue Doppler imaging.20 Color-
coded tissue Doppler images of the left ventricle were obtained in apical  4-chamber view 
acquired at the highest possible frame rates ( > 150 frames/s) during end-expiration and 
stored for off-line analysis. Peak early diastolic myocardial velocities (E’) was measured 
in the basal septal mitral annulus, and the ratio of peak transmitral E wave to septal E’ 
was calculated (septal E/e’ ratio).20
Variability analysis
To determine intra- and inter-observer variabilities for global contrast-enhanced myo-
cardial T1 time, measurements were repeated in 10 randomly selected patients. The 
intra- and inter-observer variabilities for global contrast-enhanced myocardial T1 time 
expressed as mean absolute differences ± 1 standard deviation were 12.6 ± 12.7 ms and 
12.4 ± 10.0 ms respectively.
 
Figure 2. Quantification of longitudinal myocardial function by 2-dimensional speckle tracking echocardiog-
raphy. Longitudinal strain was quantified from the 3 apical (3-, 4- and 2 chamber) views. The 2-dimensional 
speckle tracking software then automatically displays the respective segmental (colored lines) and global (sin-
gle white dotted line) longitudinal strain curves. Longitudinal myocardial function was then calculated as the 
mean of the 3 individual peak global longitudinal strain values, and expressed as a percentage. Longitudinal 
strain is normally expressed as a negative percentage, indicating percentage shortening of the myocardium.
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Previous work from our laboratory has reported the intra- and inter-observer vari-
abilities for mean global longitudinal strain as mean absolute differences ± 1 standard 
deviation of 1.2 ± 0.5% and 0.9 ± 1.0% respectively.10
statistical analysis
All continuous variables were presented as mean ± 1 SD unless otherwise stated. 
Categorical variables were presented as frequencies and percentages. Comparisons 
between diabetic and control patients were performed using Mann-Whitney U test and 
Chi square test for continuous and categorical variables respectively. Pearson correla-
tion was employed to examine the linear association between 2 continuous variables. 
Multiple linear regression analyses were then performed to identify independent clinical 
and echocardiographic determinants of global longitudinal strain and septal E’ for dia-
betic patients. All univariable predictors with p < 0.20 were simultaneously entered into 
the multiple linear regression models. Validity of the multiple linear regression models 
were established by confirming the residuals to be normally distributed. A 2-tailed p 
value of < 0.05 was considered significant. All statistical analyses were performed using 
SPSS for Windows (SPSS Inc, Chicago), version 17.
ResULTs
Table 1 summarizes the baseline clinical characteristics of the 50 diabetic patients and 
19 control subjects. There were no differences in age, gender, blood pressure, hemo-
globin and GFR between the diabetic patients and control subjects. A total of 28 (56%) 
diabetic patients were treated for hypertension. A respective 31 (62.0%), 12 (24.0%) and 
7 (14.0%) diabetic patients had evidence of diabetic retinopathy, peripheral neuropathy 
and nephropathy respectively. However, no diabetic patients had a history of previous 
myocardial infarction or underlying significant coronary artery disease by virtue of the 
study exclusion criteria.
Magnetic resonance imaging and echocardiography
Table 2 summarizes the baseline MRI and echocardiographic characteristics of the dia-
betic patients and normal controls. There were no significant differences in LVEDVI (79.1 
± 14.4 vs. 79.8 ± 17.2 mL/m2, p = 0.60), LVESVI (33.3 ± 7.6 vs. 34.7 ± 7.5 mL/m2, p = 0.23), LV 
mass index (49.0 ± 7.6 vs. 50.9 ± 8.7 g/m2, p = 0.24) and LVEF (58.1 ± 4.6 vs. 56.2 ± 3.8%, p = 
0.10) between the diabetic patients and control subjects. No patients had evidence of re-
gional DCE suggestive of focal macroscopic scar/fibrosis by virtue of the study exclusion 
criteria. However, diabetic patients had significantly shorter global contrast-enhanced 
myocardial T1 time (425 ± 72 vs. 504 ± 34 ms, p < 0.001). Furthermore, there was a wide 
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Age (years) 51 ± 10 45 ± 15 0.15
Male gender (%) 54.0 63.2 0.49
Body mass index (kg/m2) 26.3 ± 3.7 26.1 ± 4.4 0.84
Medical history
Retinopathy (%) 62.0 - -
Neuropathy (%) 24.0 - -
Nephropathy (%) 14.0 - -
Systolic blood pressure (mmHg) 129 ± 10 123 ± 14 0.08
Diastolic blood pressure (mmHg) 76 ± 7 73 ± 8 0.14
Laboratory
Hemoglobin (g/dL) 14.2 ± 1.3 14.1 ± 1.1 0.76
GFR (mL/min/1.73m2) 92.8 ± 18.9 97.9 ± 18.8 0.26
HbA1c (%) 8.0 ± 1.4 - -
*p value by Mann-Whitney U test and Chi square test for continuous and categorical variables respectively. GFR = glomeru-
lar filtration rate; HbA1c = glycated hemoglobin level.







LV mass index (g/m2) 49.0 ± 7.6 50.9 ± 8.7 0.24
LVEDVI (mL/m2) 79.1 ± 14.4 79.8 ± 17.1 0.60
LVESVI (mL/m2) 33.3 ± 7.6 34.7 ± 7.5 0.23
LVEF (%) 58.1 ± 4.6 56.2 ± 3.8 0.10
Cardiac output (L/min) 6.5 ± 1.3 6.2 ± 2.2 0.44
Global contrast-enhanced myocardial 
T1 time (ms)
425 ± 72 504 ± 34  < 0.001
Echocardiography
Heart rate (beats/min) 74 ± 12 67 ± 12 0.10
Transmitral E/A ratio 1.13 ± 0.34 1.19 ± 0.52 0.97
Deceleration time (ms) 194 ± 44 266 ± 68  < 0.001
Pulmonary S/D ratio 1.31 ± 0.28 1.22 ± 0.22 0.20
Global longitudinal strain (%) -16.1 ± 1.4 -20.2 ± 1.0  < 0.001
Septal E’ (cm/s) 7.3 ± 1.1 8.7 ± 1.8 0.005
Septal E/e’ ratio 10.0 ± 3.3 8.4 ± 2.0 0.03
*p value by Mann-Whitney U test. EDVI = end-diastolic volume index; ESVI = end-systolic volume index; EF = ejection frac-
tion; LV = left ventricular.
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range of global contrast-enhanced myocardial T1 time in diabetic patients ranging from 
271 ms to 604 ms. There was no difference in the global contrast-enhanced myocardial 
T1 time in diabetic patients with and without a history of hypertension (422 ± 83 vs. 429 
± 52 ms, p = 0.74).
Global contrast-enhanced myocardial T1 time and LV function
Table 3 outlines the univariate Pearson correlations between global contrast-enhanced 
myocardial T1 time and different parameters of LV function for the entire study popula-
tion. There was no significant correlation between global contrast-enhanced myocardial 
T1 time and LVEF (r = 0.04, p = 0.76; Figure 3). Similarly, there was no significant correla-
tion between global contrast-enhanced myocardial T1 time and transmitral E/A ratio (r 
= -0.10, p = 0.44). However, there was a good correlation with global longitudinal strain 
(r = -0.71, p < 0.001; Figure 4) and septal E’ (r = 0.47, p < 0.001; Figure 5), suggesting 
that a shorter global contrast-enhanced myocardial T1 time was associated with more 
impaired myocardial systolic and diastolic function respectively.
 
 
Figure 3. Scatterplot showing no correlation between global contrast-enhanced myocardial T1 time and LVEF 
in diabetic patients (circles) and control subjects (triangles). Thus, LVEF may not accurately reflect the burden 
of diffuse interstitial fibrosis as represented by the global contrast-enhanced myocardial T1 time.
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Figure 4. Scatterplot showing correlation between global contrast-enhanced myocardial T1 time and global 
longitudinal strain for diabetic patients (circles) and control subjects (triangles). Thus, a higher burden of 
interstitial myocardial fibrosis (represented by shorter global contrast-enhanced myocardial T1 time) was as-
sociated with more impaired myocardial systolic function (represented by global longitudinal strain).
 
Figure 5. Scatterplot showing correlation between global contrast-enhanced myocardial T1 time and septal 
E’ for diabetic patients (circles) and control subjects (triangles). Thus, a higher burden of interstitial myocar-
dial fibrosis (represented by shorter global contrast-enhanced myocardial T1 time) was associated with more 
impaired myocardial diastolic function (represented by septal E’).
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Determinants of myocardial systolic function in diabetic patients
The mean global longitudinal strain for the diabetic patients was -16.1 ± 1.4%. Type 1 
diabetic patients had significantly more preserved global longitudinal strain than type 2 
diabetic patients (-16.4 ± 1.4 vs. -15.3 ± 1.2%, p = 0.009). Women had significantly more 
preserved global longitudinal strain than men (-16.6 ± 1.5 vs. -15.6 ± 1.2%, p = 0.017). 
Table 4 outlines the univariate Pearson correlations for global longitudinal strain.
Table 3. Univariate Pearson correlation coefficients between global contrast-enhanced myocardial T1 time 
and left ventricular volume and functional parameters in diabetic patients and normal controls
Variable Correlation coefficient p value
Heart rate 0.02 0.87




Cardiac output 0.32 0.01
Transmitral E/A ratio -0.10 0.44
Deceleration time 0.36 0.003
Pulmonary S/D ratio -0.03 0.83
Global longitudinal strain -0.71  < 0.001
Septal E’ 0.47  < 0.001
Septal E/e’ ratio -0.33 0.007
EDVI = end-diastolic volume index; ESVI = end-systolic volume index; EF = ejection fraction; LV = left ventricular
Table 4. Univariate Pearson correlation coefficients for global longitudinal strain and septal E’ in diabetic 
patients






Age 0.14 0.32 -0.55  < 0.001
Body mass index 0.06 0.69 0.04 0.80
Systolic blood pressure 0.24 0.10 -0.17 0.23
Diastolic blood pressure 0.08 0.60 0.01 0.95
Heart rate -0.15 0.30 0.03 0.82
LV mass index 0.20 0.17 0.18 0.20
LVEDVI -0.21 0.15 0.45 0.001
LVESVI 0.03 0.86 0.37 0.009
Transmitral E/A ratio -0.03 0.84 0.25 0.08
Deceleration time -0.21 0.15 -0.08 0.58
Pulmonary S/D ratio -0.02 0.89 -0.32 0.03
Global contrast-enhanced myocardial T1 time -0.73  < 0.001 0.54  < 0.001
EDVI = end-diastolic volume index; ESVI = end-systolic volume index; EF = ejection fraction; LV = left ventricular
Chapter 5 129
Contrast enhanced T1 mapping and subclinical dysfunction in diabetic patients
To identify independent determinants of global longitudinal strain for the diabetic pa-
tients, univariable predictors with p < 0.20 (including gender, type of diabetes, systolic 
blood pressure, deceleration time, LV mass index, LVEDVI and global contrast-enhanced 
myocardial T1 time) were all entered into a multiple linear regression model as covari-
ates (Table 5). On multivariable analysis, the contrast-enhanced myocardial T1 time was 
an independent determinant of global longitudinal strain (model R = 0.82, p < 0.001). 
Furthermore, global contrast-enhanced myocardial T1 time was the strongest determi-
nant of myocardial systolic function (standardized β = -0.626, p < 0.001). There were no 
significant interactions between global contrast-enhanced myocardial T1 time and the 
other significant covariates in the model. Figure 6 shows examples of 2 diabetic patients 
with high and low global contrast-enhanced myocardial T1 time with a corresponding 
normal and impaired global longitudinal strain respectively.
Determinants of myocardial diastolic function in diabetic patients
The mean septal E’ for the diabetic patients was 7.3 ± 1.1 cm/s. Similarly, type 1 diabetic 
patients had more preserved septal E’ compared to type 2 diabetic patients (7.6 ± 1.0 
 
Figure 6. Example of a diabetic patient with high global contrast-enhanced myocardial T1 time (508 ms) 
suggesting less interstitial fibrosis, and a corresponding global longitudinal strain of -19.0% (left panel). In 
contrast, another diabetic patient with a low global contrast-enhanced myocardial T1 time (275 ms) suggest-
ing more interstitial fibrosis, and a reduced global longitudinal strain of -14.3% (right panel). Their respective 
LVEF on MRI were 59% and 57%.
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vs. 6.5 ± 0.9 cm/s, p < 0.001). There was no difference in the septal E’ between men and 
women (7.3 ± 0.9 vs. 7.2 ± 1.4 cm/s, p = 0.64). Table 5 outlines the univariate Pearson 
correlations for septal E’.
To identify independent determinants of septal E’ for the diabetic patients, univariable 
predictors with p < 0.20 (including age, type of diabetes, LVEDVI, transmitral E/A ratio, 
pulmonary S/D ratio and global contrast-enhanced myocardial T1 time) were all entered 
into a multiple linear regression model as covariates (Table 5). On multivariable analysis, 
the contrast-enhanced myocardial T1 time was an independent determinant of septal E’ 
(model R = 0.78, p < 0.001). Similarly, global contrast-enhanced myocardial T1 time was 
the strongest determinant of myocardial function (standardized β = 0.432, p < 0.001). 
There were no significant interactions between global contrast-enhanced myocardial T1 
time and the other significant covariates in the model.
DIsCUssIon
Using MRI, the present study demonstrated that diabetic patients had a significantly 
shorter global contrast-enhanced myocardial T1 time compared to normal controls. De-
spite normal LVEF and no evidence of previous myocardial infarction, diabetic patients 
had a wide range of global contrast-enhanced myocardial T1 time. Furthermore, global 
contrast-enhanced myocardial T1 time was independently associated with and was the 
strongest determinant of both myocardial systolic and diastolic function.
Quantification of interstitial myocardial fibrosis by T1 mapping
A recent study by Iles and co-workers has histologically validated and demonstrated the 
ability of MRI T1 mapping to quantify diffuse interstitial myocardial fibrosis in chronic 
heart failure patients.8 The authors showed that the global contrast-enhanced myocar-
Table 5. Independent determinants of left ventricular global longitudinal strain and septal E’ in diabetic pa-
tients
Variable Unstandardized β standardized β p value
Global longitudinal strain
Type of diabetes 0.834 0.266 0.02
Global myocardial T1 time -0.012 -0.626  < 0.001
Septal E’
Age -0.036 -0.288 0.02
Type of diabetes -0.587 -0.231 0.06
Global myocardial T1 time 0.007 0.432  < 0.001
EDVI = end-diastolic volume index; LV = left ventricular
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dial T1 time by MRI T1 mapping was inversely correlated to the myocardial collagen con-
tent on endomyocardial biopsies.8 When compared to normal control subjects, chronic 
heart failure patients had significantly shorter global contrast-enhanced myocardial T1 
time due to an increased burden of interstitial fibrosis. Importantly, there was also a 
significant relationship between interstitial fibrosis and LV diastolic function, whereby 
patients with progressively worse LV diastolic function had increasingly shorter global 
contrast-enhanced myocardial T1 time.8
Interstitial myocardial fibrosis in diabetic patients
Although the pathogenesis of diabetic heart disease is likely to be multifactorial, the final 
common pathway is the activation of the renin-angiotensin-aldosterone system result-
ing in myocyte necrosis and deposition of collagen in the interstitial, perivascular and 
subendocardial regions.2 The deposited collagen interacts with glucose to eventually 
form advanced glycation end-products, which is thought to contribute to myocardial 
stiffness, endothelial dysfunction and atherosclerosis.2 In diabetic patients, the milieu of 
hyperglycemia, increased free fatty acid availability with altered metabolism, activation 
of renin-angiotensin-aldosterone system, and increased oxidative stress with endothe-
lial dysfunction, all contribute to the subsequent development of replacement fibrosis, 
myocardial dysfunction and diabetic heart disease.1, 2, 21, 22 In the present study, global 
contrast-enhanced myocardial T1 time using MRI T1 mapping was utilized as a surrogate 
marker of the burden of interstitial myocardial fibrosis. Consistent with previous studies, 
diabetic patients demonstrated evidence of interstitial myocardial fibrosis.5, 6 Further-
more, there was a significant association between global contrast-enhanced myocardial 
T1 time and longitudinal myocardial systolic and diastolic function.
Global contrast-enhanced myocardial T1 time and myocardial 
dysfunction
Although quantification of LV systolic function by LVEF is easy to perform, it is relatively 
insensitive in detecting subtle myocardial dysfunction.10, 23 This was reflected in the 
present study where there was a lack of relationship between LVEF and global contrast-
enhanced myocardial T1 time. In contrast, advanced echocardiographic techniques 
such as global longitudinal strain analysis by 2D speckle tracking are more sensitive 
markers of myocardial systolic function.10 Recently, in asymptomatic diabetic patients 
with normal LVEF, it has been demonstrated impaired global longitudinal systolic and 
diastolic function indicative of early subtle myocardial dysfunction.10 By quantifying 
both global contrast-enhanced myocardial T1 time, global longitudinal strain and 
septal E’, the present study demonstrated the independent association between global 
contrast-enhanced myocardial T1 time and associated myocardial systolic and dia-
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stolic dysfunction in diabetic patients, thereby contributing to the understanding of the 
pathogenesis of diabetic heart disease.
Clinical implications
Contrast-enhanced myocardial T1 mapping may non-invasively quantify diffuse inter-
stitial myocardial fibrosis in diabetic patients. The present study demonstrated a linear 
and independent relationship between global contrast-enhanced myocardial T1 time 
and myocardial systolic and diastolic dysfunction. Early diagnosis of diabetic heart 
disease by contrast-enhanced myocardial T1 mapping and 2D speckle tracking analyses 
may permit identification of patients at risk of subsequent development of clinical 
heart failure. Furthermore, a number of therapies have been postulated to inhibit the 
progression of heart failure, principally through the inhibition of the renin-angiotensin-
aldosterone system and subsequent reduction of myocardial fibrosis.10, 24-26 Similarly, 
recent studies have demonstrated the role of diffuse interstitial myocardial fibrosis in 
hypertensive heart disease.27, 28 Thus, contrast-enhanced myocardial T1 mapping may 
permit non-invasive monitoring of the effectiveness of these anti-fibrotic therapies 
targeted at patients with diabetic or hypertensive heart disease.
study limitations
The present study initially recruited approximately equal proportions of type 1 and 2 
diabetic patients. However, 15 patients were excluded due to the unexpected presence 
of DCE indicative of previous myocardial infarction, resulting in disproportionally less 
type 2 diabetic patients. This could have influenced the multivariable analysis demon-
strating a small but significantly different relationship between type of diabetes, global 
contrast-enhanced myocardial T1 time and global longitudinal strain. Therefore, the 
presence of underlying significant but undiagnosed coronary artery disease could have 
affected the results. Future larger studies will be needed to compare interstitial myocar-
dial fibrosis in type 1 versus type 2 diabetes. Furthermore, although previous studies 
have validated global contrast-enhanced myocardial T1 time with interstitial fibrosis on 
histopathology8, 29, the presence of myocardial inflammation may also have potentially 
confounded the present results.
There are currently several different MRI inversion pulse sequences that are available 
for generating contrast-enhanced myocardial T1 maps.8, 30, 31 Furthermore, T1 recovery 
time naturally increases with higher MRI field strength, and is influenced by the dosage 
and type of contrast agent used, the timing of T1 map acquisition from time of injection, 
and cardiac output (which influences gadolinium wash-out rate from the myocardium). 
Thus, the derived global myocardial T1 time from one study is not directly comparable 
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across different studies that use different protocols. Furthermore, pre-contrast T1 maps 
were not acquired during the present study.
ConCLUsIons
A shorter global contrast-enhanced myocardial T1 time (suggestive of a higher burden 
of interstitial myocardial fibrosis) in diabetic patients is independently associated with 
more impaired longitudinal myocardial systolic and diastolic function. Future larger 
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background: Current understanding of metabolic heart disease consists of myriad of 
different pathophysiological mechanisms. Epicardial adipose tissue (EAT) is increas-
ingly recognized as metabolically active and associated with adverse cardiovascular 
outcomes. The present study aimed to investigate the effect of increased EAT volume in-
dex on left ventricular (LV) myocardial fat content (LV-myoFat) and burden of interstitial 
myocardial fibrosis, and their subsequent effects on LV myocardial contractile function.
Methods: 40 volunteers (mean age 35 ± 10 years, 26 males) of varying body mass index 
(BMI: 25.0 ± 4.1 kg/m2, range 19.3–36.3 kg/m2) and without diabetes or hypertension 
were prospectively recruited. EAT volume index, LV-myoFat and extracellular volume 
(ECV) were quantified by magnetic resonance imaging (MRI). LV myocardial contractile 
function was quantified by speckle tracking echocardiography global longitudinal strain 
(GLS) on the same day as MRI examination.
Results: Mean total EAT volume index, LV-myoFat and ECV were 30.0 ± 19.6 cm3/m2, 
5.06 ± 1.18% and 27.5 ± 0.5% respectively. On multivariable analyses, increased EAT 
volume index and insulin resistance were independently associated with both increased 
LV-myoFat content and higher burden of interstitial myocardial fibrosis. Furthermore, 
increased EAT volume index was independently associated with LV GLS.
Conclusions: Increased EAT volume index and insulin resistance were independently 
associated with increased myocardial fat accumulation and interstitial myocardial fibro-
sis. Increased EAT volume index was associated with detrimental effects on myocardial 
contractile function as evidenced by a reduction in LV GLS.
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InTRoDUCTIon
There is a growing body of evidence that the altered metabolic milieu seen in obese and 
diabetic patients causes myocardial structural changes and contractile dysfunction.1 
Commonly referred to as metabolic heart disease, we have previously shown that im-
paired left ventricular (LV) myocardial systolic function as quantified by 2-dimensional 
(2D) global longitudinal strain (GLS) echocardiography was associated with increased 
myocardial fat accumulation, coronary artery disease, increased interstitial fibrosis, and 
increased epicardial adipose tissue (EAT) volume.2-5 EAT is depot of visceral fat directly 
overlying the myocardium, and is of similar embryological origin as abdominal mesen-
teric and omental visceral fat.6 Increasingly, EAT is recognized as a metabolically active 
endocrine organ that secretes adipokines associated with detrimental myocardial and 
coronary vascular dysfunction.7 Several studies have demonstrated a direct correlation 
between EAT and myocardial fat (i.e. triglyceride [TG]) accumulation,8, 9 and animal 
research suggested that EAT may directly channel fatty acids to the myocardium as 
a local energy source.10, 11 However, when the amount of free fatty acid uptake by the 
heart exceeds its oxidative capacity, it is converted and stored as intracellular TG.12 It is 
currently accepted that the intracellular myocardial TG is probable inert, but increased 
shunting of free fatty acid into the non-oxidative pathway leads to accumulation of toxic 
fatty acid intermediates such as ceramide that disrupt normal cellular signaling and 
eventually leads to cellular apoptosis and replacement fibrosis.13
Magnetic resonance imaging (MRI) techniques such as proton magnetic resonance spec-
troscopy ([1H]-MRS) and multi-echo Dixon water and fat separated imaging with variable 
projection (VARPRO) can quantify LV myocardial fat (LV-myoFat) content.14, 15 Similarly, 
the modified Look-Locker inversion recovery (MOLLI) sequence can quantify the burden 
of interstitial fibrosis by extracellular volume (ECV) expansion.16, 17 In the present study, 
volunteers of normal weight, as well as overweight and obese individuals without the 
confounding influences of diabetes or hypertension were evaluated to determine the 
effect of increased EAT volume index on LV-myoFat content and burden of LV interstitial 
fibrosis. We hypothesize that: 1) increased EAT volume index is independently associ-
ated with increased myocardial fat accumulation and interstitial fibrosis; and 2) EAT 




study population and study protocol
A total of 40 volunteers with a wide range of body mass index (BMI) were prospectively 
recruited from the community. Exclusion criteria included age < 18 years, pregnancy, 
rhythm other than sinus rhythm, hypertension, diabetes mellitus, previously known 
underlying coronary artery disease, LV systolic dysfunction or previous myocardial 
infarction, moderate or severe valvular stenosis or regurgitation, pre-existing hepatic 
or renal disorders, active smoker, current use of any regular medications, inability to 
provide informed consent, and inability to undergo a cardiac MRI. All participants’ blood 
tests, transthoracic echocardiogram and cardiac MRI examinations were performed on 
the same day after an overnight fast.
Figure 1 outlines the study protocol. In brief, a subset of 15 randomly selected volun-
teers underwent “clinical reference standard” [1H]-MRS to validate LV-myoFat content 
by VARPRO. All 40 volunteers underwent cardiac MRI to quantify LV volumes, LV mass, 
EAT volume, LV-myoFat content by the VARPRO, and burden of LV interstitial fibrosis by 
ECV using the MOLLI sequence. 4, 16, 17 All 40 volunteers also underwent echocardiograms 
to quantify myocardial contractile function by 2D LV GLS.
 
Figure 1. Outline of study protocol. Subset of 15 volunteers underwent quantification of myocardial TG by 
[1H]-MRS to validate LV-myoFat by the VARPRO sequence. All 40 volunteers underwent fasting blood tests, 
cardiac MRI and echocardiography on the same day after an overnight fast. LV-myoFat = left ventricular myo-
cardial fat; [1H]-MRS = proton magnetic resonance imaging; HDL = high density lipoprotein; LDL = low density 
lipoprotein; TG = triglyceride; HOMA-IR = homeostatic model assessment index of insulin resistance; HbA1c = 
glycated hemoglobin; VARPRO = variable projection; MOLLI = modified Look-Locker inversion recovery; LV = left 
ventricle/ventricular; 2D = 2-dimensional; GLS = global longitudinal strain.
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The study was approved by the institutional ethics committee and all subjects provided 
written informed consent. The data, analytic methods, and study materials will not be 
made available to other researchers for purposes of reproducing the results or replicat-
ing the procedure for competitive reasons.
Demographic, anthropomorphic and metabolic data
All subjects underwent an overnight fast of at least 8 hours. Clinical data collected in-
cluded age, gender, height, weight, waist/hip ratio, and resting blood pressures. Waist 
circumference was measured midway between the lower rib margin and iliac crest. 
Hip circumference was measured at the level of widest circumference over greater 
trochanters.18 Blood tests included fasting lipid profile, fasting plasma glucose, glycated 
hemoglobin (HbA1c), insulin, and glomerular filtration rates (GFR) calculated by the 
Modification of Diet in Renal Disease formula.19
High-density lipoprotein (HDL) cholesterol was measured as a homogeneous assay in 
liquid phase (Boehringer Mannheim, Mannheim, Germany) on a Hitachi 747 autoana-
lyzer. Low-density lipoprotein (LDL) cholesterol was calculated according to the Friede-
wald equation: LDL-cholesterol (mmol/L) = Total cholesterol – HDL-cholesterol – TG / 2.2.
Fasting plasma glucose was measured by enzymatic assay (Dade Behring, Newark, DE, 
USA). Serum insulin was evaluated using a chemiluminescent enzyme immunoassay 
(Immulite 2000; Diagnostic Products, Los Angeles, CA, USA). The homeostatic model as-
sessment (HOMA) index of insulin resistance (HOMA-IR) was computed using the HOMA 
calculator that utilizes the HOMA2 model as previously reported.20 HbA1c measurements 
were performed using high performance liquid chromatography cation-exchange ana-
lyzers by Bio-Rad D-10TM Hemoglobin Testing System (Bio-Rad Laboratories, Inc., Hercu-
les, CA). This assay is National Glycohemoglobin Standardization Program (NGSP) and 
International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) certified, 
and standardized to the Diabetes Control and Complications Trial (DCCT) assay.
Cardiac magnetic resonance imaging
All participants underwent a cardiac MRI examination using a 1.5T Siemens Magnetom 
Avanto (Erlangen, Germany) system on the same day as their transthoracic echocar-
diogram and blood tests. During the examination, the entire heart was imaged in the 
short-axis orientation with retrospective ECG-gating and breath-hold. Typical imaging 
parameters were: balanced steady state free-precession imaging, echo time (TE) = 1.0 
ms, repetition time (TR) = 3.1 ms, flip angle = 54°, slice thickness = 8 mm with a gap of 2 
mm, field of view = 340x340 mm, reconstructed matrix size = 156x192.
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LV end-diastolic mass index, LV end-diastolic volume index (EDVI) and LV end-systolic 
volume index (ESVI) were measured and corrected for body surface area.21 LV ejection 
fraction (LVEF) was calculated and expressed as a percentage. Differences in LV end-
diastolic and end-systolic volumes were used to calculate stroke volume, multiplied by 
heart rate to calculate cardiac output, and corrected for body surface area to calculate 
cardiac index. Peripheral vascular resistance was calculated as the ratio of mean blood 
pressure to cardiac output. Images were digitally stored on hard disks and analyzed of-
fline using dedicated quantitative software (MASS V2010-EXP, Leiden University Medical 
Center, Leiden, The Netherlands).
MRI quantification of myocardial triglyceride/fat content
Quantification of myocardial TG content by [1H]-MRS is considered the “clinical reference 
standard”, but is time consuming to perform (mean scan duration 13.2 ± 4.5min).13, 22 
In contrast, newer MRI techniques such as VARPRO can rapidly obtain fat and water 
separated images to quantify LV-myoFat content in a single breath-hold. Furthermore, 
it can avoid contamination from EAT. Therefore, a subset of 15 volunteers underwent 
concomitant [1H]-MRS to validate LV-myoFat by VARPRO.
Quantification of myocardial triglyceride content by [1H]-MRS
Cardiac [1H]-MRS was performed as previously described (Figure 2, top panels).2, 22 Briefly, 
[1H]-MRS spectra were obtained by point resolved spectroscopy sequence (PRESS) with 
an 6mL voxel (1x2x3 cm) placed in the interventricular septum using the 4-chamber and 
short-axis views at end-diastole. Spectroscopic data acquisitions were double-triggered 
with ECG triggering and respiratory navigator echoes to minimize motion artifacts. End-
diastolic spectra were acquired with the following parameters: TE = 25 ms, TR = 2000 ms, 
1024 data points, bandwidth 1000Hz. Automatic shimming was performed before the 
spectroscopy data acquisition using the gradient-recalled echo shim technique whereby 
a field map was generated from a single-slab double-echo 3D gradient-recalled echo 
acquisition with two in-phase TEs with respect to fat and water, which were then used to 
calculate the shim currents to improve B0 homogeneity. Water-suppressed spectra were 
acquired with 128 signal averages to quantify myocardial TG. Non-water suppressed 
spectra were acquired with 16 signal averages and used as an internal standard.
[1H]-MRS data were then fitted by use of Java-based MR user interface software ( jMRUI 
version 2.2, Leuven, Belgium) AMARES algorithm as previously described.2 Resonance 
frequency estimates for myocardial TG were described by assuming Gaussian line 
shapes and summing the amplitudes of lipid resonances at 0.9 and 1.3 ppm. Resonance 
frequency estimate for water used for internal standardization was described by as-
suming a Lorentzian line shape that peaks at 4.7ppm. Myocardial TG content relative 
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to water was calculated and expressed as a percentage based on: (signal amplitude of 
myocardial TG)/(signal amplitude of water)x100%.2
Quantification of LV-myoFat content by VARPRO sequence
The VARPRO multi-point Dixon algorithm is a multi-echo gradient sequence with fat 
and water separation.14, 23, 24 This multi-echo Dixon fat-water separation jointly estimates 
the fieldmap, fat, and water images (Figure 2, middle panel). The sequence was ECG 
triggered, with 2 R-R intervals between inversions, and used an echo-train readout with 
4 echoes. Typical imaging parameters were: gradient echo, TE = 1.27, 3.18, 5.09, 7.00 
ms, TR = 11.2 ms, flip angle = 24°, slice thickness 6 mm, field of view = 360 x 292 mm, 
reconstructed matrix size = 256x218, bandwidth = 1502 Hz/pixel. The LV basal and mid-
ventricular short-axis slices by the VARPRO sequence were obtained at exactly the same 
LV level as quantification of interstitial fibrosis by MOLLI sequence (see below).
During analysis, the LV contours at the basal and mid-ventricular short axis slices were 
deliberately drawn in the mid-myocardium to exclude and avoid contamination by EAT 
and the LV blood pool using MASS research software. Although the LV apical segments 
were also acquired during the VARPRO image acquisitions, it was not included in the 
analyses due to partial volume effects from EAT and LV blood pool secondary to the 
curvature of the LV apex that will compromise accurate quantifications of LV-myoFat 
content. LV-myoFat fat content was calculated and expressed as a percentage based 
on: (mean pixel signal intensity of LV fat-only image)/(mean pixel signal intensity of LV 
water-only image)x100%.
MRI quantification of LV interstitial fibrosis by MoLLI sequence
The MOLLI T1 mapping sequence was used to quantify the burden of interstitial fibrosis 
by ECV.16, 17 All participants received 0.1mmol/kg of gadolinium diethylenetriamine 
penta-acetic acid. The MOLLI sequence imaging parameters were: single-shot steady-
state free precession read out with trigger delay to coincide with end-diastole, TE = 1.0 
ms, TR = 2.7 ms, flip angle = 35°, slice thickness = 8mm, field of view = 340x340 mm, 
reconstructed matrix size = 106x192 pixels, trigger delay = 300ms. The LV basal and 
mid-ventricular short-axis slices by the MOLLI sequence were obtained at exactly the 
same LV level as quantification of LV-myoFat content by VARPRO. These images were 
then processed with a curve fitting technique to generate T1 maps as described below.
To quantify the ECV, LV endocardial and epicardial borders were outlined using MASS 
research software.4, 25 Contours were deliberately drawn to ensure the inclusion of only 
myocardium and the exclusion of EAT and LV blood pool. The software then performs 
automatic pixel-by-pixel quantification of myocardial T1 time by fitting data acquired 
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at the various inversion times.4, 25 A mean global native and post-contrast myocardial 
T1 time were subsequently automatically calculated as the average of all the individual 
myocardial T1 time from each pixel. ECV was calculated as per previous publication and 
expressed as a percentage 16:
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A higher ECV is indicative of increased collagen deposition and thus a greater 
degree of myocardial interstitial fibrosis.  A higher ECV is indicative of increased collagen deposition and thus a greater degree of 
myocardial interstitial fibrosis.
MRI quantification of epicardial adipose tissue volume
Total EAT volume was quantified using a T1 weighted double inversion recovery Half-
Fourier-Acquired Single-shot Turbo spin Echo (HASTE) black blood imaging (Figure 2, 
bottom panels). Manual contours were drawn whereby mediastinal fat and pericardial 
fat (outside the visceral pericardium and on the external surface of the parietal pericar-
dium) were excluded. The volumes of EAT in all the slices were calculated by converting 
the number of pixels to square centimetres multiplied by the slice thickness. Total EAT 
volume was subsequently calculated by summing the volumes of all slices from the level 
of pulmonary artery bifurcation to the diaphragm and indexed to body surface area. 
Typical imaging parameters were: turbo spin echo, TE = 26.0 ms, TR = 1000 ms depend-
ing on RR interval, flip angle = 160°, slice thickness 6 mm with a gap of 6 mm, field of view 
= 440x440 mm, reconstructed matrix size = 256x176.
MRI quantification of visceral adiposity
Abdominal visceral fat depots were quantified by using the VARPRO sequence with 
similar imaging parameters as outlined previously. Six consecutive transverse images 
were obtained with the middle image at the middle of the fourth lumbar vertebra. Simi-
larly, manual contours were drawn to include only the abdominal visceral fat, and the 
volumes of the visceral fat depots in each slice was calculated by converting the number 
of pixels to square centimeters multiplied by the slice thickness. The total L4 visceral fat 
volume was calculated by summing the volumes of all 6 slices.
echocardiography
Transthoracic echocardiography was performed with the subjects at rest using a com-
mercially available ultrasound system (Vivid E9, 4V probe, GE-Vingmed, Horten, Norway) 
on the same day as their cardiac MRI and blood tests. A complete 2D, color, pulsed 
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and continuous-wave Doppler echocardiogram was performed according to standard 
techniques.26 All images were digitally stored on hard disks for offline analysis (EchoPAC 
version 113, GE-Vingmed, Horten, Norway).
Doppler assessment
Mitral inflow velocities were recorded using conventional pulsed-wave Doppler echocar-
diography in the apical 4-chamber view using a 2 mm sample volume. Transmitral early 
(E wave) and late (A wave) diastolic velocities as well as deceleration time were recorded 
at the mitral leaflet tips. Pulsed-wave tissue Doppler velocities were recorded at the 
septal mitral annulus in the apical 4-chamber view at end-expiration as recommended 
to obtain the mitral annular early diastolic (e’) velocity.27 LV filling pressure (septal E/e’) 
was calculated as the ratio of transmitral E wave to septal mitral annular e’ velocity.
 
 
Figure 2. Quantification of myocardial TG by “clinical reference standard” [1H]-MRS with the voxel of interest 
placed in the interventricular septum (top left panel). Myocardial TG was calculated from the summation of 
the lipid resonance amplitudes at 0.9 and 1.3ppm (top right panel). Quantification of LV-myoFat by VARPRO 
where epicardial and endocardial borders were deliberately drawn in the mid-myocardium to avoid contami-
nation from EAT and LV blood pool (middle panels). The “water only” (middle left panel) and “fat only” (middle 
right panel) were obtained simultaneously from VARPRO, and both the endocardial and epicardial contours 




2D speckle tracking analyses were performed on standard grey scale images in the apical 
2-, 3- and 4-chamber views. During analysis, the endocardial border was manually traced 
at end-systole and the region of interest width adjusted to include the entire myocardi-
um. LV GLS was calculated from the 3 individual apical global longitudinal strain curves.
statistical analysis
All continuous variables were tested for Gaussian distribution. Continuous variables 
were presented as mean ±1 SD unless otherwise stated, and categorical variables were 
presented as frequencies and percentages. Unpaired Student’s t-test and Mann-Whitney 
U test were used to compare 2 groups of continuous variables of Gaussian and non-
Gaussian distribution respectively. Pearson correlation was used to determine the 
association between 2 continuous variables. Intraclass correlation and Bland-Altman 
plot were used to validate VARPRO to quantify LV-myoFat content against “clinical refer-
ence standard” myocardial TG content by [1H]-MRS. Multiple linear regression analyses 
were performed to identify independent variables associated with LV-myoFat content 
by VARPRO sequence, ECV as a measure of LV interstitial fibrosis, and 2D LV GLS by 
speckle tracking echocardiography. In each multiple linear regression model, significant 
univariables with p  < 0.05 were entered as covariates and independent variables were 
identified using the backward elimination method. To avoid potential multicollinearity, 
a tolerance of  > 0.4 (equating to a Variance Inflation Factor of  > 2.5) was set. To deter-
mine if EAT volume index was independently associated with LV-myoFat, ECV, and 2D LV 
GLS (rather than just a measure of overall visceral adiposity), all multivariable analyses 
were repeated with L4 visceral fat volume forced into the models. A 2-tailed p value of  < 
0.05 was considered significant. All statistical analyses were performed using IBM SPSS 
Statistics for Windows, version 21.0 (Armonk, NY).
ResULTs
A total of 40 volunteers (26 males) with a mean age of 35 ± 10 years were recruited. The 
mean heart rate, LVEDVI, LVESVI, LVEF and LV mass index were 61 ± 9 beats/min, 90 ± 15 
mL/m2, 40 ± 8 mL/m2, 55 ± 4% and 43 ± 8 g/m2 respectively.
The mean BMI was 25.0 ± 4.1 kg/m2 (range 19.3 to 36.3 kg/m2), and the mean waist/hip 
ratio was 0.88 ± 0.11 (range 0.74 to 1.33). Twenty-two volunteers (55.0%) were identified 
as overweight/obese based on waist/hip ratio as classified by the World Health Orga-
nization cut-off values. The mean total EAT volume index was 30.0 ± 19.6 cm3/m2, and 
there was no gender difference in EAT volume index (p = 0.28).
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Age (years) 35 ± 10 35 ± 11 36 ± 9 0.79
Male gender 26 (65%) 16 (64%) 10 (67%) 0.86
Waist/hip ratio 0.88 ± 0.11 0.88 ± 0.10 0.89 ± 0.14 0.92
Heart rate (beats/min) 61 ± 9 61 ± 10 60 ± 8 0.83
Systolic BP (mmHg) 128 ± 11 129 ± 11 126 ± 12 0.51
Diastolic BP (mmHg) 79 ± 9 79 ± 9 79 ± 10 0.97
Biochemical
Total cholesterol (mmol/L) 4.82 ± 0.72 4.85 ± 0.72 4.78 ± 0.74 0.77
LDL cholesterol (mmol/L) 2.92 ± 0.56 2.93 ± 0.51 2.91 ± 0.66 0.89
HDL cholesterol (mmol/L) 1.44 ± 0.39 1.47 ± 0.47 1.40 ± 0.23 0.60
Plasma triglyceride (mmol/L) 1.03 ± 0.52 1.02 ± 0.48 1.04 ± 0.59 0.93
Fasting plasma glucose (mmol/L) 5.0 ± 0.5 5.0 ± 0.6 5.0 ± 0.3 0.67
HbA1c (%) 5.2 ± 0.2 5.2 ± 0.2 5.2 ± 0.3 0.93
Fasting Insulin (mU/L) 5.8 ± 5.1 6.2 ± 5.7 5.2 ± 4.1 0.99
HOMA-IR 1.30 ± 1.11 1.39 ± 1.24 1.16 ± 0.88 0.92
GFR (mL/min/1.73m2) 99 ± 16 97 ± 17 101 ± 13 0.52
MRI
LV mass index (g/m2) 43 ± 8 43 ± 6 43 ± 10 0.89
LVEDVI (mL/m2) 90 ± 15 91 ± 11 89 ± 21 0.74
LVESVI (mL/m2) 40 ± 8 41 ± 6 39 ± 10 0.48
LVEF (%) 55 ± 4 55 ± 3 55 ± 4 0.58
Stroke volume (mL) 95 ± 19 95 ± 15 96 ± 25 0.81
Cardiac output (L/min) 5.7 ± 1.1 5.7 ± 1.1 5.7 ± 1.2 0.96
Cardiac index (L/min/m2) 3.0 ± 0.6 3.0 ± 0.6 2.9 ± 0.6 0.80
Peripheral vascular resistance (dyn.s/cm5) 1385 ± 288 1393 ± 318 1371 ± 240 0.82
L4 visceral fat volume (cm3) 324 ± 239 227 ± 200 264 ± 219 0.60
EAT volume index (cm3/m2) 30.0 ± 19.6 27.3 ± 16.0 34.6 ± 24.3 0.26
LV-myoFat content (%) 5.1 ± 1.2 5.0 ± 1.1 5.2 ± 1.3 0.51
ECV (%) 27.5 ± 0.5 27.3 ± 0.5 27.8 ± 0.4 0.037
Echocardiography
Transmitral E velocity (m/s) 0.77 ± 0.17 0.77 ± 0.18 0.78 ± 0.16 0.98
Transmitral E/A ratio 1.8 ± 0.8 1.8 ± 0.9 1.9 ± 0.6 0.77
Deceleration time (ms) 166 ± 28 169 ± 31 159 ± 20 0.26
Septal E’ velocity (cm/s) 12.3 ± 3.0 11.9 ± 3.1 12.9 ± 2.6 0.30
Septal E/e’ ratio 6.6 ± 1.8 6.8 ± 1.8 6.2 ± 1.8 0.33
2D LV GLS -19.0 ± 2.4 -19.0 ± 2.7 -19.2 ± 2.0 0.77
*p value by unpaired Student’s t-test or Mann-Whitney U test for continuous variables of Gaussian and non-Gaussian dis-
tribution respectively, and Chi square test for categorical variables. 2D: 2-dimensional; BP: blood pressure; EAT: epicardial 
adipose tissue; ECV: extracellular volume; EDVI: end-diastolic volume index; ESVI: end-systolic volume index; EF: ejection 
fraction; GFR: glomerular filtration rate; GLS: global longitudinal strain; HbA1c: glycated hemoglobin; HDL: high density 
lipoprotein; LDL: low density lipoprotein; HOMA-IR: homeostatic model assessment index of insulin resistance; LV: left 
ventricular; LV-myoFat: left ventricular myocardial fat content by VARPRO sequence.
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Validation of VaRPRo sequence against [1H]-MRs
A subset of 15 randomly volunteers underwent “clinical reference standard” [1H]-MRS to 
quantify myocardial TG content. Table 1 outlines the baseline clinical, MRI and echocar-
diographic characteristics between the 15 randomly selected volunteers against the rest 
of the cohort. Other than a slight difference in ECV between these 2 groups (27.3 ± 0.5 vs. 
27.8 ± 0.4%, p = 0.037), there were no significant differences in other variables. Figures 




Validation of VARPRO sequence against [1H]-MRS  
A subset of 15 randomly volunteers underwent “clinical reference standard” 
[1H]-MRS to quantify myocardial TG conte t. Table 1 outlines the baseline clinical, 
MRI and echocardiographic characteristics between the 15 randomly selected 
volunteers against the rest of the cohort. Other than a slight difference in ECV 
between these 2 groups (27.3 ± 0.5 vs. 27.8 ± 0.4%, p = 0.037), there were no 
significant differences in other variables. Figures 3 and 4 show LV-myoFat content 
by VARPRO overestimated myocardial TG content compared to [1H]-MRS: 
LV-myoFat content by VARPRO  




Figure 3. Scatterplot showing excellent reliability of VARPRO quantification of LV-myoFat against “clinical 
reference standard” quantification of myocardial TG content by [1H]-MRS.
 
Figure 4. Bland-Altman plot showing overestimation of VARPRO quantification of LV-myoFat against “clinical 
reference standard” quantification of myocardial TG content by [1H]-MRS.
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However, LV-myoFat content quantification by VARPRO had excellent reliability com-
pared to the “clinical reference standard” myocardial TG quantification by [1H]-MRS with 
an intraclass correlation for consistency of r = 0.92 (95% confidence interval 0.75-0.97).
Determinants of LV-myofat content
The mean LV-myoFat content by VARPRO for all 40 volunteers was 5.06 ± 1.18%. There 
was no gender difference in LV-myoFat content (p = 0.36). LV-myoFat content increased 
with older age (r = 0.51, p = 0.001), higher insulin resistance (HOMA-IR, r = 0.51, p = 0.001) 
and increasing measures of obesity by EAT volume index (r = 0.61, p < 0.001), waist/
hip ratio (r = 0.59, p < 0.001) and L4 visceral fat volume (r = 0.60, p < 0.001). There was 
also a correlation between LV-myoFat content and plasma TG (r = 0.48, p = 0.002), LDL-
cholesterol (r = 0.33, p = 0.038) and HDL-cholesterol (r = -0.37, p = 0.018), but not total 
cholesterol (p = 0.23).
To identify the independent variables associated with LV-myoFat content, significant 
univariables (age, HOMA-IR, EAT volume index, waist/hip ratio, plasma TG, LDL-choles-
terol and HDL-cholesterol) were entered as covariates into a multiple linear regression 
model. On multivariable analysis, only HOMA-IR (standardized β = 0.32, p = 0.024) and 
EAT volume index (standardized β = 0.47, p = 0.002) were independently associated with 
LV-myoFat content.
To determine if increased EAT volume index was truly independently associated with 
LV-myoFat content rather than just a measure of overall visceral adiposity, waist/hip 
ratio was replaced with L4 visceral fat volume in the multiple linear regression model. 
Although L4 visceral fat volume was highly correlated with EAT volume index (r = 0.69, 
p < 0.001), it was forced into the multivariable model. Despite that, similar results were 
obtained with only HOMA-IR (standardized β = 0.32, p = 0.024) and EAT volume index 
(standardized β = 0.47, p = 0.002) remaining as significantly associated with LV-myoFat 
content.
Determinants of burden of LV interstitial fibrosis
The mean ECV was 27.5 ± 0.5%, and there was no gender difference (p = 0.88). On univari-
able analysis, ECV was significantly correlated with higher LV-myoFat content (r = 0.71, p 
< 0.001), older age (r = 0.64, p = 0.002), higher HOMA-IR (r = 0.51, p = 0.021) and increasing 
EAT volume index (r = 0.69, p = 0.001).
To identify the independent variables associated with ECV, significant univariables 
(age, LV-myoFat, HOMA-IR and EAT volume index) were entered as covariates into a 
multiple linear regression model. EAT volume index (standardized β = 0.46, p = 0.025) 
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and LV-myoFat content (standardized β = 0.41, p = 0.045) were independently associated 
with ECV. The results did not change when L4 visceral fat volume was forced into the 
multivariable model.
Determinants of LV myocardial function
The mean 2D LV GLS was -19.0 ± 2.4%, and women had significantly higher GLS than men 
(-20.3 ± 2.2 vs. -18.4 ± 2.3%, p = 0.013). 2D LV GLS was significantly correlated with age 
(r = 0.44, p = 0.005), HOMA-IR (r = 0.60, p < 0.001), EAT volume index (r = 0.66, p < 0.001), 
LV-myoFat (r = 0.50, p < 0.001) and ECV (r = 0.70, p < 0.001).
On multivariable analysis whereby age, gender, HOMA-IR, EAT volume index, LV-myoFat 
and ECV were entered into the model, only EAT volume index was independently as-
sociated with 2D LV GLS (standardized β = 0.44, p = 0.041). Similarly, when L4 visceral 
fat volume was forced into the model, only EAT volume index remained independently 
associated with 2D LV GLS.
Variability analysis
We have previously reported the intra- and inter-observer measurement variabilities for 
LV GLS expressed as mean absolute difference ± 1 SD were 1.2 ± 0.5% and 0.9 ± 1.0% 
respectively.28 Table 2 outlines the intra- and inter-observer measurement variabilities 
for ECV, LV-myoFat content and EAT volume index expressed as mean absolute differ-
ences ± 1 SD and intraclass correlation for agreement in 10 randomly selected subjects.
DIsCUssIon
The present study evaluated the complex interplay between insulin resistance, in-
creased EAT volume, myocardial fat accumulation and LV interstitial fibrosis, leading to 
LV myocardial systolic dysfunction in volunteers with normal weight, as well as over-


























CI: Confidence interval; EAT: Epicardial adipose tissue; ECV: Extracellular volume; ICC: Intraclass correlation; LV-myoFat: 
left ventricular myocardial fat content by VARPRO sequence.
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weight and obese individuals. This study showed that insulin resistance and EAT volume 
index were independently associated with increased myocardial fat accumulation and 
LV interstitial fibrosis. On multivariable analyses, EAT volume index was independently 
associated with impaired LV myocardial systolic contractile function.
Quantification of LV-myofat by VaRPRo versus [1H]-MRs
In the present study, VARPRO significantly overestimated LV-myoFat content compared 
to [1H]-MRS. This is likely secondary to its inherent T1 bias, especially with its high flip 
angle. As previously shown by Kühn et al and Liu et al, increasing flip angle (≥5-10°) will 
overestimate fat fraction by chemical shift imaging compared to [1H]-MRS.29, 30 However, 
a lower flip angle will significantly reduce the signal-to-noise ratio, and the noise can 
lead to incorrect estimation of the true fat fraction.30 Although VARPRO significantly 
overestimated LV-myoFat content, it still had excellent correlation and reliability when 
compared to [1H]-MRS (Figure 3).
However, VARPRO has significant advantages over [1H]-MRS. Firstly, it permits regional 
and global LV quantification of LV-myoFat, whereas [1H]-MRS is limited to the inter-
ventricular septum due to the risk of contamination from EAT. Secondly, VARPRO is 
performed with a single breath-hold, whereas [1H]-MRS will require double respiratory 
and cardiac gating that will significantly increase scan duration.22 Finally, slice position-
ing for various imaging sequences (e.g. VARPRO for LV-myoFat and MOLLI for interstitial 
fibrosis) can be consistently and completely matched as demonstrated in the present 
study.
epicardial adipose tissue, insulin resistance and myocardial steatosis
The myocardium has a very high energy demand in order to perform cardiac contraction 
and relaxation. Under normal physiological conditions, it predominately metabolizes 
free fatty acids through β-oxidation which accounts for approximately 50-70% of its 
energy production.7 Although the source of this free fatty acid is generally derived from 
circulating plasma triglyceride and free fatty acid, it is now recognized that EAT is a 
readily available local store of TG that directly release free fatty acid to the myocardium 
at times of increased cardiac fatty acid metabolism.10, 11, 31 As such, the present study 
demonstrated that both increased EAT volume index and insulin resistance were inde-
pendently associated with increased myocardial fat accumulation. This is consistent 
with previous studies that showed increased EAT volume in obese patients was associ-
ated with increased myocardial fat accumulation.8, 9 In addition, type 2 diabetes, the 
archetypal disease where pathophysiology is characterized by insulin resistance, is also 
associated with increased myocardial fat accumulation.2
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epicardial adipose tissue and myocardial interstitial fibrosis
However, EAT is also now increasingly recognized as an endocrine organ that secretes 
adipokines.7 Both EAT and the underlying myocardium share the same coronary micro-
circulation with no anatomical fascial boundary separating the 2 structures. As such, 
adipokines and cytokines secreted by EAT have a direct vasocrine and paracrine effect 
on coronary and myocardial function.32 Secretions of pro-inflammatory adipokines 
such as IL-6, MCP-1, leptin and visfatin are increased with larger EAT volumes, while the 
secretions of anti-inflammatory adipokines such as adiponectin and adrenomedullin 
are decreased, all leading to increased coronary vasoconstriction, inflammation and 
atherosclerosis.7 Furthermore, increased secretion of TNF-α from EAT has also been 
shown to induce cardiomyocyte apoptosis leading to replacement fibrosis.33 Mazurek 
and colleagues previously demonstrated higher levels of pro-inflammatory cytokines 
such as IL-6 and TNF-α in EAT harvested from patients undergoing coronary artery 
bypass grafting compared to subcutaneous adipose tissue.33 TNF-α worsens insulin 
resistance and causes vasoconstriction, which is also associated with increased produc-
tion of angiotensin II and endothelin-1.34, 35
Previous studies have shown increased TNF-α is associated with cardiac dilatation, in-
creased interstitial inflammatory infiltrates, abnormal calcium homeostasis, increased 
apoptosis, extracellular matrix remodeling, ventricular arrhythmias and death.36, 37 To 
the best of the authors’ knowledge, the present in-vivo study is the first to demonstrate 
larger EAT volumes is associated with increased myocardial interstitial fibrosis in hu-
mans.
epicardial adipose tissue and myocardial contractility
In-vitro studies of EAT derived from guinea pigs fed a high fat diet 38 and diabetic patients 
undergoing coronary bypass surgery 39 showed that unlike subcutaneous adipose tissue, 
EAT have altered secretory profiles that directly contribute to cardiomyocyte contractile 
dysfunction. Mediated through adipokines including activin A and angiopoietin-2, they 
adversely affect cytosolic Ca2+ metabolism and reduce sarcomere shortening in a dose 
dependent manner.38, 39 We have previously shown increased EAT volume was associ-
ated with myocardial systolic contractile dysfunction.5 The present study extends these 
findings by showing that the observed myocardial contractile dysfunction often seen in 
obese and diabetic patients is likely secondary to functional (i.e. direct cardio-depres-
sant effects of adipokines) and structural changes (i.e. increased myocardial interstitial 
fibrosis from inflammation secondary to adipokines) in the myocardium mediated by an 
increased EAT volume.
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Clinical implications
The present findings suggest that EAT is a marker of visceral adiposity with direct 
adverse effects on myocardial structure and function. Therefore, it may be a target for 
pharmacological therapy and serve as a prognostic indicator. Previous small studies us-
ing hydroxymethyl glutaryl-CoAreductase inhibitors (i.e. statins) 40, dipeptidyl peptidase 
4 inhibitors (e.g. sitagliptin) 41 and glucagon-like peptide-1 (e.g. liraglutide) 42 have been 
shown to reduce EAT volume. The effects of EAT volume reduction on myocardial struc-
tural and functional changes need to be assessed in future studies.
study limitations
While the present study provides new and novel findings on myocardial structural and 
functional changes associated with EAT, the study only recruited volunteers of varying 
BMI but without diabetes or hypertension. This was to avoid potential confounding 
influences of diabetes and hypertension on myocardial interstitial fibrosis and altered 
myocardial contractile function. Therefore, the present results serve as a pilot for fu-
ture studies in diabetic patients. Secondly, although the present study demonstrated 
significant independent associations between increased EAT volume index, increased 
LV-myoFat, increased interstitial fibrosis and LV myocardial contractile dysfunction, it 
does not equate to causality in humans despite various published in-vitro basic science 
as well as animal studies.
ConCLUsIons
The current findings demonstrate that increased EAT was associated with LV myocardial 
fat accumulation and increased interstitial fibrosis. Both increased EAT and increased 
interstitial fibrosis were independently associated with myocardial contractile function. 
Therefore, therapeutic interventions targeting EAT may serve to modulate the detrimen-
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background: Left ventricular (LV) global longitudinal strain (GLS) can detect subclinical 
myocardial systolic dysfunction in individuals with diabetes. The present study inves-
tigates the clinical usefulness and incremental net benefit of identifying subclinical 
myocardial systolic dysfunction in individuals with diabetes.
Methods: A cohort of 397 type 2 diabetic individuals were followed up for the occurrence 
of all-cause mortality. Both clinical and echocardiographic data of diabetic patients 
were assessed retrospectively. LV GLS was evaluated on transthoracic echocardiography 
using speckle tracking imaging.
Results: Subclinical LV systolic dysfunction was defined as LV GLS > -17.0% from 104 
healthy volunteers recruited from the community. A total of 178 (44.8%) diabetic indi-
viduals had evidence of subclinical LV systolic dysfunction and 46 (11.6%) died during 
follow up. The presence of subclinical LV systolic dysfunction was independently as-
sociated with all-cause mortality on follow-up (HR 2.83, 95% CI 1.40 – 5.71, p = 0.004). 
Diabetic individuals without subclinical LV systolic dysfunction had similar survival as 
the general population (standardized mortality ratio 0.94, 95% CI 0.52 – 1.58). Decision 
curve analysis showed identification of subclinical LV systolic dysfunction and quantifi-
cation of LV GLS provided an incremental net clinical benefit at risk stratifying patients 
for risk of death at 5 years. 
Conclusions: Subclinical LV systolic dysfunction is independently associated with 
all-cause mortality in diabetic patients. Decision curve analyses suggest use of LV GLS 
and identification of subclinical LV systolic dysfunction is clinically useful, and provided 
incremental net clinical benefit for diabetic individuals.
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InTRoDUCTIon
Diabetes mellitus is the most common endocrinological disease in the world and its 
presence portends an increased risk for the subsequent development of cardiovascular 
disease, heart failure and death. 1, 2 Echocardiographic techniques such as 2-dimensional 
(2D) speckle tracking global longitudinal strain analysis permits early identification of 
subclinical left ventricular (LV) systolic dysfunction despite preserved LV ejection frac-
tion (EF) in asymptomatic type 2 diabetic individuals.3 However, limited data exist on 
the prevalence and prognostic implications of subclinical LV systolic dysfunction with 
preserved LVEF in diabetic population. Thus, we conducted a multicenter study aimed 
to:
4. evaluate the prevalence of subclinical LV systolic dysfunction with preserved LVEF 
in type 2 diabetic individuals by using 2D speckle tracking global longitudinal strain 
cut-off value derived from normal healthy volunteers; and
5. determine the prognostic implications of subclinical LV systolic dysfunction in type 2 
diabetic patients and compare it with the general population; and
6. determine the clinical usefulness and incremental net benefit of identifying subclini-
cal LV systolic dysfunction on echocardiography.
MeTHoDs
A total of 104 healthy volunteers were prospectively recruited from the community 
(Liverpool Hospital, Australia; and Princess Alexandra Hospital, Australia) to derive a 
cut-off value for normal global longitudinal strain and define subclinical LV systolic 
dysfunction. All the healthy volunteers had normal physical examinations, in normal 
sinus rhythm and had normal echocardiograms. Exclusion criteria for the healthy volun-
teers included history of diabetes, hypertension, smoking, use of cardiac medications, 
known underlying significant coronary artery disease, previous myocardial infarction 
and cardiomyopathy. As the LV global longitudinal strain from this normal population 
demonstrated a unimodal Gaussian distribution, the lower limit of normal was defined 
as 2 standard deviations from the mean. Thus, subclinical LV systolic dysfunction was 
defined as an LV global longitudinal strain > 2 standard deviations from the mean.
The definition of subclinical LV systolic dysfunction was subsequently applied to 397 
type 2 diabetic patients (Leiden University Medical Center, The Netherlands) who were 
followed-up to evaluate the adverse risk of subclinical LV systolic dysfunction. These 
patients were identified from the departmental echocardiographic database, and all 
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clinical data were originally prospectively entered in the departmental Cardiology Infor-
mation System (EPD-Vision®, Leiden University Medical Center).
Type 2 diabetes was diagnosed according to World Health Organization criteria.4 All 
diabetic patients were in normal sinus rhythm and had normal LVEF defined as ≥ 50%. 
Exclusion criteria for all the diabetic patients included history of heart failure, known 
pre-existing underlying significant coronary artery disease, previous myocardial infarc-
tion, presence of segmental wall motion abnormalities on echocardiogram, or ≥ moder-
ate valvular stenosis or regurgitation.
Baseline clinical variables that were recorded included cardiac risk factors, hemoglobin 
level, glycated hemoglobin (HbA1c) and glomerular filtration rates (GFR) calculated 
by the Modification of Diet in Renal Disease formula as recommended by the National 
Kidney Foundation, Kidney Disease Outcomes Quality Initiative Guidelines.5 Heart rate 
and blood pressures were recorded at the time of echocardiographic examination. 
Baseline echocardiographic variables recorded included LV volumes, LVEF, and LV global 
longitudinal strain.
All diabetic individuals were followed-up after the baseline echocardiographic examina-
tion for the occurrence of death. The prognostic significance of subclinical LV systolic 
dysfunction was determined. Furthermore, to validate the cut-off value for the definition 
of subclinical LV dysfunction in the diabetic population, their survival was compared to 
the general Dutch population matched by age, gender, and time period using life-tables 
provided by the Dutch Central Bureau of Statistics. The clinical usefulness of identifying 
subclinical LV systolic dysfunction was also analyzed using decision curve analysis.
All the institutional review boards approved the study. All healthy volunteers prospec-
tively recruited from the community provided written informed consent (Liverpool 
Hospital and Princess Alexandra Hospital, Australia). For the diabetic population, the 
Leiden University Medical Center institutional review board waived the need for patient 
written informed consent as all clinically acquired data were retrospectively analyzed 
and anonymously handled.
Transthoracic echocardiography was performed in all subjects at rest using commercially 
available ultrasound systems (Vivid 7 and E9, GE-Vingmed, Horten, Norway). All images 
were digitally stored on hard disks. All offline analyses were performed using a single 
software system (EchoPAC version 108.1.5, GE-Vingmed, Horten, Norway) at the Leiden 
University Medical Center echocardiography core laboratory by 2 operators (ACTN and 
MB). A complete 2D, color, pulsed and continuous-wave Doppler echocardiogram was 
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performed. LV end-diastolic volume index (EDVI) and end-systolic volume index (ESVI) 
were calculated using Simpson’s biplane method of discs and corrected for body surface 
area. LVEF was calculated and expressed as a percentage. LV mass index was calculated 
from the formula as recommended by the American Society of Echocardiography and 
the European Association of Cardiovascular Imaging.6
Quantification of LV global longitudinal strain was performed using 2D speckle tracking 
echocardiography in the 3 apical (2-, 3- and 4 chamber) views. During image analysis, 
the LV endocardial border was manually traced at end-systole and the region of inter-
est width adjusted to include the entire myocardium. The 2D speckle tracking software 
then automatically tracks the motion of LV myocardial segments throughout the entire 
cardiac cycle. From the 3 individual apical views, peak LV global longitudinal strain was 
calculated. Previous work has reported that the intra- and inter-observer variabilities 
(expressed as mean absolute difference ± 1 standard deviation and intraclass correla-
tion coefficient) for LV global longitudinal strain were 1.2 ± 0.5% and 0.939 and 0.9 ± 
1.0% and 0.942, respectively.3
statistical analysis
All continuous variables were tested for Gaussian distribution using the Kolmogorov-
Smirnov test for normality. Continuous variables are presented as mean ± 1 standard 
deviation and categorical variables are presented as frequencies and percentages. The 
unpaired Student’s t-test was used to compare 2 independent groups of continuous 
variables and the Chi-square test was used to compare categorical variables. Cumula-
tive event rates were calculated using the Kaplan-Meier method and between group 
comparisons were made using the log-rank tests with respect to the primary outcome 
of all-cause mortality.7
Comparison of the diabetic cohort against the mortality of the total Dutch population 
matched by age, gender and time period was performed using standardized mortality 
ratios (SMR). The SMR is the ratio of the observed number of deaths in the study cohort 
relative to the expected number of deaths in the general population. Multivariate Cox 
proportional-hazards models were then constructed to determine the independent 
prognostic value of subclinical LV systolic dysfunction and LV global longitudinal strain, 
adjusted for baseline clinical, biochemical and echocardiographic characteristics (age, 
hemoglobin, GFR, and LV mass index).8 These variables were selected as they were 
significant determinants of all-cause mortality on univariable analysis. The first model 
included LV global longitudinal strain as a categorical variable defined as the presence 
or absence of subclinical LV systolic dysfunction. The second model included LV global 
longitudinal strain as a continuous variable in increments of per unit (1%) worsening. 
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The Cox proportional-hazards models were used to estimate hazard ratios (HR) and 95% 
confidence intervals (CI) for all independent predictors of all-cause mortality. A Pear-
son’s correlation coefficient of > 0.7 was used to identify high colinearity between the 
univariable predictors and avoid concurrent inclusion in the multivariable Cox regres-
sion model. Validity of the Cox regression assumption of proportionality was confirmed 
for all continuous covariates by scaled Schoenfeld residuals. For categorical variables, 
the assumption of proportionality was confirmed by log minus log plots.
To determine the incremental prognostic value of identifying subclinical LV systolic dys-
function using LV global longitudinal strain, the integrated discrimination improvement 
(IDI) and the continuous net reclassification improvement (NRI) were initially used.9, 10 
Next, a formal cost-benefit analysis using decision curve analysis was undertaken to 
determine the clinical usefulness of identifying subclinical LV systolic dysfunction using 
LV global longitudinal strain to predict all-cause mortality at 5 years.11 It compares the 
clinical usefulness and net benefits of the model 1 (i.e. “traditional” risk factors that 
included age, GFR, hemoglobin and LV mass index) versus model 2 (model 1 + subclini-
cal LV dysfunction/LV global longitudinal strain), against 2 default clinical strategies: 1) 
assume all diabetic patients have subclinical LV systolic dysfunction and therefore per-
form an echocardiographic quantification of LV global longitudinal strain in everyone, 
or 2) assume all diabetic individuals are well and do not have subclinical LV dysfunction 
and therefore quantify LV global longitudinal strain in no one.11
A 2-tailed p value of < 0.05 was considered significant. All statistical analyses were 
performed using SPSS for Windows (SPSS Inc, Chicago) version 16, STATA version 10 
(StatCorp, Texas) and R version 3.3.2 (R Foundation for Statistical Computing, Vienna, 
Austria).
ResULTs
The mean age of the 104 normal healthy volunteers was 50 ± 9 years, and 56.7% were 
male. The mean heart rate, systolic and diastolic blood pressures were 68 ± 11 beats/min, 
123 ± 12 mmHg and 82 ± 9 mmHg respectively. All normal healthy volunteers had normal 
echocardiograms by virtue of the inclusion criteria. The mean LV mass index, LVEDVI, 
LVESVI and LVEF were 69.2 ± 12.4 g/m2, 52.9 ± 8.1 mL/m2, 12.5 ± 3.8 mL/m2 and 57.8 ± 
4.6% respectively. The mean LV global longitudinal strain for the healthy volunteers was 
-20.5 ± 1.8%. Although there was no correlation between LV global longitudinal strain 
and age, there was a significant gender difference (men -19.8 ± 1.6%, women -21.4 ± 
1.7%,  p < 0.001). To define subclinical myocardial dysfunction, the lower limit of normal 
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is calculated as 2 standard deviations from the mean. Therefore, in order to simplify 
and increase clinical utility, the lower cut-off value of -17% for LV global longitudinal 
strain was used (Figure 1). Thus, all diabetic individuals with normal LVEF but LV global 
longitudinal strain worse than -17% (less negative) were considered to have subclinical 
LV systolic dysfunction.
Table 1 outlines the clinical, biochemical and echocardiographic characteristics of the 
397 diabetic individuals. Using the LV global longitudinal strain cut-off value of -17.0%, 
178 (44.8%) diabetic individuals had evidence of subclinical LV systolic dysfunction.
After a mean follow-up period of 3.6 ± 1.6 years (median 3.5 years, 25th and 75th percen-
tile 2.8 and 4.5 years respectively), 46 diabetic individuals died. Patients who died were 
significantly older (68.3 ± 11.7 vs. 57.1 ± 11.8 years, p < 0.001), and had lower hemoglo-
bin (13.2 ± 1.6 vs. 13.9 ± 1.6 g/dL, p = 0.009) and lower GFR (63.5 ± 34.0 vs. 86.3 ± 26.3 
mL/min/1.73m2, p < 0.001). On echocardiography, patients who died had significantly 
higher LV mass index (108.9 ± 23.9 vs. 91.8 ± 22.9 g/m2, p < 0.001) and worse LV global 
longitudinal strain (-15.4 ± 2.3 vs. -17.5 ± 2.2%, p < 0.001) compared to patients who 
were alive. There were no significant differences in LV volumes or LVEF. The Kaplan Meier 
survival curves in Figure 2 show the patients with subclinical LV systolic dysfunction had 
significantly lower survival compared to patients with preserved LV systolic function 
(log rank p < 0.001), and significantly lower survival compared to the general population 
(SMR 2.61, 95% CI 1.78 – 3.68, one-sided log rank p < 0.001). A SMR above unity indicates 
 
Figure 1. Distribution of LV global longitudinal strain values in the normal controls. The mean LV global lon-
gitudinal strain was -20.5 ± 1.8%. Therefore, the normal global longitudinal strain cut-off value was -17.0% 
(based on 2 standard deviations below the mean).
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that the mortality of the study cohort is higher than the general population, adjusted for 
age distribution, gender, and calendar time. Thus, diabetic individuals with subclinical 
myocardial dysfunction were 161% more likely to die on follow-up compared to the 
general population. In contrast, there was no difference in survival between diabetic 
individuals with preserved LV systolic function and the general population (SMR 0.94, 
95% CI 0.52 – 1.58, one-sided log rank p = not significant).
Table 2 outlines the all significant univariable determinants of all-cause mortality on 
follow up (including presence of subclinical LV systolic dysfunction, age, hemoglobin, 
GFR and LV mass index). On multivariate Cox proportional-hazards models, the pres-
ence of subclinical LV systolic dysfunction (HR 2.83, 95% CI 1.40 – 5.71, p = 0.004) in 
diabetic individuals was independently associated with increased all-cause mortality 
on follow-up after adjusting for baseline clinical and echocardiographic characteristics. 













Age (years) 58 ± 12 58 ± 12 59 ± 12 0.34
Men 63.7% 62.6% 65.2% 0.59
Body mass index (kg/m2) 28.8 ± 5.5 27.3 ± 5.0 30.5 ± 5.7  < 0.001
Systolic blood pressure (mmHg) 141 ± 22 139 ± 20 143 ± 23 0.032
Diastolic blood pressure (mmHg) 81 ± 11 80 ± 11 83 ± 12 0.023
Hyperlipidemia 50.0% 48.6% 51.7% 0.54
Hypertension 57.8% 55.7% 60.5% 0.34
Smoker 16.9% 15.6% 18.5% 0.44
Hemoglobin (g/dL) 13.8 ± 1.6 13.9 ± 1.6 13.8 ± 1.7 0.56
HbA1c (%) 7.3 ± 1.5 7.1 ± 1.5 7.6 ± 1.4 0.013
GFR (mL/min/1.73m2) 83.8 ± 28.1 86.3 ± 27.4 80.7 ± 28.7 0.052
Heart rate (beats/min) 74 ± 13 72 ± 13 75 ± 12 0.05
Transmitral E velocity (m/s) 0.66 ± 0.17 0.70 ± 0.18 0.65 ± 0.18 0.014
Transmitral E/A ratio 0.98 ± 0.33 1.00 ± 0.34 0.91 ± 0.28 0.005
Deceleration time (ms) 197 ± 54 198 ± 54 201 ± 54 0.60
LV mass index (g/m2) 93.8 ± 23.7 91.2 ± 23.2 96.7 ± 23.9 0.016
LVEDVI (mL/m2) 46.0 ± 11.2 45.9 ± 10.7 46.2 ± 11.8 0.75
LVESVI (mL/m2) 18.7 ± 5.6 18.1 ± 5.1 19.6 ± 6.0 0.007
LVEF (%) 59.5 ± 5.4 60.8 ± 5.3 57.9 ± 5.0  < 0.001
Global longitudinal strain (%) -17.3 ± 2.3 -18.9 ± 1.5 -15.3 ± 1.4  < 0.001
* p value by unpaired Student’s t-test and Chi-square test for continuous and categorical variables respectively. EDVI: end-
diastolic volume index; ESVI: end-systolic volume index; EF: ejection fraction; GFR: glomerular filtration rate; HbA1c: gly-
cated hemoglobin; LV: left ventricular.
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Similarly, when LV global longitudinal strain was modeled as a continuous variable, it 
was still independently associated with increased all-cause mortality on follow-up (HR 
1.29, 95% CI 1.14 – 1.46, p < 0.001) (Table 3).
 
Figure 2. Kaplan Meier survival curves for diabetic individuals with subclinical LV systolic dysfunction and pre-
served LV systolic function compared to the general population. There was no significant difference in long-
term survival for diabetic individuals with preserved LV systolic function and the general population (p = ns). 
In contrast, diabetic individuals with normal LVEF but with subclinical LV systolic dysfunction had significantly 
lower long term survival compared to the general population (p < 0.001).





p value Hazard ratio
(95% CI)
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(per 10 year increase)
1.89
(1.43 – 2.50)





















CI: confidence interval; GFR: glomerular filtration rate; LV: left ventricular.
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Figure 3 graphically illustrates the IDI and continuous NRI between the baseline Cox 
model 1 (age, GFR, hemoglobin and LV mass index [thick line]) and Cox model 2 (model 
1 + subclinical myocardial dysfunction [thin line]). The identification of subclinical LV 
systolic dysfunction significantly improved the predictive value of the Cox model based 
on the IDI (point estimate 0.054, 95% confidence interval 0.002 – 0.163, p = 0.040) and 
continuous NRI (point estimate 0.362, 95% confidence interval 0.062 – 0.587, p = 0.013).
Figures 4 and 5 are the decision curve analyses illustrating the net clinical benefit of 
identifying subclinical LV systolic dysfunction and LV global longitudinal strain re-
spectively. In these figures, the net benefit in risk stratifying diabetic individuals using 
echocardiography to identify subclinical LV systolic dysfunction is represented by the 
y-axis, and plotted over varying thresholds of risk for death at 5 years on the x-axis. This 
is compared against the 2 “extreme theoretical” clinical strategies: perform echocardio-
grams in all diabetic individual (gray solid line) vs. not performing any echocardiograms 
in all diabetic individual (black solid line). Both figures demonstrate that using LV global 
longitudinal strain either as a categorical variable (i.e. presence of subclinical LV systolic 
dysfunction, Figure 4) or continuous variable (Figure 5) to inform clinical decisions will 
lead to superior predictive outcomes when the threshold probability of death at 5 years 
is above 8% (arrow, Figure 4) to 10% (arrow, Figure 5). Importantly, once the patient’s 
5 year probability of death is > 50-70%, there is no net benefit in identifying subclini-
cal LV systolic dysfunction or quantifying LV global longitudinal strain respectively on 
echocardiogram.
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(1.14 – 1.45)








CI: confidence interval; GFR: glomerular filtration rate; LV: left ventricular.
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Figure 3. Graphical representation of the incremental prognostic value of subclinical LV systolic dysfunction 
in predicting all-cause mortality in the overall multivariable Cox regression model in diabetic individuals at 
5 years. Model 1 (age, GFR, hemogloblin and LV mass index) and model 2 (model 1 + subclinical myocardial 
dysfunction as categorical variable) are represented by the thick and thin lines respectively. The difference 
between the 2 curves (area under the curve) represents the IDI, and the distances between the 2 black dots 
vertically and the 2 gray dots horizontally represents the continuous NRI and difference in medians for the 
2 curves respectively. The larger the separation between the 2 curves, the larger the improvement in model 
performance when including subclinical LV systolic dysfunction as a prognostic marker.
 
Figure 4. Decision curve analysis for model 1 (age, GFR, hemogloblin and LV mass index) and model 2 (model 
1 + subclinical LV systolic dysfunction as categorical variable). Once the threshold probability of death ap-
proaches 10% (arrow), performing echocardiograms to identify subclinical LV systolic dysfunction (model 2) 
provide a superior net clinical benefit across a large range of death risk at 5 years follow up. GFR: glomerular 




It is well recognized that LVEF is a poor marker for identifying myocardial dysfunction as 
it remains well preserved until significant impairment of longitudinal, circumferential 
and radial deformations.3 Depending on the echocardiographic modality used, the 
prevalence of myocardial dysfunction in diabetics ranged from 21% to 63%.12, 13 In the 
present study, up to 45% of diabetic individuals had evidence of subclinical LV systolic 
dysfunction as defined by 2D speckle tracking LV global longitudinal strain. This was 
identical to a previous publication by Holland et al.14
Myocardial dysfunction in diabetics has a multifactorial pathophysiology. Proposed 
mechanisms include metabolic derangements, autonomic dysfunction, abnormal cal-
cium homeostasis, endothelial dysfunction, altered structural proteins and interstitial 
fibrosis.15, 16 As such, the diabetic myocardium has accentuated cellular damage, re-
duced structural and function reserve, and is more prone to future decompensation and 
eventual failure when exposed to adverse cardiac events. This was highlighted in the 
seminal work by From et al that showed increased incidence of new-onset heart failure 
in diabetic patients with pre-clinical diastolic dysfunction.17 Although it is traditionally 
held that diastolic dysfunction precedes systolic dysfunction, recent work suggested 
that subclinical LV systolic dysfunction detected by LV global longitudinal strain may be 
 
Figure 5. Decision curve analysis for model 1 (age, GFR, hemogloblin and LV mass index) and model 2 (model 
1 + LV global longitudinal strain as continuous variable). Once the threshold probability of death approaches 
8% (arrow), quantifying LV global longitudinal strain (model 2) provide a superior net clinical benefit across a 
large range of death risk at 5 years follow up. GFR: glomerular filtration rate, LV: left ventricular.
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the first sign of diabetic heart disease instead.18 Even though it is clear that prognosis is 
very poor once clinical heart failure is established,19 there is a paucity of research data 
on prognosis of the earlier subclinical dysfunction stage.
To our knowledge, only 2 previous publications have demonstrated adverse long-term 
prognosis associated with subclinical LV systolic dysfunction using LV global longitudi-
nal strain.14, 20 Holland et al included 230 diabetic patients and showed increased all-
cause mortality and hospitalization in patients with subclinical LV systolic dysfunction 
compared to those with preserved LV global longitudinal strain.14 However, the primary 
outcome was primarily driven by hospitalization, and the causes of hospitalizations 
were unknown. Liu et al included 247 diabetic patients and showed that an impaired LV 
global longitudinal strain was associated with an increased incidence of cardiovascular 
events defined as a composite of acute coronary syndrome, cerebrovascular stroke, car-
diovascular death and hospitalization for heart failure.20 In contrast, the present study is 
the largest to date to include 397 diabetic patients with a primary end-point of all-cause 
mortality. Not only did our results corroborate the previous 2 publications demonstrat-
ing similar adverse prognosis associated with subclinical LV systolic dysfunction, it is 
also first to show diabetic individuals with preserved LV systolic function had similar 
long term survival rates as the general population.
In both studies by Holland et al 14 and Liu et al 20, the “incremental” prognostic value of 
LV global longitudinal strain were based on the Chi square change in the multivariable 
Cox model, which is a statistical measure of the overall model performance related to 
the concept of “goodness-of-fit” (i.e. a better model results in smaller distances between 
predicted and observed outcomes).21 However, it fails to inform both the doctor and 
patient if the test is clinically useful. In contrast, the use of a decision curve analysis 
in the present study illustrated the net clinical benefit of identifying subclinical LV sys-
tolic dysfunction (binary data, Figure 4) and LV global longitudinal strain (continuous 
data, Figure 5) in diabetic individuals over the baseline prediction model (age, GFR, 
hemogloblin and LV mass index) by incorporating the clinical consequences across a 
large range of all-cause mortality risk. As the relative weights of benefits and harms in 
identifying subclinical LV systolic dysfunction in asymptomatic diabetic population will 
differ individually, the decision curve analysis allows the setting of individual patient’s 
thresholds for predicting the probability of death at 5 years. It showed that the identi-
fication of subclinical LV systolic dysfunction is only of incremental net clinical benefit 
if the risk of death at 5 years is between 10% and 50%. As for quantification of LV global 
longitudinal strain as a continuous variable, the incremental net clinical benefit is pres-
ent if the risk of death at 5 years is between 8% and 70%. Therefore, the identification of 
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subclinical LV systolic dysfunction provided superior net clinical benefit across a wide 
range of probabilities of death at 5 years.
Although the present study included healthy volunteers and diabetic individuals across 
3 different institutions, all diabetic individuals were recruited from a single center. 
Sub-group analyses based on cardiovascular and non-cardiovascular mortality were 
not available. Finally, by virtue of the study design, we did not evaluate the progression 
of subclinical LV systolic dysfunction over time. However, that research was previously 
reported by our group.22
ConCLUsIons
Diabetic patients with subclinical LV systolic dysfunction have increased risk of all-cause 
mortality compared to diabetic patients without subclinical LV systolic dysfunction. 
Furthermore, diabetic patients without subclinical LV systolic dysfunction had similar 
survival as the general population. Decision curve analyses suggest that identifying 
subclinical LV systolic dysfunction is clinically useful.
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Both obese and diabetic patients can develop changes in myocardial structure and func-
tion independent of coronary artery disease. Collectively known as metabolic heart dis-
ease, this thesis attempted to illuminate its pathogenesis and prognostic implications.
The thesis began by summarizing the various imaging modalities used to quantifying 
changes in myocardial structure and contractile function. Specifically, magnetic reso-
nance imaging techniques such as spectroscopy and T1 mapping can be used to quantify 
myocardial energy substrate utilization and extent of interstitial fibrosis respectively. 
In addition, myocardial deformation imaging using 2-dimensional speckle tracking 
echocardiography provides an accurate quantification of myocardial contractility. This 
technique has previously been validation against the “gold standard” myocardial strain 
imaging using magnetic resonance imaging myocardial tagging sequence.
In Chapter 2, asymptomatic type 2 male diabetic patients without any associated 
diabetic complications were prospectively recruited to undergo 2-dimensional speckle 
tracking echocardiography. These diabetic patients were compared to male controls 
matched to age and body mass index. This study was first to demonstrate impaired 
myocardial contractility in asymptomatic diabetic patients, with an impaired longitu-
dinal but preserved circumferential and radial functions. This study established global 
longitudinal strain as the most sensitive marker for identifying subclinical myocardial 
dysfunction in diabetic patients.
Chapter 3 explored the combined detrimental effects of increasing body mass index 
and diabetes on myocardial contractile. In this multicenter study, we demonstrated 
that both diabetes and increasing body mass index were independent determinants of 
global longitudinal strain. Secondly, the adverse impact of increasing body mass index 
and diabetes were additive. Finally, increasing body mass index was a stronger determi-
nant of impaired global longitudinal strain compared to diabetes.
In Chapters 4 to 6, we attempted to evaluate the pathogenesis of subclinical myocar-
dial dysfunction associated with diabetes and increasing body mass index. In a process 
analogous to fatty liver disease, diabetic patients can accumulate triglyceride within 
the cytoplasm of myocytes. Under normal physiological conditions, the heart uses both 
free fatty acids and glucose as its energy source. However, diabetes is characterized by 
insulin resistance and the heart preferentially uses free fatty acid for metabolism despite 
the prevailing hyperglycemia. The intracellular triglyceride is a source of free fatty acid 
and eventually, the excessive triglyceride/free fatty acid concentration exceeds the myo-
cardial β-oxidative capacity. Consequently, there is accumulation of toxic intermediates 
such as ceramide and diacylglycerol that results in cellular dysfunction. Using proton 
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magnetic resonance spectroscopy double gated to ECG and respiratory motion, we can 
quantify the concentration of intramyocardial triglyceride. Furthermore, recent ad-
vances in magnetic resonance imaging using post-contrast T1 mapping techniques, we 
can also quantify the extent of interstitial myocardial fibrosis (i.e. myocardial structural 
change).
In Chapter 4, intramyocardial triglyceride concentration was quantified using proton 
magnetic resonance spectroscopy in asymptomatic male diabetic patients, and patients 
were dichotomized into 2 groups based on the median intramyocardial triglyceride 
concentration. In this study, patients with higher intramyocardial triglyceride concen-
tration was independently associated with impaired left and right ventricular global 
longitudinal strain.
In Chapter 5, the burden of interstitial fibrosis was quantified using post-contrast T1 
maps in 50 diabetic patients without underlying coronary artery disease or macroscopic 
scar. Compared to healthy controls, diabetic patients had more interstitial fibrosis was 
reflected by a shorter post-contrast T1 time. Furthermore, post-contrast T1 time was the 
strongest determinant of global longitudinal strain on multivariable analysis (standard-
ized β  = -0.626, p < 0.001).
In Chapter 6, we evaluated the combined effects of myocardial steatosis and intersti-
tial fibrosis on myocardial contractile function in patients with increasing body mass 
index. Importantly, patients with underlying diabetes and hypertension were excluded 
to avoid any potential confounding influences. In this study, epicardial fat volume (a 
measure of visceral adiposity) was an independent determinant of both intramyocardial 
triglyceride accumulation and the burden of interstitial fibrosis. On univariable analysis, 
epicardial fat volume, intramyocardial triglyceride concentration and interstitial fibrosis 
were associated with left ventricular global longitudinal strain. However, only epicardial 
fat volume was independently associated with global longitudinal strain on multivari-
able analysis.
Finally, in Chapter 7, we aimed to determine the prognostic implications of subclinical 
myocardial dysfunction as identified by global longitudinal strain. In this multicenter 
study, “normal” global longitudinal strain cut-off value of > -17.0% was defined from 104 
healthy volunteers recruited from the community. Applying this normal global longitu-
dinal strain cut-off value to 397 type 2 diabetic patients with normal left ventricular ejec-
tion fraction, up to 45% of patients had evidence of subclinical myocardial dysfunction. 
At follow-up, the presence of subclinical myocardial dysfunction in diabetic patients was 
independently associated with increased all-cause mortality on follow-up (hazard ratio 
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2.83, 95% confidence interval 1.40 – 5.71, p = 0.004). Vice versa, diabetic patients with-
out subclinical myocardial dysfunction had similar survival as the general population 
(standardized mortality ratio 0.94, 95% confidence interval 0.52 – 1.58). Using decision 
curve analysis, quantifying global longitudinal strain and identifying subclinical myo-
cardial dysfunction was clinically useful and provided incremental net clinical benefit 
for diabetic patients.
Conclusions and future directions
Echocardiographic 2-dimensional speckle tracking analysis is now a well-established 
tool that is widely used in routine clinical practice. It is now well accepted that global 
longitudinal strain is superior to “traditional” left ventricular ejection fraction in detect-
ing early subtle changes and prognosticating adverse outcomes on follow-up. In this 
thesis, we determined that up to 45% of diabetic patients had evidence of subclinical 
myocardial dysfunction despite normal left ventricular ejection fraction or known 
underlying significant coronary artery disease. Using state-of-the-art cardiac magnetic 
resonance imaging, we have attempted to elucidate the pathophysiology of metabolic 
heart disease. We have identified increased epicardial adipose tissue, myocardial ste-
atosis and interstitial fibrosis were associated with myocardial contractile dysfunction. 
Future research should aim at corroborating these findings, risk stratify patients, and 
identifying effective therapeutic interventions (e.g. medically or surgically induced 
weight loss, diabetic medications such as sodium-glucose transport protein 2 (SGLT2) 






Zowel obese als diabetische patiënten kunnen onafhankelijk van coronairlijden ver-
anderingen in myocardstructuur en -functie ontwikkelen. In deze thesis is geprobeerd 
de pathogenese en de prognostische implicaties van deze veranderingen, algemeen 
bekend als metabole hartziekten, te belichten.
De thesis begon met het samenvatten van de verschillende beeldvormingstechnieken 
die worden gebruikt om de veranderingen in myocardstructuur en contractiele functie 
te kwantificeren. Met name beeldvorming met magnetische resonantie (MRI) zoals 
spectroscopie en T1 gewogen opnames kunnen worden gebruikt om respectievelijk 
het myocardiale energie substraat en de mate van interstitiële fibrose te kwantificeren. 
Daarnaast kan beeldvorming van myocardiale deformatie door middel van 2-dimen-
sionale speckle tracking echocardiografie de myocardiale contractiliteit accuraat 
kwantificeren. Deze techniek is eerder gevalideerd tegen de “gouden standaard” van 
myocardiale strain beeldvorming door MRI met myocardial tagging.
In hoofdstuk 2 werden asymptomatische mannen met diabetes type 2 zonder diabeti-
sche complicaties prospectief onderzocht met 2-dimensionale speckle tracking echo-
cardiografie. Deze patiënten werden vergeleken met mannelijke controles die waren 
gematcht voor leeftijd en body mass index (BMI). Deze studie was de eerste die vermin-
derde myocardiale contractiliteit, met een verminderde longitudinale strain maar een 
behouden circumferente en radiale strain, in asymptomatische diabetici aantoonde. De 
studie stelde vast dat globale longitudinale strain de meest sensitieve marker is voor het 
identificeren van subklinische myocardiale dysfunctie in patiënten met diabetes.
In hoofdstuk 3 werd het gecombineerde schadelijke effect van toename van BMI en dia-
betes op myocardiale contractiliteit onderzocht. In deze multicenter studie werd gede-
monstreerd dat zowel diabetes als toename van BMI onafhankelijke determinanten van 
globale longitudinale strain waren. Daarnaast waren de negatieve impact van toename 
van BMI en diabetes additief. Tenslotte was toename van BMI een sterkere determinant 
van verminderde globale longitudinale strain vergeleken met diabetes.
In hoofdstukken 4 tot 6 hebben we gepoogd de pathogenese van subklinische myocar-
diale dysfunctie geassocieerd met diabetes en toename van BMI te evalueren. In een 
proces dat analoog is aan leververvetting kunnen diabetici triglyceriden accumuleren in 
het cytoplasma van myocyten. Onder normale fysiologische omstandigheden gebruikt 
het hart vrije vetzuren en glucose als energiebron. Echter wordt diabetes gekarakteri-
seerd door insuline resistentie en waardoor het hart vrije vetzuren gebruikt voor het 
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metabolisme ondanks de continue hyperglycemie. De intracellulaire triglyceriden zijn 
een bron van vrije vetzuren en uiteindelijk zal de verhoogde concentratie  triglyceriden/
vrije vetzuren de capaciteit van de myocardiale β-oxidatieve capaciteit overschrijden. 
Daardoor ontstaat een accumulatie van toxische tussenproducten zoals ceramide en di-
acylglycerol wat resulteert in cellulaire dysfunctie. Door middel van proton magnetische 
resonantie spectroscopie gekoppeld aan het elektrocardiogram en ademhalingsbewe-
gingen, kunnen we de concentratie van de intramyocardiale triglyceriden kwantificeren. 
Daarnaast kunnen we door recente vooruitgang in MRI technieken met post-contrast 
T1 gewogen opnames de omvang van interstitiële myocardiale fibrose kwantificeren 
(bijvoorbeeld myocardiale structurele veranderingen).
In hoofdstuk 4 is de concentratie intramyocardiale tryglyceriden gekwantificeerd behulp 
van proton magnetische resonantie spectroscopie in mannelijke, asymptomatische 
patiënten met diabetes. Patienten werden onderverdeeld in 2 groepen gebaseerd op de 
mediane intramyocardiale triglyceride concentratie. In deze studie was een hogere in-
tramyocardiale triglyceride concentratie onafhankelijk geassocieerd met verminderde 
linker en rechter ventriculaire globale longitudinale strain.
In hoofdstuk 5 werd de hoeveelheid interstitiële fibrose gekwantificeerd door middel 
van post-contrast T1 gewogen opnames in 50 patiënten met diabetes zonder onderlig-
gend coronairlijden of macroscopisch littekenweefsel. Vergeleken met gezonde contro-
les hadden de patiënten met diabetes meer interstitiële fibrose, wat gereflecteerd werd 
door een kortere post-contrast T1 tijd. Daarnaast was post-contrast T1 tijd de sterkste 
determinant van globale longitudinale strain in multivariate analyse (gestandaardi-
seerde β  = -0.626, p < 0.001).
In hoofdstuk 6 is het gecombineerde effect van myocardiale steatose en interstiti-
ele fibrose op myocardiale contractiele functie in patiënten met toename van BMI 
geëvalueerd. Hierbij werden patiënten met onderliggende diabetes en hypertensie als 
potentiele confounders geëxcludeerd. In deze studie was epicardiaal vetvolume (een 
maat van viscerale adipositas) een onafhankelijke determinant voor accumulatie van 
intramyocardiale tryglyceriden en voor de hoeveelheid interstitiële fibrose. In univariate 
analyse waren epicardiaal vetvolume, intramyocardiale tryglyceride concentratie en 
interstitiële fibrose geassocieerd met linker ventriculaire globale longitudinale strain. 
Echter was alleen epicardiaal vetvolume in de multivariate analyse onafhankelijk geas-
socieerd met globale longitudinale strain.
Tenslotte werd in hoofdstuk 7 de prognostische implicatie van subklinische myocardiale 
dysfunctie, vastgesteld met globale longitudinale strain, onderzocht. In deze multicen-
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ter studie werd een “normale” globale longitudinale strain gedefinieerd als > -17.0% op 
basis van 104 gezonde vrijwilligers uit de algemene populatie. Bij het toepassen van deze 
afkapwaarde voor normale globale longitudinale strain op 397 patiënten met diabetes 
type 2 en een normale linker ventriculaire ejectiefractie, bleek 45% van de patiënten 
subklinische myocardiale dysfunctie te hebben. Bij follow-up was de aanwezigheid 
van subklinische myocardiale dysfunctie in diabetici onafhankelijk geassocieerd met 
verhoogde kans op sterfte (hazard ratio 2.83, 95% betrouwbaarheidsinterval 1.40 – 5.71, 
p = 0.004). Patiënten met diabetes zonder subklinische myocardiale dysfunctie hadden 
daarentegen een vergelijkbare overleving met de algemene populatie (gestandaardi-
seerde sterfte ratio 0.94, 95% betrouwbaarheidsinterval 0.52 – 1.58). Volgens de decision 
curve analyse was het kwantificeren van globale longitudinale strain en het identificeren 
van subklinische myocardiale dysfunctie bruikbaar in de kliniek, en verschafte het incre-
menteel klinisch voordeel voor patiënten met diabetes.
Conclusies en toekomstperspectieven
Echocardiografische 2-dimensionale speckle tracking analyse is een hulpmiddel dat 
momenteel veel gebruikt wordt in routine onderzoeken in de klinische praktijk. Het is 
tegenwoordig algemeen geaccepteerd dat globale longitudinale strain superieur is aan 
de “traditionele” linker ventriculaire ejectie fractie in het detecteren van vroege subtiele 
veranderingen en het voorspellen van ongunstige uitkomsten tijdens follow-up. In deze 
thesis hebben we vastgesteld dat tot 45% van de patiënten met diabetes aanwijzingen 
hadden voor subklinische myocardiale dysfunctie, ondanks normale linker ventriculaire 
ejectie fractie en de afwezigheid van bekend onderliggend coronairlijden. Door middel 
van state-of-the-art cardiale MRI hebben we geprobeerd de pathofysiologie van meta-
bole hartziekten te verhelderen. Toekomstig onderzoek zou als doel moeten hebben 
om deze uitkomsten te bevestigen, risicostratificatie voor patiënten te ontwikkelen en 
effectieve therapeutische interventies te identificeren (bijvoorbeeld medicamenteus 
of chirurgisch geïnduceerd gewichtsverlies, diabetes medicatie zoals natrium-glucose-
cotransporter 2 (SGLT2) remmers, etc) waardoor potentieel subklinische myocardiale 
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